var title_f30_48_31488="Multiple nodules in sarcoidosis";
var content_f30_48_31488=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F79390&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F79390&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Sarcoidosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 324px; height: 315px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Chest radiograph demonstrates multiple bilateral pulmonary nodules and masses in a patient with the nummular form of pseudoalveolar sarcoidosis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_48_31488=[""].join("\n");
var outline_f30_48_31488=null;
var title_f30_48_31489="Modified Semont maneuver";
var content_f30_48_31489=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F60002&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F60002&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 546px\">",
"   <div class=\"ttl\">",
"    Modified semont maneuver",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 526px; height: 344px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The modified Semont maneuver is illustrated for left posterior canalithiasis. The seated patient begins by turning the head 45&ordm; to the right. The patient then quickly drops the trunk to the left side (1) with the head turned 45&ordm; to the right. This position is held for at least 30 seconds or until any provoked vertigo subsides. The patient then quickly sits up and lies down on the right side without stopping in the upright position (2), all the while keeping the head turned 45&ordm; to the right so that the head now faces partly down into the bed. This position is held for 30 seconds or until vertigo subsides. Then patient returns to the upright position (3). This maneuver is repeated three times a day until the patient is asymptomatic. For right posterior canalithiasis, the maneuver must be performed in the opposite direction, starting with the head turned toward the left.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Modified from Radtke, A, von Brevern, M, Tiel-Wilck, K, et al. Self- treatment of benign paroxysmal positional vertigo. Neurology 2004; 63:150.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_48_31489=[""].join("\n");
var outline_f30_48_31489=null;
var title_f30_48_31490="Diagnosis of interstitial cystitis/bladder pain syndrome";
var content_f30_48_31490=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Diagnosis of interstitial cystitis/bladder pain syndrome (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?30/48/31490/contributors\">",
"       Author",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/48/31490/contributors\" id=\"au3806\">",
"       J Quentin Clemens, MD, FACS, MSCI",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?30/48/31490/contributors\">",
"       Section Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/48/31490/contributors\" id=\"se158\">",
"       Michael P O'Leary, MD, MPH",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?30/48/31490/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/48/31490/contributors\" id=\"de8761\">",
"       Fenny H Lin, MD",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"mobipreview.htm?30/48/31490?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      INTRODUCTION",
"     </span>",
"    </p>",
"    <p>",
"     Interstitial",
"     <span class=\"nowrap\">",
"      cystitis/bladder",
"     </span>",
"     pain syndrome",
"     <span class=\"nowrap\">",
"      (IC/BPS)",
"     </span>",
"     is a group of symptoms, including mild to severe bladder pain and an urgent",
"     <span class=\"nowrap\">",
"      and/or",
"     </span>",
"     frequent need to urinate. The disorder can affect women and men but is more common in women. It can be difficult to diagnose and treat because the underlying cause is not well understood.",
"    </p>",
"    <p>",
"     The symptoms and diagnosis of",
"     <span class=\"nowrap\">",
"      IC/BPS",
"     </span>",
"     will be discussed here. Treatment of this disorder is reviewed separately. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?17/22/17764?source=see_link\">",
"      \"Patient information: Treatment of interstitial cystitis/bladder pain syndrome (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      DEFINITIONS",
"     </span>",
"    </p>",
"    <p>",
"     The definition of interstitial",
"     <span class=\"nowrap\">",
"      cystitis/bladder",
"     </span>",
"     pain syndrome",
"     <span class=\"nowrap\">",
"      (IC/BPS)",
"     </span>",
"     has evolved over the years, and will probably continue to change as the cause is better understood. The American Urological Association (AUA) defines",
"     <span class=\"nowrap\">",
"      IC/BPS",
"     </span>",
"     as an unpleasant sensation (pain, pressure, discomfort) perceived to be related to the urinary bladder, associated with lower urinary tract symptoms of more than six weeks duration, in the absence of infection of other identifiable causes.",
"    </p>",
"    <p>",
"     It is difficult to know for sure how many people are affected by",
"     <span class=\"nowrap\">",
"      IC/BPS,",
"     </span>",
"     but research indicates that",
"     <span class=\"nowrap\">",
"      IC/BPS",
"     </span>",
"     symptoms occur in about 2 percent of women. However, many fewer than that are diagnosed with the disorder, perhaps because it is unrecognized.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H5\">",
"     <span class=\"h1\">",
"      PAINFUL BLADDER CAUSES",
"     </span>",
"    </p>",
"    <p>",
"     Little is known about the cause of interstitial",
"     <span class=\"nowrap\">",
"      cystitis/bladder",
"     </span>",
"     pain syndrome",
"     <span class=\"nowrap\">",
"      (IC/BPS).",
"     </span>",
"     Many studies have shown that patients with this disorder have abnormalities in the lining of the bladder. However, it is not known if these bladder abnormalities are the cause of symptoms or if the abnormalities develop as a result of some unknown underlying disorder that also causes painful bladder symptoms.",
"    </p>",
"    <p>",
"     It is likely that the nerves in the bladder become highly sensitive to pain and pressure as",
"     <span class=\"nowrap\">",
"      IC/BPS",
"     </span>",
"     develops. Nerves outside the bladder, including nerves of the abdomen, pelvis, and hips, and legs, may also become more sensitive.",
"    </p>",
"    <p>",
"     One or more events may lead to the symptoms of",
"     <span class=\"nowrap\">",
"      IC/BPS,",
"     </span>",
"     including:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Urinary tract infection",
"      </li>",
"      <li>",
"       An episode of vaginitis or prostatitis (eg, an infection of the vagina or a bacterial infection of the prostate)",
"      </li>",
"      <li>",
"       Bladder, pelvic, back, or other type of surgery",
"      </li>",
"      <li>",
"       Trauma (eg, fall onto the tailbone [coccyx] or car accident)",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     However, in many people, there is no clear explanation for why or how the symptoms of",
"     <span class=\"nowrap\">",
"      IC/BPS",
"     </span>",
"     first began.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H6\">",
"     <span class=\"h1\">",
"      PAINFUL BLADDER SYMPTOMS",
"     </span>",
"    </p>",
"    <p>",
"     The symptoms of interstitial",
"     <span class=\"nowrap\">",
"      cystitis/bladder",
"     </span>",
"     pain syndrome",
"     <span class=\"nowrap\">",
"      (IC/BPS)can",
"     </span>",
"     vary from one person to another and from one episode to another. All patients with",
"     <span class=\"nowrap\">",
"      IC/BPS",
"     </span>",
"     have bladder pain that is relieved at least partially by urinating. Symptoms usually include a frequent and urgent need to urinate during the day",
"     <span class=\"nowrap\">",
"      and/or",
"     </span>",
"     night. Most, although not all, people with",
"     <span class=\"nowrap\">",
"      IC/BPS",
"     </span>",
"     do not have urinary leakage (incontinence). Most people describe pain in the suprapubic area (in the lower abdomen, above the pubic bone) or urethral area (",
"     <a class=\"graphic graphic_figure graphicRef79864 \" href=\"mobipreview.htm?26/28/27072\">",
"      figure 1",
"     </a>",
"     ). The severity of pain ranges from mild burning to severe and debilitating pelvic pain.",
"    </p>",
"    <p>",
"     Most people describe symptoms that begin gradually, with worsening discomfort, urgency, and frequency over a period of months. A smaller subset of patients describes symptoms that are severe from the beginning. When symptoms of",
"     <span class=\"nowrap\">",
"      IC/BPS",
"     </span>",
"     begin suddenly, some patients are able to name the exact date on which symptoms began (see",
"     <a class=\"local\" href=\"#H5\">",
"      'Painful bladder causes'",
"     </a>",
"     above).",
"    </p>",
"    <p>",
"     Some people with",
"     <span class=\"nowrap\">",
"      IC/BPS",
"     </span>",
"     also have other types of chronic pain, such as irritable bowel syndrome, painful menstrual periods, endometriosis, vulvar pain (vulvodynia), fibromyalgia, or prostatitis.",
"     <span class=\"nowrap\">",
"      IC/BPS",
"     </span>",
"     symptoms are sometimes at their worst during times when other pain symptoms are also at their worst. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?3/53/3926?source=see_link\">",
"      \"Patient information: Irritable bowel syndrome (Beyond the Basics)\"",
"     </a>",
"     and",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?25/63/26611?source=see_link\">",
"      \"Patient information: Endometriosis (Beyond the Basics)\"",
"     </a>",
"     and",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?24/17/24854?source=see_link\">",
"      \"Patient information: Fibromyalgia (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     Symptoms may vary from one day to the next. Worsening of",
"     <span class=\"nowrap\">",
"      IC/BPS",
"     </span>",
"     symptoms may occur after consuming certain foods or drinks (eg, coffee, alcoholic drinks, spicy foods), during the luteal phase of the menstrual cycle (14 to 28 days after the first day of the last period), during stressful times, or after activities such as exercise, sexual intercourse, or being seated for long periods of time (eg, during a plane trip).",
"    </p>",
"    <p>",
"     A person with severe disease may have to urinate several times per hour, which can seriously disrupt daily activities and sleep. As a result of these symptoms, home and work life are often disrupted, interest in sex may be minimal, and the person may have difficulty coping with chronic pain and fatigue. In surveys, 50 percent of patients reported being unable to work full-time, 75 percent described pain with intercourse, 70 percent reported sleep disturbance, and 90 percent reported that",
"     <span class=\"nowrap\">",
"      IC/BPS",
"     </span>",
"     affected their daily activities [",
"     <a class=\"abstract\" href=\"mobipreview.htm?30/48/31490/abstract/1\">",
"      1",
"     </a>",
"     ].",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H7\">",
"     <span class=\"h1\">",
"      PAINFUL BLADDER EVALUATION",
"     </span>",
"    </p>",
"    <p>",
"     The diagnosis of interstitial",
"     <span class=\"nowrap\">",
"      cystitis/bladder",
"     </span>",
"     pain syndrome",
"     <span class=\"nowrap\">",
"      (IC/BPS)is",
"     </span>",
"     based upon a person's symptoms and examination. A careful medical history, physical examination, and sometimes laboratory testing are needed to confirm the diagnosis and also to be sure that another condition (eg, bladder infection or kidney stone) is not the cause of symptoms. There is no single test that can definitively diagnose",
"     <span class=\"nowrap\">",
"      IC/BPS.",
"     </span>",
"     (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?31/18/32036?source=see_link\">",
"      \"Patient information: Urinary tract infections in adolescents and adults (Beyond the Basics)\"",
"     </a>",
"     and",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?27/53/28499?source=see_link\">",
"      \"Patient information: Kidney stones in adults (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H8\">",
"     <span class=\"h2\">",
"      Physical examination",
"     </span>",
"     &nbsp;&mdash;&nbsp;The physical examination usually includes a complete pelvic examination with a brief rectal exam. Often, patients with",
"     <span class=\"nowrap\">",
"      IC/BPS",
"     </span>",
"     have tenderness in the lower abdomen, hips, and buttocks. Women often have tenderness in the vagina and around the bladder, and men may have tenderness in the scrotum and penis. For this reason, being examined can be uncomfortable.",
"    </p>",
"    <p>",
"     If an examination is too uncomfortable, some healthcare providers will recommend that the patient begin a course of treatment for",
"     <span class=\"nowrap\">",
"      IC/BPS",
"     </span>",
"     without further testing. If improvement is not seen, it may be necessary to perform more testing to confirm the diagnosis.",
"    </p>",
"    <p>",
"     Some providers will measure the amount of urine remaining in the bladder after the patient urinates; this is called a post-void residual. This measurement can be done by inserting a small catheter into the bladder or by using ultrasound. While it is normal to have some urine in the bladder after voiding, having a large amount of urine is not normal. Urinary retention is the medical term for retaining urine in the bladder, and is not typical of",
"     <span class=\"nowrap\">",
"      IC/BPS.",
"     </span>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H9\">",
"     <span class=\"h2\">",
"      Laboratory tests",
"     </span>",
"     &nbsp;&mdash;&nbsp;Most clinicians will perform a urine test to ensure that a person's symptoms are not related to another condition, such as a kidney stone or bladder infection. If a urinary tract infection is discovered, the person will be treated with antibiotics. If blood is detected in the urine, further urine",
"     <span class=\"nowrap\">",
"      and/or",
"     </span>",
"     diagnostic testing (eg, cystoscopy) may be recommended. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?31/18/32036?source=see_link\">",
"      \"Patient information: Urinary tract infections in adolescents and adults (Beyond the Basics)\"",
"     </a>",
"     and",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?9/53/10066?source=see_link\">",
"      \"Patient information: Blood in the urine (hematuria) in adults (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11\">",
"     <span class=\"h2\">",
"      Cystoscopy",
"     </span>",
"     &nbsp;&mdash;&nbsp;Cystoscopy is a test that allows a doctor to examine the inside of the bladder. Cystoscopy is not required to diagnose",
"     <span class=\"nowrap\">",
"      IC/BPS,",
"     </span>",
"     but may be recommended in certain situations. Cystoscopy can be done in the office, after a numbing gel is applied inside the urethra. It can also be done in an operating room while a patient is under anesthesia, sometimes in combination with other procedures.",
"    </p>",
"    <p>",
"     To perform cystoscopy, a physician inserts a thin telescope with a camera through the urethra and into the bladder. The physician examines the inside (lining) of the bladder to determine if there are any abnormalities. A person with",
"     <span class=\"nowrap\">",
"      IC/BPS",
"     </span>",
"     may have either a normal or abnormal-appearing bladder. If an abnormality is seen, further testing may be recommended.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H13\">",
"     <span class=\"h1\">",
"      PAINFUL BLADDER TREATMENT",
"     </span>",
"    </p>",
"    <p>",
"     A topic review that discusses the treatment of interstitial",
"     <span class=\"nowrap\">",
"      cystitis/bladder",
"     </span>",
"     pain syndrome",
"     <span class=\"nowrap\">",
"      (IC/BPS)is",
"     </span>",
"     available separately. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?17/22/17764?source=see_link\">",
"      \"Patient information: Treatment of interstitial cystitis/bladder pain syndrome (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H14\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H2287491557\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11170676\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?20/11/20658?source=see_link\">",
"      Patient information: Bladder pain syndrome (interstitial cystitis) (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?42/60/43970?source=see_link\">",
"      Patient information: Dyspareunia (painful sex) (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?35/33/36370?source=see_link\">",
"      Patient information: Vulvar pain (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11170692\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?17/22/17764?source=see_link\">",
"      Patient information: Treatment of interstitial cystitis/bladder pain syndrome (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?3/53/3926?source=see_link\">",
"      Patient information: Irritable bowel syndrome (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?25/63/26611?source=see_link\">",
"      Patient information: Endometriosis (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?24/17/24854?source=see_link\">",
"      Patient information: Fibromyalgia (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?31/18/32036?source=see_link\">",
"      Patient information: Urinary tract infections in adolescents and adults (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?27/53/28499?source=see_link\">",
"      Patient information: Kidney stones in adults (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?9/53/10066?source=see_link\">",
"      Patient information: Blood in the urine (hematuria) in adults (Beyond the Basics)",
"     </a>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H15\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/26/41384?source=see_link\">",
"      Causes of chronic pelvic pain in women",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/8/8330?source=see_link\">",
"      Pathogenesis, clinical features, and diagnosis of interstitial cystitis/bladder pain syndrome",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/22/43369?source=see_link\">",
"      Management of interstitial cystitis/bladder pain syndrome",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/15/13561?source=see_link\">",
"      Acute uncomplicated cystitis and pyelonephritis in women",
"     </a>",
"     <br/>",
"     <br/>",
"     The following organizations also provide reliable health information [",
"     <a class=\"abstract\" href=\"mobipreview.htm?30/48/31490/abstract/1-5\">",
"      1-5",
"     </a>",
"     ]:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Library of Medicine",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/healthtopics.html\">",
"      www.nlm.nih.gov/medlineplus/healthtopics.html",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Institute of Diabetes and Digestive and Kidney Diseases",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://kidney.niddk.nih.gov/kudiseases/pubs/interstitialcystitis/\">",
"      file://kidney.niddk.nih.gov/kudiseases/pubs/interstitialcystitis/",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Interstitial Cystitis Association",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.ichelp.org/\">",
"      file://www.ichelp.org/",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Interstitial Cystitis Network",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.ic-network.com/\">",
"      www.ic-network.com",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       European Society for the Study of Interstitial Cystitis",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.essic.eu/\">",
"      www.essic.eu",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       United States Department of Health and Human Services",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://womenshealth.gov/publications/our-publications/fact-sheet/interstitial-cystitis.cfm\">",
"      womenshealth.gov/publications/our-publications/fact-sheet/interstitial-cystitis.cfm",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       International Painful Bladder Foundation",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     (",
"     <a class=\"external\" href=\"file://www.painful-bladder.org/index.html\">",
"      www.painful-bladder.org/index.html",
"     </a>",
"     )",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 20, 2012.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"mobipreview.htm?30/48/31490?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/48/31490/abstract/1\">",
"      Koziol JA. Epidemiology of interstitial cystitis. Urol Clin North Am 1994; 21:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/48/31490/abstract/2\">",
"      Rosenberg MT, Hazzard M. Prevalence of interstitial cystitis symptoms in women: a population based study in the primary care office. J Urol 2005; 174:2231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/48/31490/abstract/3\">",
"      Wesselmann U. Interstitial cystitis: a chronic visceral pain syndrome. Urology 2001; 57:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/48/31490/abstract/4\">",
"      Bogart LM, Berry SH, Clemens JQ. Symptoms of interstitial cystitis, painful bladder syndrome and similar diseases in women: a systematic review. J Urol 2007; 177:450.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/48/31490/abstract/5\">",
"      FitzGerald MP, Brensinger C, Brubaker L, et al. What is the pain of interstitial cystitis like? Int Urogynecol J Pelvic Floor Dysfunct 2006; 17:69.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f30_48_31490=[""].join("\n");
var outline_f30_48_31490=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           INTRODUCTION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           DEFINITIONS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H5\">",
"           PAINFUL BLADDER CAUSES",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H6\">",
"           PAINFUL BLADDER SYMPTOMS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H7\">",
"           PAINFUL BLADDER EVALUATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H13\">",
"           PAINFUL BLADDER TREATMENT",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H14\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"       <h1>",
"        GRAPHICS",
"       </h1>",
"       <div id=\"relatedGraphics\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          FIGURES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?26/28/27072\" title=\"figure 1\">",
"           Urinary tract anatomy PI",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f30_48_31491="Pierre Robin sequence";
var content_f30_48_31491=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F68928&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F68928&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Pierre Robin sequence",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 374px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A) The small, undershot chin and mandible give a birdlike facial appearance. The resultant inspiratory ball valve airway obstruction caused by glossoptosis within these tiny jaw confines made tracheostomy necessary. B) Isolated cleft palate.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Gold DH, MD, and Weingeist TA, MD, PhD. Color Atlas of the Eye in Systemic Disease. Baltimore: Lippincott Williams &amp; Wilkins, 2001. Copyright &copy;2001 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_48_31491=[""].join("\n");
var outline_f30_48_31491=null;
var title_f30_48_31492="Inverse psoriasis chest";
var content_f30_48_31492=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F78531&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F78531&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Inverse psoriasis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 278px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A well-defined erythematous plaque is present in the inframammary area.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Goodheart, HP. Goodheart's Photoguide of Common Skin Disorders, 2nd ed, Lippincott Williams &amp; Wilkins, Philadelphia 2003. Copyright &copy; 2003 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_48_31492=[""].join("\n");
var outline_f30_48_31492=null;
var title_f30_48_31493="Cyclospora infection";
var content_f30_48_31493=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Cyclospora infection",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/48/31493/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/48/31493/contributors\">",
"     Peter F Weller, MD, FACP",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/48/31493/contributors\">",
"     Karin Leder, MBBS, FRACP, PhD, MPH, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/48/31493/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/48/31493/contributors\">",
"     Edward T Ryan, MD, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/48/31493/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/48/31493/contributors\">",
"     Elinor L Baron, MD, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?30/48/31493/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 28, 2011.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cyclospora cayetanensis is a foodborne and waterborne parasitic cause of diarrheal illness in children and adults. Cyclospora can occur as a locally-acquired infection, among travelers or in patients with",
"    <span class=\"nowrap\">",
"     HIV/AIDS",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31493/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. The initial cases were noted in the 1980s when the AIDS epidemic emerged and Cryptosporidium was identified as an important opportunistic infection; initially, in some cases, Cyclospora oocysts observed on acid-fast stains were misidentified as Cryptosporidia.",
"   </p>",
"   <p>",
"    C. cayetanensis gained significant attention in the 1990s because of a large foodborne outbreaks associated with importation of fruits and vegetables from developing countries [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31493/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. Waterborne outbreaks have also been reported.",
"   </p>",
"   <p>",
"    Cyclospora is an intestinal coccidian that is recognized as a distinct protozoan genus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31493/abstract/1\">",
"     1",
"    </a>",
"    ]. Other coccidial organisms that can cause gastrointestinal infections in humans are Isospora belli, Cryptosporidium, Sarcocystis, and Toxoplasma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31493/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. (See related topics).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cyclospora cayetanensis has a broad geographic distribution. The organism is most frequently reported in Latin America, the Indian subcontinent, and Southeast Asia, and many of the cases reported elsewhere have been imported by international travellers or contaminated food [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31493/abstract/7-13\">",
"     7-13",
"    </a>",
"    ]. Illness due to Cyclospora has also been reported in the United States [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31493/abstract/14,15\">",
"     14,15",
"    </a>",
"    ], Canada [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31493/abstract/16\">",
"     16",
"    </a>",
"    ], Europe [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31493/abstract/17,18\">",
"     17,18",
"    </a>",
"    ], and the Caribbean [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31493/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Humans are the only natural hosts of C. cayetanensis; additional Cyclospora species that infect insectivores and rodents have been described [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31493/abstract/20\">",
"     20",
"    </a>",
"    ]. Risk factors for infection in endemic areas include contaminated water, food or soil, poor sanitation, and low socioeconomic status [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31493/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Increasing globalization of the fresh food supply and global travel have contributed to spread of C. cayetanensis to non-endemic areas [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31493/abstract/2,21\">",
"     2,21",
"    </a>",
"    ]. Outbreaks in 1995-1997 in the United States were traced to contaminated raspberries imported from Guatemala [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31493/abstract/3,4,22\">",
"     3,4,22",
"    </a>",
"    ]. Other garden produce has been linked to outbreaks. Basil seasoning in salads was implicated in two separate outbreaks in Missouri in 1999 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31493/abstract/23\">",
"     23",
"    </a>",
"    ], while an outbreak of cyclosporiasis associated with Guatemalan snow peas occurred in Pennsylvania in 2004 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31493/abstract/24\">",
"     24",
"    </a>",
"    ]. An outbreak of cyclosporiasis in Canada was linked with imported Thai basil [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31493/abstract/16\">",
"     16",
"    </a>",
"    ]. In a Vietnamese study, contamination with Cyclospora spp oocysts was observed in 11 percent of market herb and water samples and 8 percent of farm samples [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31493/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The Cyclospora oocyst is small and relatively chlorine insensitive, which facilitates waterborne spread. Soil-related transmission is also thought to occur [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31493/abstract/7,26\">",
"     7,26",
"    </a>",
"    ]. The role of animals as natural reservoirs is uncertain, and it is unclear whether zoonotic transmission occurs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31493/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4844379\">",
"    <span class=\"h1\">",
"     MICROBIOLOGY AND PATHOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;C. cayetanensis is an obligate intracellular parasite. Both asexual and sexual stages have been observed in hosts, suggesting that only a single human host is required to complete the entire lifecycle [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31493/abstract/27\">",
"     27",
"    </a>",
"    ]. Oocysts of C. cayetanensis passed in the feces are shed in a non-infective form and require several days before they become infectious. Thus, direct person-to-person transmission is not likely.",
"   </p>",
"   <p>",
"    Variable seasonal effects on cyclosporiasis have been observed; infection is often associated with the rainy season. It is unclear how Cyclospora oocysts become infectious in the environment or how infectious forms have contaminated produce [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31493/abstract/3\">",
"     3",
"    </a>",
"    ]. In the Guatemalan raspberry outbreak, it is likely that environmental contamination occurred, since the fruit came from a number of farms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31493/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A low infectious dose (10 to 100 organisms) is probably sufficient for infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31493/abstract/6\">",
"     6",
"    </a>",
"    ]. In the US outbreak that occurred with imported Guatemalan raspberries, the median attack rate was 92 percent among individuals who consumed raspberries; serving sizes were estimated between 1 and 12 berries.",
"   </p>",
"   <p>",
"    Small bowel biopsies in symptomatic patients have demonstrated several developmental forms of the parasite within epithelial cells. There is also jejunal inflammation with heightened numbers of intraepithelial lymphocytes and degrees of villous atrophy and crypt hyperplasia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31493/abstract/8,27\">",
"     8,27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Nucleotide sequence variability has been described, but no virulence factors of the organism have been identified.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cyclospora infection is characterized by anorexia, nausea, flatulence, fatigue, abdominal cramping, diarrhea, low-grade fever, and weight loss [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31493/abstract/1,7,8,21\">",
"     1,7,8,21",
"    </a>",
"    ]. The clinical presentation is somewhat different in endemic areas, where asymptomatic infections are more frequent, although more severe clinical symptoms occur in young children and the elderly [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31493/abstract/2\">",
"     2",
"    </a>",
"    ]. Infections tend to be milder as children get older, as the duration of the infection is shorter and the severity of disease decreases. In areas where Cyclospora is not endemic, infections are almost invariably symptomatic, and there are reports of severe clinical manifestations. Symptoms are more severe in patients with",
"    <span class=\"nowrap\">",
"     HIV/AIDS",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31493/abstract/19\">",
"     19",
"    </a>",
"    ], although asymptomatic Cyclospora infection in the setting of HIV has also been described [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31493/abstract/29\">",
"     29",
"    </a>",
"    ],",
"   </p>",
"   <p>",
"    The median incubation period is about seven days following ingestion before symptoms develop [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31493/abstract/3,30\">",
"     3,30",
"    </a>",
"    ]. Infected patients may have a single self-limited episode, or a prolonged waxing and waning course or sustained diarrhea, anorexia, and upper gastrointestinal symptoms lasting for weeks or months can occur [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31493/abstract/14,31\">",
"     14,31",
"    </a>",
"    ]. In one series, for example, the average duration of symptoms was more than three weeks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31493/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Biliary disease has been reported in association with Cyclospora infection. Acalculous cholecystitis has been described in patients with HIV, and resolved after initiation of treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31493/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Detection of oocysts in the stool of symptomatic patient is considered presumptive evidence of infection. Cyclospora cayetanensis oocysts can be detected by modified acid-fast staining of stool (8 to 10 microns in diameter) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31493/abstract/33\">",
"     33",
"    </a>",
"    ]. It is important to distinguish the Cyclospora oocysts from those of Cryptosporidium, which are also acid-fast but smaller (5 microns in diameter). Fluorescence microscopy can also be used for detection of oocysts, which are autofluorescent. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/40/13961?source=see_link&amp;anchor=H12#H12\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of cryptosporidiosis\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are no serologic assays available. PCR-based diagnostic tests have also been developed but are generally not widely available [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31493/abstract/21,34-37\">",
"     21,34-37",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of choice for cyclosporiasis in immunocompetent adults is",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/58/5034?source=see_link\">",
"     trimethoprim-sulfamethoxazole",
"    </a>",
"    (TMP-SMX; one double-strength 160",
"    <span class=\"nowrap\">",
"     mg/800",
"    </span>",
"    mg tablet orally twice daily) for 7 to 10 days. This was illustrated in a randomized trial including 40 adult expatriates in Nepal with Cyclospora infection; after seven days of therapy, Cyclospora was detected in stool less frequently among those treated with TMP-SMX than those treated with placebo (6 versus 88 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31493/abstract/31\">",
"     31",
"    </a>",
"    ]. Eradication of the organism correlated with clinical improvement, without relapse.",
"   </p>",
"   <p>",
"    Among patients with HIV infection, higher doses or longer courses of antibiotic therapy may be needed for effective treatment. Among 28 patients with HIV infection and Cyclospora infection in one series, all responded to treatment with oral TMP-SMX therapy; recurrent symptomatic disease within one month was observed in 43 percent of cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31493/abstract/19\">",
"     19",
"    </a>",
"    ]. These patients received TMP-SMX three times a week as secondary prophylaxis, with a single recurrence after seven months. The optimal dose and duration of TMP-SMX for patients with HIV infection and cyclosporiasis is uncertain; TMP-SMX (one double-strength 160",
"    <span class=\"nowrap\">",
"     mg/800",
"    </span>",
"    mg tablet orally four times a day) for up to three or four weeks has been suggested.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/45/35536?source=see_link\">",
"     Ciprofloxacin",
"    </a>",
"    may be used as an alternative therapy for patients with sulfa allergy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31493/abstract/38\">",
"     38",
"    </a>",
"    ]. This was illustrated in a randomized trial including 20 HIV-infected patients with C. cayetanensis treated with TMP-SMX (one double-strength 160",
"    <span class=\"nowrap\">",
"     mg/800",
"    </span>",
"    mg tablet) or ciprofloxacin (500 mg) orally twice daily for seven days [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31493/abstract/38\">",
"     38",
"    </a>",
"    ]. The response to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/58/5034?source=see_link\">",
"     trimethoprim-sulfamethoxazole",
"    </a>",
"    was superior to ciprofloxacin (at day 7 of therapy, 100 versus 90 percent with cessation of diarrhea; 100 versus 64 percent with a negative stool culture). Patients who responded clinically and microbiologically received prophylaxis for 10 weeks (1 tablet orally, three times per week); TMP-SMX was more effective than ciprofloxacin for secondary prophylaxis (100 versus 93 percent)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/24/5508?source=see_link\">",
"     Nitazoxanide",
"    </a>",
"    (500 mg twice daily for seven days) may be an acceptable alternative agent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31493/abstract/39-41\">",
"     39-41",
"    </a>",
"    ]. Other antibiotics, such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/43/33456?source=see_link\">",
"     azithromycin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/9/16536?source=see_link\">",
"     norfloxacin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/14/5349?source=see_link\">",
"     tinidazole",
"    </a>",
"    , nalidixic acid, and quinacrine have been evaluated without success [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31493/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4844824\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cyclospora cayetanensis is a foodborne and waterborne parasitic cause of diarrheal illness in children and adults. Cyclospora can occur as a locally-acquired infection, among travelers or in patients with",
"      <span class=\"nowrap\">",
"       HIV/AIDS.",
"      </span>",
"      Humans are the only natural hosts. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      C. cayetanensis is most frequently reported in Latin America, the Indian subcontinent, and Southeast Asia; many of the cases reported elsewhere have been imported by international travellers or contaminated food. Risk factors for infection in endemic areas include contaminated water, food or soil, poor sanitation and low socioeconomic status. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      C. cayetanensis is an obligate intracellular parasite. Oocysts of C. cayetanensis passed in the feces are shed in a non-infective form and require several days before they become infectious, so person-to-person transmission is not likely. A low infectious dose (10 to 100 organisms) is probably sufficient for infection. (See",
"      <a class=\"local\" href=\"#H4844379\">",
"       'Microbiology and pathology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Cyclospora infection is characterized by anorexia, nausea, flatulence, fatigue, abdominal cramping, diarrhea, low-grade fever, and weight loss. In endemic areas, asymptomatic infections are more frequent, although more severe clinical symptoms occur in young children and the elderly. The median incubation period is about seven days following ingestion before symptoms develop. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of cyclosporiasis is made by detection of oocysts stool (8 to 10 microns in diameter) on modified acid fast staining of stool. It is important to distinguish the Cyclospora oocysts from those of Cryptosporidium, which are also acid-fast but smaller (5 microns in diameter). (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?4/58/5034?source=see_link\">",
"       trimethoprim-sulfamethoxazole",
"      </a>",
"      (TMP-SMX; one double-strength 160",
"      <span class=\"nowrap\">",
"       mg/800",
"      </span>",
"      mg tablet orally twice daily for 7 to 10 days) for treatment of cyclosporiasis in immunocompetent hosts (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Among patients with HIV infection, higher doses or longer courses of antibiotic therapy may be needed for effective treatment.",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/45/35536?source=see_link\">",
"       Ciprofloxacin",
"      </a>",
"      is an acceptable alternative therapy for patients with sulfa allergy. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/48/31493/abstract/1\">",
"      Ortega YR, Sterling CR, Gilman RH, et al. Cyclospora species--a new protozoan pathogen of humans. N Engl J Med 1993; 328:1308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/48/31493/abstract/2\">",
"      Chac&iacute;n-Bonilla L. Epidemiology of Cyclospora cayetanensis: A review focusing in endemic areas. Acta Trop 2010; 115:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/48/31493/abstract/3\">",
"      Herwaldt BL, Ackers ML. An outbreak in 1996 of cyclosporiasis associated with imported raspberries. The Cyclospora Working Group. N Engl J Med 1997; 336:1548.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/48/31493/abstract/4\">",
"      Herwaldt BL. Cyclospora cayetanensis: a review, focusing on the outbreaks of cyclosporiasis in the 1990s. Clin Infect Dis 2000; 31:1040.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/48/31493/abstract/5\">",
"      Relman DA, Schmidt TM, Gajadhar A, et al. Molecular phylogenetic analysis of Cyclospora, the human intestinal pathogen, suggests that it is closely related to Eimeria species. J Infect Dis 1996; 173:440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/48/31493/abstract/6\">",
"      Pieniazek NJ, Herwaldt BL. Reevaluating the molecular taxonomy: is human-associated Cyclospora a mammalian Eimeria species? Emerg Infect Dis 1997; 3:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/48/31493/abstract/7\">",
"      Hoge CW, Shlim DR, Rajah R, et al. Epidemiology of diarrhoeal illness associated with coccidian-like organism among travellers and foreign residents in Nepal. Lancet 1993; 341:1175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/48/31493/abstract/8\">",
"      Bendall RP, Lucas S, Moody A, et al. Diarrhoea associated with cyanobacterium-like bodies: a new coccidian enteritis of man. Lancet 1993; 341:590.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/48/31493/abstract/9\">",
"      Madico G, McDonald J, Gilman RH, et al. Epidemiology and treatment of Cyclospora cayetanensis infection in Peruvian children. Clin Infect Dis 1997; 24:977.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/48/31493/abstract/10\">",
"      Lontie M, Degroote K, Michiels J, et al. Cyclospora sp.: a coccidian that causes diarrhoea in travellers. Acta Clin Belg 1995; 50:288.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/48/31493/abstract/11\">",
"      Petry F, Hofst&auml;tter J, Schulz BK, et al. Cyclospora cayetanensis: first imported infections in Germany. Infection 1997; 25:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/48/31493/abstract/12\">",
"      Crowley B, Path C, Moloney C, Keane CT. Cyclospora species--a cause of diarrhoea among Irish travellers to Asia. Ir Med J 1996; 89:110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/48/31493/abstract/13\">",
"      Kansouzidou A, Charitidou C, Varnis T, et al. Cyclospora cayetanensis in a patient with travelers' diarrhea: case report and review. J Travel Med 2004; 11:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/48/31493/abstract/14\">",
"      Huang P, Weber JT, Sosin DM, et al. The first reported outbreak of diarrheal illness associated with Cyclospora in the United States. Ann Intern Med 1995; 123:409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/48/31493/abstract/15\">",
"      Ooi WW, Zimmerman SK, Needham CA. Cyclospora species as a gastrointestinal pathogen in immunocompetent hosts. J Clin Microbiol 1995; 33:1267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/48/31493/abstract/16\">",
"      Hoang LM, Fyfe M, Ong C, et al. Outbreak of cyclosporiasis in British Columbia associated with imported Thai basil. Epidemiol Infect 2005; 133:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/48/31493/abstract/17\">",
"      Cann, KJ, Chalmers, RM, Nichols, G, O'Brien, SJ. Cyclospora infections in England and Wales: 1993 to 1998. Commun Dis Public Health 2000; 3:46.,.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/48/31493/abstract/18\">",
"      D&ouml;ller PC, Dietrich K, Filipp N, et al. Cyclosporiasis outbreak in Germany associated with the consumption of salad. Emerg Infect Dis 2002; 8:992.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/48/31493/abstract/19\">",
"      Pape JW, Verdier RI, Boncy M, et al. Cyclospora infection in adults infected with HIV. Clinical manifestations, treatment, and prophylaxis. Ann Intern Med 1994; 121:654.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/48/31493/abstract/20\">",
"      Eberhard ML, da Silva AJ, Lilley BG, Pieniazek NJ. Morphologic and molecular characterization of new Cyclospora species from Ethiopian monkeys: C. cercopitheci sp.n., C. colobi sp.n., and C. papionis sp.n. Emerg Infect Dis 1999; 5:651.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/48/31493/abstract/21\">",
"      Ortega YR, Sanchez R. Update on Cyclospora cayetanensis, a food-borne and waterborne parasite. Clin Microbiol Rev 2010; 23:218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/48/31493/abstract/22\">",
"      Ho, AY, Lopez, AS, Eberhart, MG, et al. Outbreak of cyclosporiasis associated with imported raspberries, Philadelphia, Pennsylvania, 2000. In: Emerg Infect Dis 2002; 8:783.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/48/31493/abstract/23\">",
"      Lopez AS, Dodson DR, Arrowood MJ, et al. Outbreak of cyclosporiasis associated with basil in Missouri in 1999. Clin Infect Dis 2001; 32:1010.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/48/31493/abstract/24\">",
"      Centers for Disease Control and Prevention (CDC). Outbreak of cyclosporiasis associated with snow peas--Pennsylvania, 2004. MMWR Morb Mortal Wkly Rep 2004; 53:876.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/48/31493/abstract/25\">",
"      Tram NT, Hoang LM, Cam PD, et al. Cyclospora spp. in herbs and water samples collected from markets and farms in Hanoi, Vietnam. Trop Med Int Health 2008; 13:1415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/48/31493/abstract/26\">",
"      Chac&iacute;n-Bonilla L. Transmission of Cyclospora cayetanensis infection: a review focusing on soil-borne cyclosporiasis. Trans R Soc Trop Med Hyg 2008; 102:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/48/31493/abstract/27\">",
"      Sun T, Ilardi CF, Asnis D, et al. Light and electron microscopic identification of Cyclospora species in the small intestine. Evidence of the presence of asexual life cycle in human host. Am J Clin Pathol 1996; 105:216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/48/31493/abstract/28\">",
"      Osterholm MT. Lessons learned again: cyclosporiasis and raspberries. Ann Intern Med 1999; 130:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/48/31493/abstract/29\">",
"      Maggi P, Brandonisio O, Larocca AM, et al. Cyclospora in AIDS patients: not always an agent of diarrhoic syndrome. New Microbiol 1995; 18:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/48/31493/abstract/30\">",
"      Fleming CA, Caron D, Gunn JE, Barry MA. A foodborne outbreak of Cyclospora cayetanensis at a wedding: clinical features and risk factors for illness. Arch Intern Med 1998; 158:1121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/48/31493/abstract/31\">",
"      Hoge CW, Shlim DR, Ghimire M, et al. Placebo-controlled trial of co-trimoxazole for Cyclospora infections among travellers and foreign residents in Nepal. Lancet 1995; 345:691.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/48/31493/abstract/32\">",
"      Sifuentes-Osornio J, Porras-Cort&eacute;s G, Bendall RP, et al. Cyclospora cayetanensis infection in patients with and without AIDS: biliary disease as another clinical manifestation. Clin Infect Dis 1995; 21:1092.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/48/31493/abstract/33\">",
"      Eberhard ML, Pieniazek NJ, Arrowood MJ. Laboratory diagnosis of Cyclospora infections. Arch Pathol Lab Med 1997; 121:792.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/48/31493/abstract/34\">",
"      Varma, M, Hester, JD, Schaefer, FW, et al. Detection of Cyclospora cayetanensis using a quantitative real-time PCR assay. In: J Microbiol Methods 2003; 53:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/48/31493/abstract/35\">",
"      Verweij JJ, Laeijendecker D, Brienen EA, et al. Detection of Cyclospora cayetanensis in travellers returning from the tropics and subtropics using microscopy and real-time PCR. Int J Med Microbiol 2003; 293:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/48/31493/abstract/36\">",
"      Lalonde LF, Gajadhar AA. Highly sensitive and specific PCR assay for reliable detection of Cyclospora cayetanensis oocysts. Appl Environ Microbiol 2008; 74:4354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/48/31493/abstract/37\">",
"      Mundaca CC, Torres-Slimming PA, Araujo-Castillo RV, et al. Use of PCR to improve diagnostic yield in an outbreak of cyclosporiasis in Lima, Peru. Trans R Soc Trop Med Hyg 2008; 102:712.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/48/31493/abstract/38\">",
"      Verdier RI, Fitzgerald DW, Johnson WD Jr, Pape JW. Trimethoprim-sulfamethoxazole compared with ciprofloxacin for treatment and prophylaxis of Isospora belli and Cyclospora cayetanensis infection in HIV-infected patients. A randomized, controlled trial. Ann Intern Med 2000; 132:885.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/48/31493/abstract/39\">",
"      Fox LM, Saravolatz LD. Nitazoxanide: a new thiazolide antiparasitic agent. Clin Infect Dis 2005; 40:1173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/48/31493/abstract/40\">",
"      Diaz E, Mondragon J, Ramirez E, Bernal R. Epidemiology and control of intestinal parasites with nitazoxanide in children in Mexico. Am J Trop Med Hyg 2003; 68:384.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/48/31493/abstract/41\">",
"      Zimmer SM, Schuetz AN, Franco-Paredes C. Efficacy of nitazoxanide for cyclosporiasis in patients with sulfa allergy. Clin Infect Dis 2007; 44:466.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5724 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-213.131.41.98-853D91569B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_48_31493=[""].join("\n");
var outline_f30_48_31493=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H4844824\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4844379\">",
"      MICROBIOLOGY AND PATHOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4844824\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/40/13961?source=related_link\">",
"      Epidemiology, clinical manifestations, and diagnosis of cryptosporidiosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f30_48_31494="Pseudomonas aeruginosa pneumonia";
var content_f30_48_31494=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Pseudomonas aeruginosa pneumonia",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/48/31494/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/48/31494/contributors\">",
"     Souha S Kanj, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/48/31494/contributors\">",
"     Daniel J Sexton, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/48/31494/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/48/31494/contributors\">",
"     Stephen B Calderwood, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/48/31494/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/48/31494/contributors\">",
"     Allyson Bloom, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?30/48/31494/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 6, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pseudomonas aeruginosa is one of the most important and most commonly considered pathogens in the differential diagnosis of gram-negative infections. Most strains of P. aeruginosa have multiple virulence factors that include exotoxins and enzymes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31494/abstract/1\">",
"     1",
"    </a>",
"    ]. P. aeruginosa also may produce biofilms that may protect the pathogen from the environment and the host&rsquo;s immune system [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31494/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    P. aeruginosa may cause infections in both immunocompromised and immunocompetent individuals. In either type of host, it may cause severe infection; it is especially feared by clinicians for its propensity to cause fatal nosocomial infections in immunocompromised hosts. Furthermore, P. aeruginosa is often resistant to commonly used antibiotics. Thus, the choice of empiric therapy for seriously ill patients is typically affected by whether P. aeruginosa is likely to be present.",
"   </p>",
"   <p>",
"    P. aeruginosa is a non-fermentative gram-negative aerobic rod that is ubiquitous in the environment and grows easily on a variety of media. A characteristic sweet grape-like odor, the elaboration of green pigment, and its oxidase-positive property are helpful in confirming its presence on culture plates. Occasionally, identification by laboratory personnel may be delayed because some isolates lack pigments or produce unusual characteristics such as a \"rotten-potato\" odor [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31494/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The epidemiology, clinical manifestations, diagnosis, and treatment of P. aeruginosa pneumonia will be reviewed here. The epidemiology, pathogenesis, and treatment of other P. aeruginosa infections are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/38/39528?source=see_link\">",
"     \"Treatment of Pseudomonas aeruginosa infections\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/32/27145?source=see_link&amp;anchor=H12#H12\">",
"     \"Epidemiology and pathogenesis of Pseudomonas aeruginosa infection\", section on 'Acute invasive P. aeruginosa infections'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/27/14775?source=see_link\">",
"     \"Pseudomonas aeruginosa bacteremia and endocarditis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/8/43142?source=see_link\">",
"     \"Pseudomonas aeruginosa skin, soft tissue, and bone infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Nosocomial pneumonia",
"    </span>",
"    &nbsp;&mdash;&nbsp;P. aeruginosa is a common cause of gram-negative nosocomial pneumonia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31494/abstract/4-8\">",
"     4-8",
"    </a>",
"    ]. This was illustrated in a prospective series of 556 patients in which P. aeruginosa was the most common gram-negative pathogen implicated in both hospital-acquired and ventilator-associated pneumonia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31494/abstract/4\">",
"     4",
"    </a>",
"    ]. In a large multicenter survey of gram-negative aerobic bacteria isolated from patients in intensive care units (ICUs) in the US, P. aeruginosa was the most commonly isolated gram-negative aerobic bacterium (23 percent) and was the most recurrent bacterium isolated from the respiratory tract (32 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31494/abstract/9\">",
"     9",
"    </a>",
"    ]. Nosocomial pneumonia can occur via aspiration of endogenous oral flora or via aspiration of organisms from contamination of ventilator tubing or other healthcare devices [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31494/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. Pulmonary infections due to P. aeruginosa may also arise hematogenously [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31494/abstract/12\">",
"     12",
"    </a>",
"    ]. P. aeruginosa is also an important cause of nosocomial tracheobronchitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31494/abstract/5\">",
"     5",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/57/12183?source=see_link\">",
"     \"Epidemiology, pathogenesis, microbiology, and diagnosis of hospital-acquired, ventilator-associated, and healthcare-associated pneumonia in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Pulmonary infections due to P. aeruginosa typically have high mortality rates [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31494/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Equipment-related nosocomial outbreaks",
"    </span>",
"    &nbsp;&mdash;&nbsp;Outbreaks of P. aeruginosa infection have been linked to contaminated healthcare equipment such as endoscopes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31494/abstract/14-16\">",
"     14-16",
"    </a>",
"    ]. Bronchoscope contamination has been linked to defective design, bronchoscope damage, and inadequate disinfection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31494/abstract/13\">",
"     13",
"    </a>",
"    ]. One outbreak related to defective bronchoscopes led to 32 cases of P. aeruginosa infections and three deaths prior to a voluntary recall of the endoscopes by the manufacturer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31494/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Community-acquired pneumonia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Community-acquired P. aeruginosa pneumonia occurs mainly in immunocompromised individuals (eg, HIV-infected patients, solid organ or hematopoietic cell transplant recipients, or neutropenic hosts), those with recent prior antibiotic use, and those with structural lung abnormalities such as cystic fibrosis, bronchiectasis, or repeated exacerbations of chronic obstructive pulmonary disease requiring frequent glucocorticoid",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    antibiotic use [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31494/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. Additional risk factors for community-acquired pneumonia (CAP) due to P. aeruginosa include history of recent hospitalization [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31494/abstract/18\">",
"     18",
"    </a>",
"    ], intubation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31494/abstract/19\">",
"     19",
"    </a>",
"    ], or enteral tube feeding [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31494/abstract/20\">",
"     20",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/45/27351?source=see_link\">",
"     \"Cystic fibrosis: Clinical manifestations of pulmonary disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    P. aeruginosa causes 5 to 7 percent of cases of CAP in HIV-infected patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31494/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. In one series of P. aeruginosa pneumonia in patients with HIV infection, 15 of 16 cases were community-acquired and 15 of 16 patients had AIDS with low CD4 cell counts [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31494/abstract/23\">",
"     23",
"    </a>",
"    ]. Other traditional risk factors for P. aeruginosa pulmonary infection were missing in most of these patients. Importantly, 11 of 16 patients either presented with or subsequently developed cavitary infiltrates.",
"   </p>",
"   <p>",
"    Person-to-person transmission of P. aeruginosa in the community is rare, but has been reported in a few isolated instances. As an example, household spread was documented when a daughter passed a P. aeruginosa strain to her mother, causing cavitary pneumonia and lung abscess; the two isolates were confirmed to be identical using pulsed-field gel electrophoresis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31494/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Occasionally, P. aeruginosa pneumonia occurs in previously healthy patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31494/abstract/25\">",
"     25",
"    </a>",
"    ]. As an example, one report described an isolated case of necrotizing P. aeruginosa pneumonia in an immunocompetent patient that was attributed to contact with a contaminated hot tub filter. This case highlights the importance of following the United States Centers for Disease Control and Prevention (CDC) guidelines for hot tub maintenance to prevent Pseudomonas overgrowth [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31494/abstract/26\">",
"     26",
"    </a>",
"    ]. In one study, P. aeruginosa pneumonia was responsible for 39 out of 559 cases of community-acquired pneumonia, although previous hospital admission and pulmonary comorbidity were predictive of the occurrence of this infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31494/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     CLINICAL, RADIOLOGIC, AND PATHOLOGIC FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;P. aeruginosa pneumonia is usually characterized by cough productive of purulent sputum, dyspnea, fever, chills, confusion, and severe systemic toxicity. None of these manifestations reliably distinguish this infection from pneumonia caused by other pyogenic organisms or Legionella.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Radiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Radiographic findings are variable and no single finding is predictive or characteristic of P. aeruginosa pneumonia. Diffuse bilateral infiltrates, with or without pleural effusion, may be present. Many patients have multifocal airspace consolidation. Other radiographic features include nodular infiltrates with tree-in-bud opacities and necrosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31494/abstract/27\">",
"     27",
"    </a>",
"    ]. Infiltrates in patients with pneumonia due to P. aeruginosa may also occur in a nodular pattern; occasionally, areas of radiolucency may be present. Classic lobar consolidation is uncommon.",
"   </p>",
"   <p>",
"    When P. aeruginosa pneumonia arises from hematogenous spread of the organism, early radiographic findings may include pulmonary congestion and interstitial edema. However, diffuse interstitial and alveolar infiltrates often develop 24 to 48 hours later in such patients. Large hemorrhagic nodules with central necrosis or cavities may rarely occur later in the course.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Pathology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Histopathologic changes in patients with pneumonia due to P. aeruginosa typically include microabscesses with focal hemorrhage, and necrosis of the alveolar septae without evidence of bacterial invasion of vessel walls or vascular necrosis. Pathologic changes in patients with pneumonia due to hematogenous spread usually include intraalveolar hemorrhage and necrosis around pulmonary vessels. Small (2 to 15 mm), firm, yellow-brown necrotic nodules with dark red hemorrhagic parenchyma may also be present along with liquefactive necrosis or bacterial invasion of the alveolar cell walls.",
"   </p>",
"   <p>",
"    One autopsy study of eight infants with P. aeruginosa pneumonia revealed two distinct histopathological patterns. Seven cases demonstrated evidence of a distinctive paucicellular coagulative confluent bronchopneumonia with perivascular bacillary infiltration. These changes occurred in immunocompromised patients with sepsis and rapid deterioration. The eighth case, a patient with an unusually protracted clinical course, had pathologic changes typical of bacterial pneumonia without evidence of perivascular organisms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31494/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Until antimicrobial susceptibility results are available, known or suspected cases of P. aeruginosa pneumonia should be initially treated with combination therapy that includes two antibiotics from different classes to which the isolate is likely to be susceptible. The evidence for combination versus monotherapy is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/38/39528?source=see_link&amp;anchor=H3#H3\">",
"     \"Treatment of Pseudomonas aeruginosa infections\", section on 'Combination versus monotherapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Guidelines",
"    </span>",
"    &nbsp;&mdash;&nbsp;Guidelines from the Infectious Diseases Society of America and the American Thoracic Society on the empiric management of community-acquired and hospital-acquired pneumonia recommend the following approach in patients who have risk factors for P. aeruginosa pneumonia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31494/abstract/17,29\">",
"     17,29",
"    </a>",
"    ]. Antimicrobial selection should also include consideration of local antimicrobial resistance patterns.",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      An antipseudomonal beta-lactam PLUS an antipseudomonal quinolone",
"     </li>",
"     <li>",
"      An antipseudomonal beta-lactam PLUS an aminoglycoside",
"     </li>",
"     <li>",
"      An antipseudomonal quinolone PLUS an aminoglycoside",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Antipseudomonal beta-lactams include",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/41/24216?source=see_link\">",
"     piperacillin-tazobactam",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/0/17415?source=see_link\">",
"     ceftazidime",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/33/16919?source=see_link\">",
"     cefepime",
"    </a>",
"    , imipenem, and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/38/32359?source=see_link\">",
"     meropenem",
"    </a>",
"    .",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/25/43414?source=see_link\">",
"     Aztreonam",
"    </a>",
"    may be substituted for one of these in the setting of penicillin allergy. Antipseudomonal quinolones include",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/45/35536?source=see_link\">",
"     ciprofloxacin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/46/33504?source=see_link\">",
"     levofloxacin",
"    </a>",
"    (750 mg dose). Antibiotic dosing for management of Pseudomonas is outlined in detail separately (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/38/39528?source=see_link\">",
"     \"Treatment of Pseudomonas aeruginosa infections\"",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Duration of therapy should be tailored to signs and symptoms of clinical improvement. We recommend treatment for at least two weeks; minimum treatment duration should be extended to three weeks in severely ill or neutropenic patients. The airway may remain colonized with Pseudomonas even in the setting of clinical response. Symptomatic improvement is a more important indicator than organism eradication for decisions regarding timing of antibiotic discontinuation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Controversies about therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some clinicians streamline empiric combination therapy to a single antibiotic after susceptibility results are available, whereas others continue combination therapy to minimize emergence of antimicrobial resistance. There are insufficient data to guide a consensus approach in this matter. In a multicenter study of 183 patients with ventilator-associated pneumonia due to P. aeruginosa, use of combination therapy or monotherapy tailored to susceptibility results did not influence mortality, length of stay, recurrent infection rate, or development of resistance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31494/abstract/30\">",
"     30",
"    </a>",
"    ]. In general, aminoglycosides should",
"    <strong>",
"     not",
"    </strong>",
"    be used as monotherapy for pneumonia because they perform poorly in an acidic environment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Salvage therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Alternative intravenous agents and inhaled antimicrobial therapy for treatment of Pseudomonas pneumonia are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/38/39528?source=see_link\">",
"     \"Treatment of Pseudomonas aeruginosa infections\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/63/36858?source=see_link&amp;anchor=H1077595#H1077595\">",
"     \"Treatment of hospital-acquired, ventilator-associated, and healthcare-associated pneumonia in adults\", section on 'Aerosolized antibiotics'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     OUTCOME AND PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;P. aeruginosa pneumonia is associated with high in-hospital mortality rates and prolonged lengths of stay [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31494/abstract/7\">",
"     7",
"    </a>",
"    ]. Injury to the alveolar epithelium allows the release of proinflammatory mediators into the circulation that are primarily responsible for septic shock [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31494/abstract/31\">",
"     31",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/10/24744?source=see_link\">",
"     \"Sepsis and the systemic inflammatory response syndrome: Definitions, epidemiology, and prognosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    P. aeruginosa pneumonia accompanied by P. aeruginosa bacteremia is associated with a particularly poor prognosis, with death occurring three to four days after the first signs of infection in the majority of cases.",
"   </p>",
"   <p>",
"    Other factors significantly associated with a poor prognosis include [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31494/abstract/7,32,33\">",
"     7,32,33",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Advanced age",
"     </li>",
"     <li>",
"      Serious underlying disease",
"     </li>",
"     <li>",
"      Septic shock",
"     </li>",
"     <li>",
"      Acute respiratory distress syndrome",
"     </li>",
"     <li>",
"      Previous surgery",
"     </li>",
"     <li>",
"      Use of broad-spectrum antibiotics in previous six months",
"     </li>",
"     <li>",
"      Multidrug-resistant organisms",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H469449585\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pseudomonas aeruginosa is one of the most important and most commonly considered pathogens in the differential diagnosis of gram-negative infections. P. aeruginosa is feared by clinicians because of its capability to cause severe or fatal nosocomial infections, especially in immunocompromised hosts. Furthermore, it is often resistant to commonly used antibiotics. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Nosocomial pneumonia can occur via aspiration of endogenous oral flora or via aspiration of organisms from contaminated ventilator tubing or other healthcare devices. It may also arise hematogenously. P. aeruginosa is a common cause of gram-negative nosocomial pneumonia. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Nosocomial pneumonia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Community-acquired P. aeruginosa pneumonia occurs mainly in immunocompromised patients (eg, HIV-infected patients, solid organ or stem cell transplant recipients, or neutropenic hosts), those with recent prior antibiotic use, and those with structural lung abnormalities such as cystic fibrosis, bronchiectasis, or repeated exacerbations of chronic obstructive pulmonary disease requiring frequent glucocorticoid",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      antibiotic use. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Community-acquired pneumonia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      P. aeruginosa pneumonia is usually characterized by cough productive of purulent sputum, dyspnea, fever, chills, confusion, and severe systemic toxicity. None of these manifestations firmly distinguish this infection from pneumonia caused by other pyogenic organisms or Legionella. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Clinical, radiologic, and pathologic features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Known or suspected P. aeruginosa pneumonia should be treated initially using combination therapy with two antibiotics from different classes to which the isolate is likely to be susceptible. Guidelines from the Infectious Diseases Society of America and the American Thoracic Society on the empiric management of community-acquired and hospital-acquired pneumonia recommend the following approach in patients who have risk factors for P. aeruginosa pneumonia. Antimicrobial selection should also include consideration of local antimicrobial resistance patterns:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      An antipseudomonal beta-lactam",
"      <strong>",
"       plus",
"      </strong>",
"      an antipseudomonal quinolone",
"     </li>",
"     <li>",
"      An antipseudomonal beta-lactam",
"      <strong>",
"       plus",
"      </strong>",
"      an aminoglycoside",
"     </li>",
"     <li>",
"      An antipseudomonal quinolone",
"      <strong>",
"       plus",
"      </strong>",
"      an aminoglycoside (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Some clinicians streamline empiric combination therapy to a single antibiotic after susceptibility results are available, whereas others continue combination therapy to minimize emergence of antimicrobial resistance. &nbsp;(See",
"      <a class=\"local\" href=\"#H9\">",
"       'Treatment'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H11\">",
"       'Controversies about therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      P. aeruginosa pneumonia is associated with high in-hospital mortality rates and prolonged lengths of stay. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Outcome and prognosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/48/31494/abstract/1\">",
"      Sadikot RT, Blackwell TS, Christman JW, Prince AS. Pathogen-host interactions in Pseudomonas aeruginosa pneumonia. Am J Respir Crit Care Med 2005; 171:1209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/48/31494/abstract/2\">",
"      Ma L, Conover M, Lu H, et al. Assembly and development of the Pseudomonas aeruginosa biofilm matrix. PLoS Pathog 2009; 5:e1000354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/48/31494/abstract/3\">",
"      Labarca JA, Pegues DA, Wagar EA, et al. Something's rotten: a nosocomial outbreak of malodorous Pseudomonas aeruginosa. Clin Infect Dis 1998; 26:1440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/48/31494/abstract/4\">",
"      Weber DJ, Rutala WA, Sickbert-Bennett EE, et al. Microbiology of ventilator-associated pneumonia compared with that of hospital-acquired pneumonia. Infect Control Hosp Epidemiol 2007; 28:825.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/48/31494/abstract/5\">",
"      Nseir S, Di Pompeo C, Pronnier P, et al. Nosocomial tracheobronchitis in mechanically ventilated patients: incidence, aetiology and outcome. Eur Respir J 2002; 20:1483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/48/31494/abstract/6\">",
"      Rello J, Quintana E, Ausina V, et al. Incidence, etiology, and outcome of nosocomial pneumonia in mechanically ventilated patients. Chest 1991; 100:439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/48/31494/abstract/7\">",
"      Crabtree TD, Gleason TG, Pruett TL, Sawyer RG. Trends in nosocomial pneumonia in surgical patients as we approach the 21st century: a prospective analysis. Am Surg 1999; 65:706.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/48/31494/abstract/8\">",
"      Gales AC, Sader H HS, Jones RN. Respiratory tract pathogens isolated from patients hospitalized with suspected pneumonia in Latin America: frequency of occurrence and antimicrobial susceptibility profile: results from the SENTRY Antimicrobial Surveillance Program (1997-2000). Diagn Microbiol Infect Dis 2002; 44:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/48/31494/abstract/9\">",
"      Neuhauser MM, Weinstein RA, Rydman R, et al. Antibiotic resistance among gram-negative bacilli in US intensive care units: implications for fluoroquinolone use. JAMA 2003; 289:885.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/48/31494/abstract/10\">",
"      Agodi A, Barchitta M, Cipresso R, et al. Pseudomonas aeruginosa carriage, colonization, and infection in ICU patients. Intensive Care Med 2007; 33:1155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/48/31494/abstract/11\">",
"      Vall&eacute;s J, Mariscal D, Cort&eacute;s P, et al. Patterns of colonization by Pseudomonas aeruginosa in intubated patients: a 3-year prospective study of 1,607 isolates using pulsed-field gel electrophoresis with implications for prevention of ventilator-associated pneumonia. Intensive Care Med 2004; 30:1768.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/48/31494/abstract/12\">",
"      Kumar PD, Ravakhah K, West BC. Disseminated Pseudomonas aeruginosa and necrotizing pneumonia with complete recovery. South Med J 2001; 94:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/48/31494/abstract/13\">",
"      Fujitani S, Sun HY, Yu VL, Weingarten JA. Pneumonia due to Pseudomonas aeruginosa: part I: epidemiology, clinical diagnosis, and source. Chest 2011; 139:909.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/48/31494/abstract/14\">",
"      Kirschke DL, Jones TF, Craig AS, et al. Pseudomonas aeruginosa and Serratia marcescens contamination associated with a manufacturing defect in bronchoscopes. N Engl J Med 2003; 348:214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/48/31494/abstract/15\">",
"      Srinivasan A, Wolfenden LL, Song X, et al. An outbreak of Pseudomonas aeruginosa infections associated with flexible bronchoscopes. N Engl J Med 2003; 348:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/48/31494/abstract/16\">",
"      Engelhart S, Krizek L, Glasmacher A, et al. Pseudomonas aeruginosa outbreak in a haematology-oncology unit associated with contaminated surface cleaning equipment. J Hosp Infect 2002; 52:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/48/31494/abstract/17\">",
"      Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007; 44 Suppl 2:S27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/48/31494/abstract/18\">",
"      Arancibia F, Bauer TT, Ewig S, et al. Community-acquired pneumonia due to gram-negative bacteria and pseudomonas aeruginosa: incidence, risk, and prognosis. Arch Intern Med 2002; 162:1849.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/48/31494/abstract/19\">",
"      Rello J, Rodriguez A, Torres A, et al. Implications of COPD in patients admitted to the intensive care unit by community-acquired pneumonia. Eur Respir J 2006; 27:1210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/48/31494/abstract/20\">",
"      von Baum H, Welte T, Marre R, et al. Community-acquired pneumonia through Enterobacteriaceae and Pseudomonas aeruginosa: Diagnosis, incidence and predictors. Eur Respir J 2010; 35:598.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/48/31494/abstract/21\">",
"      L&oacute;pez-Palomo C, Mart&iacute;n-Zamorano M, Ben&iacute;tez E, et al. Pneumonia in HIV-infected patients in the HAART era: incidence, risk, and impact of the pneumococcal vaccination. J Med Virol 2004; 72:517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/48/31494/abstract/22\">",
"      Madeddu G, Porqueddu EM, Cambosu F, et al. Bacterial community acquired pneumonia in HIV-infected inpatients in the highly active antiretroviral therapy era. Infection 2008; 36:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/48/31494/abstract/23\">",
"      Schuster MG, Norris AH. Community-acquired Pseudomonas aeruginosa pneumonia in patients with HIV infection. AIDS 1994; 8:1437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/48/31494/abstract/24\">",
"      Patel P, Whittier S, Frank E. Person-to-person transmission of Pseudomonas pneumonia in the community: documentation by pulsed-field electrophoresis. South Med J 2002; 95:653.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/48/31494/abstract/25\">",
"      Henderson A, Kelly W, Wright M. Fulminant primary Pseudomonas aeruginosa pneumonia and septicaemia in previously well adults. Intensive Care Med 1992; 18:430.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/48/31494/abstract/26\">",
"      Crnich CJ, Gordon B, Andes D. Hot tub-associated necrotizing pneumonia due to Pseudomonas aeruginosa. Clin Infect Dis 2003; 36:e55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/48/31494/abstract/27\">",
"      Shah RM, Wechsler R, Salazar AM, Spirn PW. Spectrum of CT findings in nosocomial Pseudomonas aeruginosa pneumonia. J Thorac Imaging 2002; 17:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/48/31494/abstract/28\">",
"      Bonifacio SL, Kitterman JA, Ursell PC. Pseudomonas pneumonia in infants: an autopsy study. Hum Pathol 2003; 34:929.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/48/31494/abstract/29\">",
"      American Thoracic Society, Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005; 171:388.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/48/31494/abstract/30\">",
"      Garnacho-Montero J, Sa-Borges M, Sole-Violan J, et al. Optimal management therapy for Pseudomonas aeruginosa ventilator-associated pneumonia: an observational, multicenter study comparing monotherapy with combination antibiotic therapy. Crit Care Med 2007; 35:1888.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/48/31494/abstract/31\">",
"      Kurahashi K, Kajikawa O, Sawa T, et al. Pathogenesis of septic shock in Pseudomonas aeruginosa pneumonia. J Clin Invest 1999; 104:743.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/48/31494/abstract/32\">",
"      Mart&iacute;nez B, G&oacute;mez J, G&oacute;mez Vargas J, et al. [Risk factors and prognosis of nosocomial pneumonia due to gram-negative bacteria in a general hospital]. Rev Esp Quimioter 2000; 13:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/48/31494/abstract/33\">",
"      Wang CY, Jerng JS, Chen KY, et al. Pandrug-resistant Pseudomonas aeruginosa among hospitalised patients: clinical features, risk-factors and outcomes. Clin Microbiol Infect 2006; 12:63.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3133 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-27.109.116.13-83254367CA-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_48_31494=[""].join("\n");
var outline_f30_48_31494=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H469449585\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Nosocomial pneumonia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Equipment-related nosocomial outbreaks",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Community-acquired pneumonia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      CLINICAL, RADIOLOGIC, AND PATHOLOGIC FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Radiology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Pathology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Guidelines",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Controversies about therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Salvage therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      OUTCOME AND PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H469449585\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/45/27351?source=related_link\">",
"      Cystic fibrosis: Clinical manifestations of pulmonary disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/32/27145?source=related_link\">",
"      Epidemiology and pathogenesis of Pseudomonas aeruginosa infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/57/12183?source=related_link\">",
"      Epidemiology, pathogenesis, microbiology, and diagnosis of hospital-acquired, ventilator-associated, and healthcare-associated pneumonia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/27/14775?source=related_link\">",
"      Pseudomonas aeruginosa bacteremia and endocarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/8/43142?source=related_link\">",
"      Pseudomonas aeruginosa skin, soft tissue, and bone infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/10/24744?source=related_link\">",
"      Sepsis and the systemic inflammatory response syndrome: Definitions, epidemiology, and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/38/39528?source=related_link\">",
"      Treatment of Pseudomonas aeruginosa infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/63/36858?source=related_link\">",
"      Treatment of hospital-acquired, ventilator-associated, and healthcare-associated pneumonia in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f30_48_31495="Wuchereria life cycle";
var content_f30_48_31495=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F74534&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F74534&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 588px\">",
"   <div class=\"ttl\">",
"    Wuchereria life cycle",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 568px; height: 467px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Different species of the following genera of mosquitoes are vectors of",
"    <em>",
"     W. bancrofti",
"    </em>",
"    filariasis depending on geographical distribution. Among them are:",
"    <em>",
"     Culex",
"    </em>",
"    (",
"    <em>",
"     C. annulirostris",
"    </em>",
"    ,",
"    <em>",
"     C. bitaeniorhynchus",
"    </em>",
"    ,",
"    <em>",
"     C. quinquefasciatus",
"    </em>",
"    , and",
"    <em>",
"     C. pipiens",
"    </em>",
"    );",
"    <em>",
"     Anopheles",
"    </em>",
"    (",
"    <em>",
"     A. arabinensis",
"    </em>",
"    ,",
"    <em>",
"     A. bancroftii",
"    </em>",
"    ,",
"    <em>",
"     A. farauti",
"    </em>",
"    ,",
"    <em>",
"     A. funestus",
"    </em>",
"    ,",
"    <em>",
"     A. gambiae",
"    </em>",
"    ,",
"    <em>",
"     A. koliensis",
"    </em>",
"    ,",
"    <em>",
"     A. melas",
"    </em>",
"    ,",
"    <em>",
"     A. merus",
"    </em>",
"    ,",
"    <em>",
"     A. punctulatus",
"    </em>",
"    , and",
"    <em>",
"     A. wellcomei",
"    </em>",
"    );",
"    <em>",
"     Aedes",
"    </em>",
"    (",
"    <em>",
"     A. aegypti",
"    </em>",
"    ,",
"    <em>",
"     A. aquasalis",
"    </em>",
"    ,",
"    <em>",
"     A. bellator",
"    </em>",
"    ,",
"    <em>",
"     A. cooki",
"    </em>",
"    ,",
"    <em>",
"     A. darlingi",
"    </em>",
"    ,",
"    <em>",
"     A. kochi",
"    </em>",
"    ,",
"    <em>",
"     A. polynesiensis",
"    </em>",
"    ,",
"    <em>",
"     A. pseudoscutellaris",
"    </em>",
"    ,",
"    <em>",
"     A. rotumae",
"    </em>",
"    ,",
"    <em>",
"     A. scapularis",
"    </em>",
"    , and",
"    <em>",
"     A. vigilax",
"    </em>",
"    );",
"    <em>",
"     Mansonia",
"    </em>",
"    (",
"    <em>",
"     M. pseudotitillans",
"    </em>",
"    ,",
"    <em>",
"     M. uniformis",
"    </em>",
"    );",
"    <em>",
"     Coquillettidia",
"    </em>",
"    (",
"    <em>",
"     C. juxtamansonia",
"    </em>",
"    ). During a blood meal, an infected mosquito introduces third-stage filarial larvae onto the skin of the human host, where they penetrate into the bite wound",
"    <strong>",
"     (1)",
"    </strong>",
"    . They develop in adults that commonly reside in the lymphatics",
"    <strong>",
"     (2)",
"    </strong>",
"    . The female worms measure 80 to 100 mm in length and 0.24 to 0.30 mm in diameter, while the males measure about 40 mm by .1 mm. Adults produce microfilariae measuring 244 to 296 &micro;m by 7.5 to 10 &micro;m, which are sheathed and have nocturnal periodicity, except the South Pacific microfilariae, which have the absence of marked periodicity. The microfilariae migrate into lymph and blood channels moving actively through lymph and blood",
"    <strong>",
"     (3)",
"    </strong>",
"    . A mosquito ingests the microfilariae during a blood meal",
"    <strong>",
"     (4)",
"    </strong>",
"    . After ingestion, the microfilariae lose their sheaths and some of them work their way through the wall of the proventriculus and cardiac portion of the mosquito's midgut and reach the thoracic muscles",
"    <strong>",
"     (5)",
"    </strong>",
"    . There the microfilariae develop into first-stage larvae",
"    <strong>",
"     (6)",
"    </strong>",
"    and subsequently into third-stage infective larvae",
"    <strong>",
"     (7)",
"    </strong>",
"    . The third-stage infective larvae migrate through the hemocoel to the mosquito's proboscis",
"    <strong>",
"     (8)",
"    </strong>",
"    and can infect another human when the mosquito takes a blood meal",
"    <strong>",
"     (1)",
"    </strong>",
"    .",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Centers for Disease Control and Prevention. Parasites and Health: Filariasis. Available at:",
"     <a href=\"file://dpd.cdc.gov/dpdx/html/Filariasis.htm\" target=\"_blank\">",
"      file://dpd.cdc.gov/dpdx/html/Filariasis.htm",
"     </a>",
"     .",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_48_31495=[""].join("\n");
var outline_f30_48_31495=null;
var title_f30_48_31496="Chinese herbal medicine for the treatment of allergic diseases";
var content_f30_48_31496=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Chinese herbal medicine for the treatment of allergic diseases",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/48/31496/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/48/31496/contributors\">",
"     Xiu-Min Li, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/48/31496/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/48/31496/contributors\">",
"     Scott H Sicherer, MD, FAAAAI",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/48/31496/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/48/31496/contributors\">",
"     Elizabeth TePas, MD, MS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?30/48/31496/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 21, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Traditional Chinese medicine (TCM) includes herbal therapy, acupuncture, massage, and dietary therapy. These practices originated in China and have been used in East Asia for centuries as a part of mainstream medical care. TCM is beginning to play a role in Western healthcare as a complementary and alternative medicine (CAM).",
"   </p>",
"   <p>",
"    This topic will discuss Chinese herbal therapy for asthma, atopic dermatitis, and food allergy. These therapies are considered experimental from the standpoint of conventional medicine. Overviews of herbal medicine and use of CAM in pediatrics are presented separately. Acupuncture for the treatment of asthma and allergic rhinitis is also discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/4/20554?source=see_link\">",
"     \"Overview of herbal medicine and dietary supplements\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/44/35529?source=see_link\">",
"     \"Overview of complementary and alternative medicine in pediatrics\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/36/33354?source=see_link&amp;anchor=H24#H24\">",
"     \"Alternative and experimental agents for the treatment of asthma\", section on 'Acupuncture'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/60/37834?source=see_link&amp;anchor=H25107508#H25107508\">",
"     \"Pharmacotherapy of allergic rhinitis\", section on 'Adjunctive and other therapies'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     OVERVIEW",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prevalence of allergic disorders such as asthma, atopic dermatitis, and food allergy has increased dramatically in industrialized countries over the past several decades. Atopic diseases are a serious public health problem, particularly in children. Conventional therapies, such as glucocorticoids, are widely used in controlling asthma and atopic dermatitis. However, these therapies are not completely effective in all patients, and there are concerns about side effects, especially in children. In addition, there is no curative treatment for food allergy, just rescue treatment of reactions. These and other issues have led patients and their families to seek complementary and alternative medicine (CAM) treatments.",
"   </p>",
"   <p>",
"    Traditional Chinese medicine (TCM) has a long history of use in China and other Asian countries, such as Japan and Korea. TCM has several features that differ significantly from Western medicine:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      TCM practice does not focus only on the disease or a single organ. Rather, it also focuses on establishing and maintaining the balance of yin-yang (two opposite, but complementary forces), the homeostasis of organ systems in the body, and interactions with the environment [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/48/31496/abstract/1\">",
"       1",
"      </a>",
"      ]. The concepts and terminology of TCM cannot be easily translated to Western medicine.",
"     </li>",
"     <li>",
"      Treatment is customized for each patient. As an example, a Chinese herbal formulation is a mixture of many herbs. The practitioner starts with one or two main ingredients that target the illness. Additional ingredients are included depending upon the patient's particular yin-yang conditions and possible need for a catalyst that makes the other components effective or an antidote that cancels out negative effects of other ingredients. Thus, the formulation used to treat a particular disease varies from patient to patient and even for an individual patient depending upon their changing needs.",
"     </li>",
"     <li>",
"      TCM has not been rigorously evaluated in randomized clinical trials. Sham acupuncture is difficult to perform, for example. In addition, the content of herbal formulations is often not standardized, and even if it is, the quality and pharmacologic activity of individual herbs in the formulation can vary.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Practitioners of Western medicine have tended to avoid recommending use of TCM, particularly herbal therapies, for a number of reasons:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Western practitioners are unfamiliar with these therapeutic methods because they are not included in conventional medical training in Western countries.",
"     </li>",
"     <li>",
"      The mechanisms of action of TCM are largely unknown, despite extensive clinical experience with these modalities in Asia.",
"     </li>",
"     <li>",
"      Randomized trials of TCM are lacking. In addition, studies published in Chinese are usually not translated into English or other languages, with the possible exception of the abstract.",
"     </li>",
"     <li>",
"      Herbal therapies are not standardized, nor are the quality of the components consistent.",
"     </li>",
"     <li>",
"      Knowledge about side effects and drug-herb interactions is limited.",
"     </li>",
"     <li>",
"      Herbal therapies may contain undeclared conventional pharmaceuticals or heavy metal contaminants.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In the United States, the National Institutes of Health (NIH) National Center for Complementary and Alternative Medicine (NCCAM) supports clinical and basic research on CAM to help eliminate some of the gaps in knowledge about these therapies. In addition, the National Committee of Acupuncture and Oriental Medicine offers a certificate in Chinese Herbology to increase the quality of practice of Chinese herbal medicine.",
"   </p>",
"   <p>",
"    Chinese herbal medicines are a major component in TCM practice, and are prescribed in China both as monotherapy and in combination with conventional (Western) medicine. In the United States, Chinese herbs are categorized as dietary supplements by the Food and Drug Administration (FDA). As such, the efficacy, safety, and quality of these products do not need to be proven, nor do postmarketing adverse events need to be reported. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/4/20554?source=see_link\">",
"     \"Overview of herbal medicine and dietary supplements\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The United States FDA has issued guidelines for investigation of botanical drug products, including complex formulas that contain several herbs, focusing on efficacy, safety, and consistency [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31496/abstract/2\">",
"     2",
"    </a>",
"    ]. Thus, TCM products currently used as dietary supplements may be investigated as new botanical drugs. One of the major differences in FDA requirements for investigation of synthetic versus botanical drugs is the Chemical, Manufacturing, and Control (CMC) Data requirement for new botanical drugs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31496/abstract/2\">",
"     2",
"    </a>",
"    ]. Quality and safety data must be supplied at three levels (raw herbs, extracts, and final product) for botanical drugs.",
"   </p>",
"   <p>",
"    TCM views allergic disease as resulting from the loss of homeostasis in interactions between human organs, such as the lungs, skin, and gut, with the environment, and foods. Asthma, allergic rhinitis, and atopic dermatitis are well documented in TCM literature. There are many widely used formulas for these disorders, although they have not been well-studied [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31496/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. Food allergy has not been reported in the TCM literature.",
"   </p>",
"   <p>",
"    Research into the efficacy and safety of several herbal formulas for asthma and atopic dermatitis using standard methods is being actively pursued in some Western medical centers, and an herbal intervention for food allergy has been derived from TCM [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31496/abstract/5\">",
"     5",
"    </a>",
"    ]. Standardization of these formulas is challenging because they contain many herbs and the active components are not clearly defined. Thus, the quality, potency, and consistency of formulas are standardized by using high performance liquid chromatography (HPLC) fingerprinting of the molecular components. Chemical markers are also identified by liquid chromatography coupled with mass spectrometry.",
"   </p>",
"   <p>",
"    Consistent quality of each individual raw herb is key for reproducibility of efficacy of herbal therapies. Factors that affect quality include authenticity, geographic location, harvest time, preprocessing methods, and storage, according to the Pharmacopoeia of Peoples Republic of China [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31496/abstract/3\">",
"     3",
"    </a>",
"    ]. Standard manufacturing procedure is important to further ensure the consistency and quality of the final product. Safety testing of the final product includes evaluation for contamination with heavy metals, and pesticide and microbial limit testing. In addition, biologic analysis, including in vitro and in vivo models that represent asthma and food allergy, may be employed to ensure safety and efficacy prior to human clinical use. This combined approach has yielded satisfactory product quality control of ASHMI and FAHF-2 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31496/abstract/5-7\">",
"     5-7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     THERAPY FOR ASTHMA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chinese herbs have been used for centuries in Asia to treat asthma. There is increasing scientific evidence to support the use of TCM herbal therapy for asthma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31496/abstract/8\">",
"     8",
"    </a>",
"    ]. Randomized trials of TCM herbal formulas for asthma have been published in the English-language literature [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31496/abstract/9\">",
"     9",
"    </a>",
"    ], including modified Mai Men Dong Tang (mMMDT) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31496/abstract/10\">",
"     10",
"    </a>",
"    ], Ding Chuan Tang (DCT) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31496/abstract/11\">",
"     11",
"    </a>",
"    ], STA-1 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31496/abstract/12\">",
"     12",
"    </a>",
"    ], and antiasthma herbal medicine intervention (ASHMI) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31496/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. ASHMI has received investigational new drug approval in the United States. The other formulas have only been studied in China.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Antiasthma herbal medicine intervention (ASHMI) formula",
"    </span>",
"    &nbsp;&mdash;&nbsp;ASHMI is a simplified formulation of the herbal formula MSSM-002 (original name MTSD) that contained 14 herbs. The modified formula contains only three herbs: Ling-Zhi (Ganoderma lucidum), Ku-Shen (Sophorae flavescentis), and Gan-Cao (Glycyrrhiza uralensis). Preliminary data suggest that ASHMI is safe and effective either as monotherapy or complementary therapy to standard treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Indications for use",
"    </span>",
"    &nbsp;&mdash;&nbsp;ASHMI has been studied in adults with moderate-to-severe persistent asthma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31496/abstract/13\">",
"     13",
"    </a>",
"    ], and in children with persistent asthma, with or without allergic rhinitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31496/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Clinical response",
"    </span>",
"    &nbsp;&mdash;&nbsp;The first randomized trial of ASHMI investigated the efficacy and tolerability of the formula compared with oral",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    therapy in 92 patients 18 to 60 years of age with moderate-to-severe asthma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31496/abstract/13\">",
"     13",
"    </a>",
"    ]. Patients in China were randomized 1:1 to receive ASHMI 3.6 g or prednisone 20 mg daily for four weeks. One patient (ASHMI group) withdrew from the study during the last week of treatment. This study found that ASHMI was nearly equivalent to prednisone in improving post-treatment lung function (forced expiratory volume in one second, FEV1, and peak expiratory flow values) and reducing symptoms and inhaled beta 2-agonist use.",
"   </p>",
"   <p>",
"    The second randomized trial of ASHMI performed in China examined the safety, tolerability, and immunologic effects of standard therapy alone versus standard therapy plus ASHMI in children 5 to 14 years of age with persistent asthma, with or without allergic rhinitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31496/abstract/14\">",
"     14",
"    </a>",
"    ]. Subjects received an inhaled glucocorticoid (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/7/32880?source=see_link\">",
"     budesonide",
"    </a>",
"    ) plus ASHMI (complementary ASHMI group, n = 28) or inhaled glucocorticoid plus placebo (standard group, n = 28) for three months. Both standard and ASHMI plus standard treatment groups had significantly improved lung function (FEV1) and clinical symptoms. The improvement in symptom scores, particularly nasal symptoms, was greater in the complementary ASHMI group than in the standard group.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Immunologic response",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both ASHMI and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    decreased peripheral blood eosinophils, serum IgE, and Th2 cytokine (IL-5 and IL-13) levels [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31496/abstract/13\">",
"     13",
"    </a>",
"    ]. Inhibition was greater in the prednisone group. However, ASHMI increased IFN-gamma secretion, unlike prednisone, which suppressed IFN-gamma secretion. Patients treated with both ASHMI and inhaled glucocorticoids showed significantly greater reduction of serum total IgE and serum eosinophil cationic protein, and higher serum levels of IFN-gamma after three months of treatment compared with children treated with standard therapy alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31496/abstract/14\">",
"     14",
"    </a>",
"    ]. In a mouse model, antigen-induced airway hyperresponsiveness and pulmonary eosinophilic inflammation were almost completely abrogated after treatment with ASHMI [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31496/abstract/15\">",
"     15",
"    </a>",
"    ]. In this model, the effects were eliminated by the neutralization of IFN-gamma, but not TGF-beta, during therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Enhanced adrenal function",
"    </span>",
"    &nbsp;&mdash;&nbsp;Glucocorticoid-induced suppression of the hypothalamic-pituitary-adrenal axis, marked by depressed cortisol levels, is an adverse side effect of systemic glucocorticoid use [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31496/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. In contrast, a beneficial effect of ASHMI treatment on adrenal function was found in one randomized trial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31496/abstract/13\">",
"     13",
"    </a>",
"    ]. Pretreatment cortisol levels were slightly below normal in both groups. After treatment, subjects in the",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    treatment group showed a significant reduction in serum cortisol levels after treatment. Conversely, patients in the ASHMI treatment group showed increased levels of serum cortisol within the normal range. Thus, ASHMI restored adrenal homeostasis. This effect may be attributed to glycyrrhizin (a component of Gan-Cao), which affects the conversion of cortisol to cortisone by inhibition of 11-beta-hydroxysteroid dehydrogenase enzyme activity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31496/abstract/2\">",
"     2",
"    </a>",
"    ]. Gan-Cao has been used for treatment of adrenal insufficiency [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31496/abstract/18\">",
"     18",
"    </a>",
"    ]. However, it is also possible that the increase in cortisol levels is due to the lack of suppression of adrenal function. Further research is required to understand the precise mechanisms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Possible mechanisms of action",
"    </span>",
"    &nbsp;&mdash;&nbsp;Potential mechanisms of action of ASHMI have been suggested by studies in murine models of asthma. ASHMI exhibits a broad spectrum of therapeutic effects on the major pathogenic mechanisms of asthma. ASHMI blocks the IgE-mediated early-phase airway response, airway hyperreactivity, pulmonary inflammation, and airway remodeling [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31496/abstract/7,19,20\">",
"     7,19,20",
"    </a>",
"    ]. These changes are accompanied by down regulation of Th2 responses and reduced histamine and leukotriene release. ASHMI also appears to directly modulate airway smooth muscle contraction by a beta 2-adrenergic receptor-independent mechanism that is associated with increased prostaglandin I2, a potent muscle relaxer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31496/abstract/7\">",
"     7",
"    </a>",
"    ]. Flavonoids in Gan-Cao inhibit eotaxin production by human fetal lung fibroblasts [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31496/abstract/21\">",
"     21",
"    </a>",
"    ]. Ku-Shen triterpenes suppress of IgE production [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31496/abstract/22\">",
"     22",
"    </a>",
"    ] and airway smooth muscle contraction (unpublished data). The possibility that several active compounds in ASHMI work synergistically in producing multiple actions relevant to asthma mechanisms requires further investigation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Side effects and interactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the study of ASHMI used as monotherapy compared with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    , all hematologic, electrocardiogram, and liver and kidney function test results were normal in both groups [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31496/abstract/13\">",
"     13",
"    </a>",
"    ]. ASHMI had no significant effect on body weight (0.8 kg increase) as compared with prednisone (2.8 kg increase). Gastric discomfort was experienced by 7 percent of patients in the ASHMI group compared with 20 percent in the prednisone group. In the pediatric study of ASHMI used in combination with an inhaled glucocorticoid versus glucocorticoid alone, no abnormalities in liver or kidney function were detected [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31496/abstract/14\">",
"     14",
"    </a>",
"    ]. No drug interactions were observed.",
"   </p>",
"   <p>",
"    The two studies discussed above were performed in China. A phase I dose escalation study was subsequently conducted in the United States [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31496/abstract/6\">",
"     6",
"    </a>",
"    ]. Twenty atopic subjects with asthma received placebo or one of three doses of ASHMI (600 mg, 1200 mg, or 1800 mg) twice daily for one week. Four active and two placebo subjects were treated at each dose level. Subjects continued to use their conventional asthma medications for the duration of the study. Eight subjects (four ASHMI and four placebo) reported mild gastrointestinal symptoms. Vital signs, laboratory studies, and electrocardiogram findings were all within normal limits at pre- and post-treatment visits. No serious adverse events were reported.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Modified Mai Men Dong Tang (mMMDT) formula",
"    </span>",
"    &nbsp;&mdash;&nbsp;Modified Mai Men Dong Tang (mMMDT) contains five herbs: Ophiopogon japonicus, Panax quinquefolium (ginseng), Pinellia ternata, Glycyrrhizae uralensis (licorice), and Tridax procumbens.",
"   </p>",
"   <p>",
"    mMMDT was studied in 100 atopic children aged 5 to 18 years with mild-to-moderate persistent asthma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31496/abstract/10\">",
"     10",
"    </a>",
"    ]. Patients were randomized 2:2:1 to mMMDT 40 or 80",
"    <span class=\"nowrap\">",
"     mg/kg/day",
"    </span>",
"    or placebo capsules daily for four months. In addition, patients were treated as needed with a number of conventional asthma medications, including",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/61/16344?source=see_link\">",
"     albuterol",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/31/30200?source=see_link\">",
"     theophylline",
"    </a>",
"    , cromolyn,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/7/33904?source=see_link\">",
"     beclomethasone",
"    </a>",
"    , and oral glucocorticoids. About 20 percent of patients withdrew from the study, none due to adverse events. Intention to treat analysis was not used. There were significant improvements in FEV1 and asthma symptom scores in the two treatment groups after four months of therapy relative to baseline measurements. No improvement in FEV1 or symptom score was seen in the placebo group. No serious adverse events were reported, and all laboratory measurements, including complete blood count and liver and kidney function tests, were within normal limits.",
"   </p>",
"   <p>",
"    Potential mechanisms of action of several of the herb components include effects on steroid metabolism (licorice) and immunomodulatory effects (ginseng) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31496/abstract/10\">",
"     10",
"    </a>",
"    ]. Further investigations are needed to confirm the findings of this study, determine which of the herbs are essential, and clarify the underlying mechanisms of action.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     STA-1 formula",
"    </span>",
"    &nbsp;&mdash;&nbsp;STA is a combination of two formulas, Mai Men Dong Tang (MMDT) and Lui Wei Di Huang Wan (LWDHW). MMDT contains Ophiopogon japonicus, Pinellia ternata, Panax quinquefolium, and Glycyrrhiza uralensis. LWDHW is comprised of Rehmannia glutinosa, Paeonia suffruticosa, Cornus officinalis, Poria cocos, Alisma orientalis, and Dioscorea opposite. STA-1 was made with crude drug powder of LWDHW and STAT-2 with a decoction (extraction by boiling of herbal material) of LWDHW.",
"   </p>",
"   <p>",
"    STA-1 was studied in 120 atopic patients aged 5 to 20 years with mild-to-moderate asthma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31496/abstract/12\">",
"     12",
"    </a>",
"    ]. Patients were randomized to STA-1 or STA-2 (n = 50 each, both 80",
"    <span class=\"nowrap\">",
"     g/kg/day)",
"    </span>",
"    or placebo (n = 20) daily for six months. In addition, patients were treated as needed with a number of conventional asthma medications, including",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/61/16344?source=see_link\">",
"     albuterol",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/31/30200?source=see_link\">",
"     theophylline",
"    </a>",
"    , cromolyn,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/7/33904?source=see_link\">",
"     beclomethasone",
"    </a>",
"    , and oral glucocorticoids. Twenty patients withdrew from the study. Intention to treat analysis was not used. Patients treated with STA-1 had improved symptoms scores, increased lung function (FEV1), less systemic glucocorticoid treatment, and decreased total and dust mite-specific IgE compared with baseline. Improved symptom control was also seen in patients treated with STA-2, but no other significant changes were found in the STA-2 group or placebo group. No adverse events were reported.",
"   </p>",
"   <p>",
"    LWDHW and a number of the individual components have been shown to have antiinflammatory and antiallergic properties. Further studies are needed to confirm the findings from this one study that had some methodologic issues, and to determine the active components and their exact mechanisms of action.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Ding Chuan Tang (DCT) formula",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ding Chuan Tang (DCT) contains nine herbs: Ginkgo biloba, Ephedra sinica, Tussilago farfara, Morus alba, Pinellia ternata, Perilla frutescens, Prunus armeniaca, Scutellaria baicalensis, and Glycyrrhiza uralensis. DCT appears less promising than other formulas. In addition, it contains ephedra, which in high doses can interfere with the effects of glucocorticoids and has been linked to serious adverse effects including death.",
"   </p>",
"   <p>",
"    DCT was studied in 58 atopic children aged 8 to 15 years with mild-to-moderate persistent asthma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31496/abstract/11\">",
"     11",
"    </a>",
"    ]. Patients were randomized 1:1 to 6 g of DCT or placebo daily for 12 weeks. In addition, patients continued their daily therapy of inhaled",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/45/39632?source=see_link\">",
"     fluticasone",
"    </a>",
"    and a beta 2-agonist as needed. Ten percent of patients withdrew from the study shortly after randomization. Intention to treat analysis was not used. Airway hyperresponsiveness to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/32/10756?source=see_link\">",
"     methacholine",
"    </a>",
"    improved in the DCT group, but not the placebo group, compared with baseline. However, no improvement in FEV1 was seen in either group. The combined symptom and medication use score was significantly better in the DCT group compared with the placebo group at the end of therapy, but there was no difference in the individual symptom and medication scores between the two groups. No hepatic, renal, or hematologic abnormalities were noted. One control patient was hospitalized for an acute asthma exacerbation. No other serious adverse events were reported.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15105480\">",
"    <span class=\"h1\">",
"     THERAPY FOR ALLERGIC RHINITIS AND CONJUNCTIVITIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are several TCM remedies for allergic rhinitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31496/abstract/23\">",
"     23",
"    </a>",
"    ]. A systematic review of studies of TCM for persistent allergic rhinitis identified seven randomized trials from 1999 to 2011 that included 533 patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31496/abstract/24\">",
"     24",
"    </a>",
"    ]. The meta-analysis results showed that TCM reduced nasal symptoms scores relative to placebo (standard mean difference [SMD], -1.82; 95% confidence interval [CI] -3.03 to -0.62). No serious adverse effects were reported in any of the trials. One trial showed persistent benefit up to one year after treatment, although the mechanisms underlying the persistent effect are unknown [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31496/abstract/25\">",
"     25",
"    </a>",
"    ]. While TCM interventions appear to have beneficial effects in patients with persistent allergic rhinitis, the published trials are small and further studies are needed before firm conclusions can be drawn.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     THERAPY FOR FOOD ALLERGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Herbal treatments for food allergy have not been reported in the TCM literature. Thus, an herbal formula was developed for the treatment of food allergy using TCM principles.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Food allergy herbal formula-2 (FAHF-2)",
"    </span>",
"    &nbsp;&mdash;&nbsp;The original food allergy herbal formula (FAHF-1) contained 11 herbs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31496/abstract/26\">",
"     26",
"    </a>",
"    ]. This formula was effective in blocking anaphylaxis in a murine model of peanut allergy. A modified formula, FAHF-2, containing nine herbs was used in subsequent studies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Indications for use",
"    </span>",
"    &nbsp;&mdash;&nbsp;FAHF-2 has been studied in murine models of peanut allergy and multiple food allergies and in humans with peanut, tree nut, fish,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    shellfish allergies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Response",
"    </span>",
"    &nbsp;&mdash;&nbsp;FAHF-2 completely prevents food-induced anaphylaxis in murine models of peanut allergy and multiple food allergies. A phase II efficacy study in humans is underway in the United States.",
"   </p>",
"   <p>",
"    Preclinical studies of efficacy and safety of FAHF-2 were performed using a well-established murine model of peanut allergy. FAHF-2 completely blocked peanut induced anaphylaxis when administered intragastrically during the development of peanut hypersensitivity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31496/abstract/27\">",
"     27",
"    </a>",
"    ], or when administered after peanut hypersensitivity was fully established [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31496/abstract/28\">",
"     28",
"    </a>",
"    ]. FAHF-2 provided persistent protection for almost a quarter of the mouse lifespan after a single course of treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31496/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Having multiple food allergies, rather than a single food allergy, is becoming more common [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31496/abstract/30\">",
"     30",
"    </a>",
"    ]. Thus, multiple food allergy murine model (peanut, egg, and fish allergies) was developed and the effect of FAHF-2 was tested in this model. FAHF-2 provided complete protection from anaphylaxis to oral challenge with peanut, egg, and fish allergens [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31496/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Mechanisms of action",
"    </span>",
"    &nbsp;&mdash;&nbsp;FAHF-2 has direct inhibitory effects on mast cells and basophils and also has immunoregulatory effects on",
"    <span class=\"nowrap\">",
"     Th1/Th2",
"    </span>",
"    responses.",
"   </p>",
"   <p>",
"    In a murine model of peanut allergy, FAHF-2 reduced peripheral blood basophil and peritoneal mast cell numbers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31496/abstract/32\">",
"     32",
"    </a>",
"    ]. Expression of the high affinity IgE receptor, FcEpsilonRI, was decreased both in vivo and in vitro. Fraction 2 from FAHF-2 also inhibited rat basophil leukemic cell and human mast cell degranulation in vivo. Dose dependent responses were seen to three major compounds in fraction 2 (jatrorrhizine, palmatine, and berberine).",
"   </p>",
"   <p>",
"    Enhancement of IFN-gamma production by CD8+ T cells may also be an important mechanism underlying the long term protection produced by FAHF-2 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31496/abstract/28,29\">",
"     28,29",
"    </a>",
"    ]. In this same murine model of peanut allergy, FAHF-2 suppressed histamine release, reduced serum IgE, and increased IgG2a [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31496/abstract/28\">",
"     28",
"    </a>",
"    ]. The protective effect was associated with up-regulation of Th1 and down-regulation of Th2 cytokines, including an increased the number of IFN-gamma producing CD8+ T. Depletion of CD8+ T cells during FAHF-2 treatment attenuated FAHF-2-mediated IFN-gamma production, suppression of peanut-specific IgE, and clinical protection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31496/abstract/29\">",
"     29",
"    </a>",
"    ]. Depletion of CD8+ T cells or neutralization of IFN-gamma significantly attenuated FAHF-2 suppression of IgE and Th2 cytokines. However, IFN-gamma neutralization did not significantly impact the ability of FAHF-2 to protect mice from symptoms of anaphylaxis immediately following treatment despite elevated IgE, although this protection was lost in a subsequent challenge four weeks later.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Side effects and interactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;FAHF-2 was tested for lethality in a murine model as a preliminary assessment of safety [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31496/abstract/27\">",
"     27",
"    </a>",
"    ]. Mice were fed 12 or 24 times the effective murine daily dose. No mouse died within the two weeks after the dose, and all mice appeared healthy. Hepatic, renal, and hematologic tests were all within the normal range two weeks after feeding the test doses. In addition, all of the major organs analyzed appeared normal.",
"   </p>",
"   <p>",
"    In a dose escalation phase I safety study of FAHF-2, 18 patients 12 to 45 years of age, who had a history of peanut, tree nut, fish, or shellfish allergy were randomized to receive placebo (n = 6) or FAHF-2 (n = 12) at a dose of 2.2 g, 3.3 g, or 6.6 g three times daily for seven days [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31496/abstract/33\">",
"     33",
"    </a>",
"    ]. No significant differences were observed in vital signs, laboratory data, electrocardiographic findings, or pulmonary function tests after treatment compared with baseline. Two patients reported mild gastrointestinal symptoms (one FAHF-2 and one placebo) that resolved without intervention. Findings were similar in an extension of this phase I trial in which patients were treated with 3.3 g of FAHF-2 three times daily for six months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31496/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     THERAPY FOR ATOPIC DERMATITIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Oral and topical preparations of Chinese herbs have been used for centuries in Asia for the treatment of skin conditions, such as atopic dermatitis (AD, eczema). However, there have been only a few randomized trials, and these studies were methodologically flawed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31496/abstract/35\">",
"     35",
"    </a>",
"    ]. Further clinical trials are needed.",
"   </p>",
"   <p>",
"    Several randomized, crossover trials of Zemaphyte, a 10-herb formula, were performed in the United Kingdom in children and adults with atopic dermatitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31496/abstract/35\">",
"     35",
"    </a>",
"    ]. Erythema and surface damage were reduced and sleep improved in two studies, but not in another. Abnormalities in liver function tests that resolved with discontinuation of the formula were reported with longer-term use. No serious adverse events were reported. Intention to treat analysis was not used despite withdrawal rates of up to 22 percent. Zemaphyte is no longer manufactured.",
"   </p>",
"   <p>",
"    A randomized trial of a five-herb formulation, PentaHerbs, was performed in China [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31496/abstract/36\">",
"     36",
"    </a>",
"    ]. This formula contains Paeonia suffruticosa, Phellodendron chinense, Lonicera japonica, Mentha haplocalyx, and Atractylodes lancea. Eighty-five children with chronic moderate-to-severe AD were randomized to PentaHerbs or placebo daily for 12 weeks. Only two children (placebo group) withdrew from the study. Intention to treat analysis was used. There were no significant differences in extent and severity of AD (SCORAD scores) between the treatment and placebo groups pre- and post-treatment, although there was greater improvement in quality of life and reduction in topical corticosteroid use in the PentaHerbs group. No serious adverse events were reported. PentaHerbs has been shown to have immunomodulatory effects [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31496/abstract/37,38\">",
"     37,38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Xiao-Feng-San (XFS), a 13-herb formula, was studied in a randomized trial in Taiwan [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31496/abstract/39\">",
"     39",
"    </a>",
"    ]. Patients with severe intractable atopic dermatitis were treated for eight weeks with oral XFS (n = 47) or placebo (n = 24). There was a significantly greater improvement in the total lesion, erythema, surface damage, pruritus, and sleep scores in the treatment group compared with placebo. These differences, except for the erythema score, were still significant four weeks after the completion of treatment.",
"   </p>",
"   <p>",
"    Preliminary observational studies suggest that the combination of Chinese herbal therapy and acupuncture may be more effective than herbal therapy alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31496/abstract/40,41\">",
"     40,41",
"    </a>",
"    ]. Controlled clinical studies are needed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Chinese herbs have been used for centuries in Asia as a part of traditional Chinese medicine. However, lack of standardization and controlled clinical trials, among other issues, have hampered their use as conventional therapies in Western medicine. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H2\">",
"       'Overview'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There is potential for developing novel therapies for atopic diseases from Chinese herbs. Several herbal formulas show early promise for the treatment of asthma, food allergies, and allergic rhinitis in randomized trials. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Therapy for asthma'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H14\">",
"       'Therapy for food allergy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H20\">",
"       'Therapy for atopic dermatitis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H15105480\">",
"       'Therapy for allergic rhinitis and conjunctivitis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Work remains to determine the active components of each herb, their mechanisms of action, and potential synergistic effects. In addition, issues with consistency of herb quality and standardization still need to be addressed.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     DISCLOSURE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Xiu-Min Li, MD, the author of this topic review, has shares of the patent for ASHMI and FAHF-2 and is a partner of Herbal Springs, LLC, that owns the patent.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     www.nccam.nih.gov/health/backgrounds/wholemed.htm (Accessed on February 11, 2010).",
"    </li>",
"    <li>",
"     Radix glycyrrhizae. In: WHO monographs on selected medicinal plants, Vol. 1, World Health Organization, Geneva 1999. p.183.",
"    </li>",
"    <li>",
"     The State Pharmacopoeia Commission of The People's Republic of, China. Pharmacopoeia of the People's Republic of China, 6th ed, People's Medical Publishing House, Beijing 2005.",
"    </li>",
"    <li>",
"     Bensky D, Barolet R. Chinese herbal medicine: Formulas and strategies, Eastland Press, Seattle 1990.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/48/31496/abstract/5\">",
"      Li XM, Brown L. Efficacy and mechanisms of action of traditional Chinese medicines for treating asthma and allergy. J Allergy Clin Immunol 2009; 123:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/48/31496/abstract/6\">",
"      Kelly-Pieper K, Patil SP, Busse P, et al. Safety and tolerability of an antiasthma herbal Formula (ASHMI) in adult subjects with asthma: a randomized, double-blinded, placebo-controlled, dose-escalation phase I study. J Altern Complement Med 2009; 15:735.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/48/31496/abstract/7\">",
"      Zhang T, Srivastava K, Wen MC, et al. Pharmacology and immunological actions of a herbal medicine ASHMI on allergic asthma. Phytother Res 2010; 24:1047.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/48/31496/abstract/8\">",
"      Bielory L, Lupoli K. Herbal interventions in asthma and allergy. J Asthma 1999; 36:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/48/31496/abstract/9\">",
"      Li XM. Traditional Chinese herbal remedies for asthma and food allergy. J Allergy Clin Immunol 2007; 120:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/48/31496/abstract/10\">",
"      Hsu CH, Lu CM, Chang TT. Efficacy and safety of modified Mai-Men-Dong-Tang for treatment of allergic asthma. Pediatr Allergy Immunol 2005; 16:76.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/48/31496/abstract/11\">",
"      Chan CK, Kuo ML, Shen JJ, et al. Ding Chuan Tang, a Chinese herb decoction, could improve airway hyper-responsiveness in stabilized asthmatic children: a randomized, double-blind clinical trial. Pediatr Allergy Immunol 2006; 17:316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/48/31496/abstract/12\">",
"      Chang TT, Huang CC, Hsu CH. Clinical evaluation of the Chinese herbal medicine formula STA-1 in the treatment of allergic asthma. Phytother Res 2006; 20:342.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/48/31496/abstract/13\">",
"      Wen MC, Wei CH, Hu ZQ, et al. Efficacy and tolerability of anti-asthma herbal medicine intervention in adult patients with moderate-severe allergic asthma. J Allergy Clin Immunol 2005; 116:517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/48/31496/abstract/14\">",
"      Li XM. Complementary and alternative medicine in pediatric allergic disorders. Curr Opin Allergy Clin Immunol 2009; 9:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/48/31496/abstract/15\">",
"      Srivastava K, Zhang T, Yang N, et al. Anti-Asthma Simplified Herbal Medicine Intervention-induced long-lasting tolerance to allergen exposure in an asthma model is interferon-&gamma;, but not transforming growth factor-&beta; dependent. Clin Exp Allergy 2010; 40:1678.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/48/31496/abstract/16\">",
"      Sorkness CA, LaForce C, Storms W, et al. Effects of the inhaled corticosteroids fluticasone propionate, triamcinolone acetonide, and flunisolide and oral prednisone on the hypothalamic-pituitary-adrenal axis in adult patients with asthma. Clin Ther 1999; 21:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/48/31496/abstract/17\">",
"      Zora JA, Zimmerman D, Carey TL, et al. Hypothalamic-pituitary-adrenal axis suppression after short-term, high-dose glucocorticoid therapy in children with asthma. J Allergy Clin Immunol 1986; 77:9.",
"     </a>",
"    </li>",
"    <li>",
"     Peirce A. The American pharmaceutical association practical guide to natural medicines, William Morrow and Company, New York 1999.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/48/31496/abstract/19\">",
"      Busse PJ, Wen MC, Huang CK, et al. Therapeutic effects of the Chinese herbal formula, MSSM-003d, on persistent airway hyperreactivity and airway remodeling. J Allergy Clin Immunol 2004; 113:S220 (Abstract).",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/48/31496/abstract/20\">",
"      Busse PJ, Schofield B, Birmingham N, et al. The traditional Chinese herbal formula ASHMI inhibits allergic lung inflammation in antigen-sensitized and antigen-challenged aged mice. Ann Allergy Asthma Immunol 2010; 104:236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/48/31496/abstract/21\">",
"      Jayaprakasam B, Doddaga S, Wang R, et al. Licorice flavonoids inhibit eotaxin-1 secretion by human fetal lung fibroblasts in vitro. J Agric Food Chem 2009; 57:820.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/48/31496/abstract/22\">",
"      Slotkin W, Lopez-Exposito I, Jones M, et al. Investigation of the individual herbs in ASHMI (Anti-Asthma Herbal Medicine Intervention) that is most responsible for reducing IgE secretion. J Allergy Clin Immunol 2009; 123:S192 (Abstract).",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/48/31496/abstract/23\">",
"      Xue CC, H&uuml;gel HM, Li CG, Story DF. Efficacy, chemistry and pharmacology of chinese herbal medicine for allergic rhinitis. Curr Med Chem 2004; 11:1403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/48/31496/abstract/24\">",
"      Wang S, Tang Q, Qian W, Fan Y. Meta-analysis of clinical trials on traditional Chinese herbal medicine for treatment of persistent allergic rhinitis. Allergy 2012; 67:583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/48/31496/abstract/25\">",
"      Hu G, Walls RS, Bass D, et al. The Chinese herbal formulation biminne in management of perennial allergic rhinitis: a randomized, double-blind, placebo-controlled, 12-week clinical trial. Ann Allergy Asthma Immunol 2002; 88:478.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/48/31496/abstract/26\">",
"      Li XM, Zhang TF, Huang CK, et al. Food Allergy Herbal Formula-1 (FAHF-1) blocks peanut-induced anaphylaxis in a murine model. J Allergy Clin Immunol 2001; 108:639.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/48/31496/abstract/27\">",
"      Srivastava KD, Kattan JD, Zou ZM, et al. The Chinese herbal medicine formula FAHF-2 completely blocks anaphylactic reactions in a murine model of peanut allergy. J Allergy Clin Immunol 2005; 115:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/48/31496/abstract/28\">",
"      Qu C, Srivastava K, Ko J, et al. Induction of tolerance after establishment of peanut allergy by the food allergy herbal formula-2 is associated with up-regulation of interferon-gamma. Clin Exp Allergy 2007; 37:846.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/48/31496/abstract/29\">",
"      Srivastava KD, Qu C, Zhang T, et al. Food Allergy Herbal Formula-2 silences peanut-induced anaphylaxis for a prolonged posttreatment period via IFN-gamma-producing CD8+ T cells. J Allergy Clin Immunol 2009; 123:443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/48/31496/abstract/30\">",
"      Simpson AB, Glutting J, Yousef E. Food allergy and asthma morbidity in children. Pediatr Pulmonol 2007; 42:489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/48/31496/abstract/31\">",
"      Srivastava K, Sampson HA, Li XM. The traditional Chinese medicine formula FAHF-2 provides complete protection from anaphylaxis in a murine model of multiple food allergy. J Allergy Clin Immunol 2009; 123:S151 (Abstract).",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/48/31496/abstract/32\">",
"      Song Y, Qu C, Srivastava K, et al. Food allergy herbal formula 2 protection against peanut anaphylactic reaction is via inhibition of mast cells and basophils. J Allergy Clin Immunol 2010; 126:1208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/48/31496/abstract/33\">",
"      Wang J, Patil SP, Yang N, et al. Safety, tolerability, and immunologic effects of a food allergy herbal formula in food allergic individuals: a randomized, double-blinded, placebo-controlled, dose escalation, phase 1 study. Ann Allergy Asthma Immunol 2010; 105:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/48/31496/abstract/34\">",
"      Patil SP, Wang J, Song Y, et al. Clinical safety of Food Allergy Herbal Formula-2 (FAHF-2) and inhibitory effect on basophils from patients with food allergy: Extended phase I study. J Allergy Clin Immunol 2011; 128:1259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/48/31496/abstract/35\">",
"      Zhang W, Leonard T, Bath-Hextall F, et al. Chinese herbal medicine for atopic eczema. Cochrane Database Syst Rev 2005; :CD002291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/48/31496/abstract/36\">",
"      Hon KL, Leung TF, Ng PC, et al. Efficacy and tolerability of a Chinese herbal medicine concoction for treatment of atopic dermatitis: a randomized, double-blind, placebo-controlled study. Br J Dermatol 2007; 157:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/48/31496/abstract/37\">",
"      Leung TF, Wong KY, Wong CK, et al. In vitro and clinical immunomodulatory effects of a novel Pentaherbs concoction for atopic dermatitis. Br J Dermatol 2008; 158:1216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/48/31496/abstract/38\">",
"      Chan BC, Hon KL, Leung PC, et al. Traditional Chinese medicine for atopic eczema: PentaHerbs formula suppresses inflammatory mediators release from mast cells. J Ethnopharmacol 2008; 120:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/48/31496/abstract/39\">",
"      Cheng H-M, Chiang L-C, Jan Y-M, et al. The efficacy and safety of a Chinese herbal product (Xiao-Feng-San) for the treatment of refractory atopic dermatitis: a randomized, double-blind, placebo-controlled trial. Int Arch Allergy Immunol 2011; 155:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/48/31496/abstract/40\">",
"      Wisniewski J, Oh M, Nowak-Wegrzyn A, et al. Efficacy and safety of traditional Chinese medicine for treatment of atopic dermatitis (AD). J Allergy Clin Immunol 2009; 123:S37 (Abstract).",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/48/31496/abstract/41\">",
"      Salameh F, Perla D, Solomon M, et al. The effectiveness of combined Chinese herbal medicine and acupuncture in the treatment of atopic dermatitis. J Altern Complement Med 2008; 14:1043.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5551 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-61.55.141.10-46FA143880-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_48_31496=[""].join("\n");
var outline_f30_48_31496=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H21\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      OVERVIEW",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      THERAPY FOR ASTHMA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Antiasthma herbal medicine intervention (ASHMI) formula",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Indications for use",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Clinical response",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Immunologic response",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Enhanced adrenal function",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Possible mechanisms of action",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Side effects and interactions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Modified Mai Men Dong Tang (mMMDT) formula",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      STA-1 formula",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Ding Chuan Tang (DCT) formula",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15105480\">",
"      THERAPY FOR ALLERGIC RHINITIS AND CONJUNCTIVITIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      THERAPY FOR FOOD ALLERGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Food allergy herbal formula-2 (FAHF-2)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Indications for use",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Response",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Mechanisms of action",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Side effects and interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      THERAPY FOR ATOPIC DERMATITIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      DISCLOSURE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/36/33354?source=related_link\">",
"      Alternative and experimental agents for the treatment of asthma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/44/35529?source=related_link\">",
"      Overview of complementary and alternative medicine in pediatrics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/4/20554?source=related_link\">",
"      Overview of herbal medicine and dietary supplements",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/60/37834?source=related_link\">",
"      Pharmacotherapy of allergic rhinitis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f30_48_31497="Rapid cycling bipolar disorder: Epidemiology, pathogenesis, clinical features, and diagnosis";
var content_f30_48_31497=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Rapid cycling bipolar disorder: Epidemiology, pathogenesis, clinical features, and diagnosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/48/31497/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/48/31497/contributors\">",
"     Ralph Kupka, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/48/31497/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/48/31497/contributors\">",
"     Paul Keck, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/48/31497/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/48/31497/contributors\">",
"     David Solomon, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?30/48/31497/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 28, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H5068102\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bipolar disorder is characterized by mood episodes that are nearly always recurrent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31497/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Patients who experience at least four episodes during a 12-month period are classified as &ldquo;rapid cycling&rdquo; [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31497/abstract/1\">",
"     1",
"    </a>",
"    ]. The term was first used in 1974 to describe bipolar patients who were unresponsive to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/11/23736?source=see_link\">",
"     lithium",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31497/abstract/3\">",
"     3",
"    </a>",
"    ]. However, it is now clear that pharmacotherapy is often less beneficial for rapid cycling patients than non-rapid cycling patients, and that lithium is not the least effective drug for rapid cycling [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31497/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This topic reviews the epidemiology, pathogenesis, clinical features, and diagnosis of rapid cycling in patients with bipolar disorder. Treatment of rapid cycling is discussed separately, as is the diagnosis and general treatment of bipolar disorder:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?41/14/42216?source=see_link\">",
"       \"Rapid cycling bipolar disorder in adults: Treatment of major depression\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?40/44/41673?source=see_link\">",
"       \"Rapid cycling bipolar disorder in adults: Treatment of mania, hypomania, and mixed episodes\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?19/11/19639?source=see_link\">",
"       \"Bipolar disorder in adults: Epidemiology and diagnosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?37/8/38026?source=see_link\">",
"       \"Bipolar disorder in adults: Pharmacotherapy for acute mania, mixed episodes, and hypomania\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?43/3/44088?source=see_link\">",
"       \"Bipolar disorder in adults: Pharmacotherapy for acute depression\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?27/9/27802?source=see_link\">",
"       \"Bipolar disorder in adults: Maintenance treatment\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H87172591\">",
"    <span class=\"h1\">",
"     DEFINITIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bipolar disorder is a mood disorder that is characterized by episodes of mania (",
"    <a class=\"graphic graphic_table graphicRef81976 \" href=\"mobipreview.htm?3/53/3932\">",
"     table 1",
"    </a>",
"    ), hypomania (",
"    <a class=\"graphic graphic_table graphicRef70757 \" href=\"mobipreview.htm?22/39/23164\">",
"     table 2",
"    </a>",
"    ), and major depression (",
"    <a class=\"graphic graphic_table graphicRef70852 \" href=\"mobipreview.htm?17/21/17756\">",
"     table 3",
"    </a>",
"    ), as well as mixed episodes (major depression concurrent with mania) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31497/abstract/1\">",
"     1",
"    </a>",
"    ]. The subtypes of bipolar disorder include bipolar I and bipolar II. Patients with bipolar I disorder experience manic and mixed episodes, and nearly always experience major depressive and hypomanic episodes. Bipolar II disorder is marked by at least one hypomanic episode, at least one major depressive episode, and the absence of manic and mixed episodes. Additional information about the clinical features and diagnosis of bipolar disorder is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/11/19639?source=see_link&amp;anchor=H4#H4\">",
"     \"Bipolar disorder in adults: Epidemiology and diagnosis\", section on 'Clinical manifestations and diagnostic criteria'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5068109\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The estimated prevalence of rapid cycling bipolar disorder is based upon community surveys and clinical studies from academic medical centers.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1412757\">",
"    <span class=\"h2\">",
"     General population",
"    </span>",
"    &nbsp;&mdash;&nbsp;The estimated 12-month prevalence of rapid cycling bipolar disorder in the general population is 0.3 percent, based upon a cross-national community study (54,257 individuals in ten countries) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31497/abstract/5\">",
"     5",
"    </a>",
"    ]. The prevalence ranged from 0.0 percent in Bulgaria, India, and Japan to 0.7 percent in the United States.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1412771\">",
"    <span class=\"h3\">",
"     Sociodemographic and clinical correlates",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rapid cycling is associated with a few sociodemographic and clinical factors. A cross-national community study found that onset of bipolar disorder occurred at a significantly younger age among rapid cycling individuals compared with non-rapid cycling individuals (mean age 17 versus 20 years) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31497/abstract/5\">",
"     5",
"    </a>",
"    ]. In addition, neglect during childhood and parental divorce were both more common in rapid cycling individuals.",
"   </p>",
"   <p>",
"    Rapid cycling appears to equally affect females and males in the general population, based upon a cross-national community study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31497/abstract/5\">",
"     5",
"    </a>",
"    ]. This is consistent with the finding that the lifetime prevalence of bipolar disorder in both sexes is approximately equal [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31497/abstract/1,6,7\">",
"     1,6,7",
"    </a>",
"    ]. However, studies in clinical settings indicate that rapid cycling is associated with female gender [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31497/abstract/1\">",
"     1",
"    </a>",
"    ]. A meta-analysis of 16 clinical studies (3394 bipolar patients, including 929 with rapid cycling) found a slightly albeit significantly larger prevalence of rapid cycling in female bipolar patients than male patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31497/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1412764\">",
"    <span class=\"h2\">",
"     Patients with bipolar disorder",
"    </span>",
"    &nbsp;&mdash;&nbsp;The estimated prevalence of rapid cycling among all bipolar patients may be higher in the general population than in clinical settings. A cross-national community study found that among all bipolar patients, approximately 30 percent had rapid cycling in the past year [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31497/abstract/5\">",
"     5",
"    </a>",
"    ]. By contrast, a review of eight clinical studies that included 2054 bipolar patients (without a priori selection of rapid cyclers) found that rapid cycling occurred in 16 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31497/abstract/8\">",
"     8",
"    </a>",
"    ]. A subsequent clinical study of 3089 bipolar patients found that rapid cycling was present in 17 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31497/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H190200559\">",
"    <span class=\"h2\">",
"     Functional impairment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Psychosocial functioning is generally impaired in rapid cycling bipolar disorder [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31497/abstract/10-13\">",
"     10-13",
"    </a>",
"    ]. A cross-national community study found that during bipolar depressive episodes in the past year, severe role impairment occurred in significantly more rapid cycling patients than non-rapid cycling patients (87 versus 67 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31497/abstract/5\">",
"     5",
"    </a>",
"    ]. During",
"    <span class=\"nowrap\">",
"     manic/hypomanic",
"    </span>",
"    episodes, rapid cycling patients were unable to function for significantly more days than non-rapid cycling patients (51 versus 21 days). &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H190200718\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pathogenesis of rapid cycling bipolar disorder is not known.",
"   </p>",
"   <p>",
"    <strong>",
"     Genetics",
"    </strong>",
"    &ndash; Although there is considerable evidence for the genetic transmission of bipolar disorder [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31497/abstract/2,14,15\">",
"     2,14,15",
"    </a>",
"    ], support for the heritability of rapid cycling is lacking. A meta-analysis of four family history studies (693 bipolar patients, including 146 with rapid cycling) found that rapid cycling did not aggregate within families [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31497/abstract/8\">",
"     8",
"    </a>",
"    ]; a subsequent study (305 bipolar patients, including 46 with rapid cycling) also failed to find evidence that rapid cycling is a familial trait [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31497/abstract/16\">",
"     16",
"    </a>",
"    ]. In addition, linkage studies have not consistently identified any specific genes associated with rapid cycling [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31497/abstract/17-22\">",
"     17-22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <strong>",
"     Hypothyroidism",
"    </strong>",
"    &ndash; Hypothyroidism does not appear to cause rapid cycling bipolar disorder; a meta-analysis of six studies (275 bipolar patients, including 121 with rapid cycling) found that hypothyroidism was present in a comparable number of rapid cycling and non-rapid cycling patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31497/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <strong>",
"     Neurobiologic correlates",
"    </strong>",
"    &ndash; Different biologic correlates of rapid cycling bipolar disorder have been identified. As an example, magnetic resonance imaging (MRI) studies have found that the ventral prefrontal cortex is significantly smaller in rapid cycling patients than in non-rapid cycling patients and healthy controls [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31497/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]. Other gray matter structures that are significantly smaller in rapid cycling patients compared with healthy controls include the medial orbital prefrontal cortex, anterior cingulate, insula, and parahippocampus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31497/abstract/23\">",
"     23",
"    </a>",
"    ]. It is not clear whether these findings represent etiologic causes or sequelae of the disorder because the studies investigated patients who already met criteria for rapid cycling.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H190200740\">",
"    <span class=\"h2\">",
"     Antidepressants",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although some authorities think that antidepressants (particularly tricyclics) can trigger and prolong rapid cycling bipolar disorder [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31497/abstract/25\">",
"     25",
"    </a>",
"    ], this is not established and remains a point of contention [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31497/abstract/8,26-29\">",
"     8,26-29",
"    </a>",
"    ]. A few observational studies have found an association between antidepressants and rapid cycling; as an example, the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD) study followed 1191 bipolar patients for up to one year and found that rapid cycling occurred nearly four times more often in patients who received antidepressants compared with patients who did not [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31497/abstract/30\">",
"     30",
"    </a>",
"    ]. By contrast, other studies refute this association; in one study that followed 345 bipolar patients for a mean of 14 years, antidepressants were not associated with onset of rapid cycling and resolution of rapid cycling was not associated with discontinuation of antidepressants [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31497/abstract/12\">",
"     12",
"    </a>",
"    ]. Contrary to the idea that antidepressants precipitate rapid cycling, it has been suggested that it is frequent episodes of major depression that are associated with rapid cycling and subsequent administration of an antidepressant [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31497/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Additional indirect evidence suggests that adjunctive antidepressants may not cause or exacerbate rapid cycling and are safe to use in many patients with rapid cycling [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31497/abstract/29\">",
"     29",
"    </a>",
"    ]. Both short-term (eg, &le; 6 months) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31497/abstract/32,33\">",
"     32,33",
"    </a>",
"    ] and long-term (&gt;6 months) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31497/abstract/34,35\">",
"     34,35",
"    </a>",
"    ] randomized trials have found that adjunctive antidepressants do not increase rates of switching from major depression to",
"    <span class=\"nowrap\">",
"     mania/hypomania.",
"    </span>",
"    In so far as patients are not switching from one pole to the other, they may not be at increased risk of rapid cycling.",
"   </p>",
"   <p>",
"    The role of antidepressants in treating rapid cycling patients with major depression is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/14/42216?source=see_link&amp;anchor=H92692348#H92692348\">",
"     \"Rapid cycling bipolar disorder in adults: Treatment of major depression\", section on 'Resistant patients'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5068116\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H173673175\">",
"    <span class=\"h2\">",
"     Number of mood episodes",
"    </span>",
"    &nbsp;&mdash;&nbsp;The essential feature of rapid cycling is the occurrence of four or more bipolar mood episodes within a 12-month period [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31497/abstract/1\">",
"     1",
"    </a>",
"    ]. The mood episodes consist of mania (",
"    <a class=\"graphic graphic_table graphicRef81976 \" href=\"mobipreview.htm?3/53/3932\">",
"     table 1",
"    </a>",
"    ), hypomania (",
"    <a class=\"graphic graphic_table graphicRef70757 \" href=\"mobipreview.htm?22/39/23164\">",
"     table 2",
"    </a>",
"    ), major depression (",
"    <a class=\"graphic graphic_table graphicRef70852 \" href=\"mobipreview.htm?17/21/17756\">",
"     table 3",
"    </a>",
"    ),",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    mixed episodes (major depression concurrent with mania or hypomania); these mood episodes can occur in any combination and order. The episodes that occur as part of a rapid cycling pattern are no different from episodes that occur as part of a non-rapid cycling pattern.",
"   </p>",
"   <p>",
"    Separate mood episodes are demarcated from each other by either [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31497/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Switching from one pole to the other",
"     </li>",
"     <li>",
"      Full or partial remission for at least two months",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Manic, hypomanic, and mixed episodes are counted as being on the same pole; thus, a switch in polarity involves one of these episodes and an episode of major depression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31497/abstract/1\">",
"     1",
"    </a>",
"    ]. As an example, a patient with mania may remit and subsequently develop major depression. The time frame for switching poles is less than two months between the point that the patient has remitted from a mood episode on one pole and the point that the patient becomes ill with an episode on the other pole. In some cases the switch occurs suddenly.",
"   </p>",
"   <p>",
"    Although there is no established definition for partial remission, most authorities define it as stabilization of the patient&rsquo;s safety and substantial improvement in the number, intensity, and frequency of psychotic and mood symptoms. Partial remission can be quantified with standardized rating scales that assess psychosis (eg, the Brief Psychiatric Rating Scale [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31497/abstract/36\">",
"     36",
"    </a>",
"    ]), mania (eg, the Young Mania Rating Scale [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31497/abstract/37\">",
"     37",
"    </a>",
"    ]), and depression (eg, the Patient Health Questionnaire &ndash; Nine Item (",
"    <a class=\"graphic graphic_table graphicRef59307 \" href=\"mobipreview.htm?14/12/14541\">",
"     table 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31497/abstract/38\">",
"     38",
"    </a>",
"    ]), but this is not standard clinical practice.",
"   </p>",
"   <p>",
"    Most authorities think it is arbitrary to use a cut-off of four mood episodes to define rapid cycling bipolar disorder [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31497/abstract/2,10,13,26,30,31,39,40\">",
"     2,10,13,26,30,31,39,40",
"    </a>",
"    ]. Although this cut-off was confirmed to some degree in studies that examined the validity of rapid cycling [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31497/abstract/41-43\">",
"     41-43",
"    </a>",
"    ], subsequent studies that examined the stability, course of illness, and heritability of rapid cycling did not support this cut-off. In addition, the number of mood episodes observed in bipolar patients during a specific time period is distributed monotonically along a continuum [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31497/abstract/10,16,31\">",
"     10,16,31",
"    </a>",
"    ]. Thus, rapid cycling appears to represent one extreme on the spectrum of episode frequency that occurs in bipolar disorder [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31497/abstract/13,16\">",
"     13,16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H173673501\">",
"    <span class=\"h2\">",
"     Duration",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prospective studies indicate that rapid cycling bipolar disorder is generally a transient phenomenon (state) rather than a stable characteristic (trait) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31497/abstract/1,2,10,30\">",
"     1,2,10,30",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A study of 356 bipolar patients with rapid cycling in the previous year found that during follow-up lasting 12 months, 91 percent converted to non-rapid cycling [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/48/31497/abstract/30\">",
"       30",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Among 89 bipolar patients who developed rapid cycling during follow-up lasting a mean of 15 years, rapid cycling resolved within two years of onset in 78 percent of the patients and within three years in 92 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/48/31497/abstract/12\">",
"       12",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A study of 58 rapid cycling bipolar patients followed for at least 12 months found that 53 percent converted to non-rapid cycling [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/48/31497/abstract/41\">",
"       41",
"      </a>",
"      ] &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, rapid cycling may persist for many years. As an example, a prospective study followed 109 rapid cycling bipolar patients for up to 36 years and found that the mean duration of rapid cycling was eight years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31497/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The long-term course of illness in patients with rapid cycling is discussed elsewhere in this topic. (See",
"    <a class=\"local\" href=\"#H92694551\">",
"     'Course of illness'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H173673637\">",
"    <span class=\"h2\">",
"     Other features",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rapid cycling can occur at any point in the bipolar patient&rsquo;s course of illness. A review of four studies, which included 181 rapid cycling patients, found that rapid cycling was present at the onset of bipolar disorder in 27 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31497/abstract/8\">",
"     8",
"    </a>",
"    ]. A study of 109 bipolar patients with past-year rapid cycling found that onset of rapid cycling followed onset of bipolar disorder by a mean of 11 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31497/abstract/44\">",
"     44",
"    </a>",
"    ]. In addition, case reports describe onset of rapid cycling in geriatric bipolar patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31497/abstract/45,46\">",
"     45,46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The sequence of mood episodes observed during rapid cycling varies greatly; a few examples include (",
"    <a class=\"graphic graphic_figure graphicRef72619 \" href=\"mobipreview.htm?8/34/8740\">",
"     figure 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Individual mood episodes that are each followed by a period of euthymia",
"     </li>",
"     <li>",
"      Continuous cycling &ndash; alternating episodes of opposite polarity (major depression on one pole and",
"      <span class=\"nowrap\">",
"       manic/hypomanic/mixed",
"      </span>",
"      episodes on the other pole) with no intervening period of euthymia",
"     </li>",
"     <li>",
"      Numerous mood episodes that form no discernible pattern",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The predominant psychopathology in rapid cycling bipolar disorder is generally depression, rather than mania or hypomania [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31497/abstract/13,40\">",
"     13,40",
"    </a>",
"    ]. As an example, among 206 bipolar patients who suffered rapid cycling during prospective follow-up lasting for one year, depressive symptoms were present for twice as many days as were",
"    <span class=\"nowrap\">",
"     manic/hypomanic",
"    </span>",
"    symptoms (145 versus 73 days) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31497/abstract/13\">",
"     13",
"    </a>",
"    ]. This is consistent with the finding that depression is the predominant mood state for bipolar patients in general [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31497/abstract/47,48\">",
"     47,48",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    Rapid cycling bipolar disorder often includes brief mood states or &ldquo;truncated episodes&rdquo; with manic, hypomanic,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    depressive symptoms that meet DSM-IV-TR symptom criteria but not duration criteria for a mood episode:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A study prospectively followed 206 rapid cycling patients for 12 months and found that an average of nine truncated episodes occurred per year, in addition to full mood episodes [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/48/31497/abstract/13\">",
"       13",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      A study prospectively followed 96 rapid cycling patients for at least 12 months and found that an average of four to eight truncated episodes occurred per year, in addition to full mood episodes [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/48/31497/abstract/41\">",
"       41",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, it is difficult to distinguish multiple truncated episodes from a single mixed episode (major depression concurrent with mania or hypomania) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31497/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Rapid cycling can occur in both bipolar I disorder and bipolar II disorder, and the frequency of rapid cycling in bipolar I and bipolar II disorder does not appear to differ. A cross-national community study found no difference in the 12-month prevalence of rapid cycling among individuals with bipolar I or bipolar II disorder [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31497/abstract/5\">",
"     5",
"    </a>",
"    ]. Although a meta-analysis of 11 clinical studies (2686 bipolar patients) found a history of rapid cycling in significantly more bipolar II patients than bipolar I patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31497/abstract/8\">",
"     8",
"    </a>",
"    ], one subsequent study (500 bipolar patients) found that the prevalence of rapid cycling in bipolar I patients and bipolar II patients was nearly identical [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31497/abstract/11\">",
"     11",
"    </a>",
"    ], and another subsequent study (539 bipolar patients) found that the prevalence of rapid cycling was significantly larger in bipolar I patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31497/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The frequency of psychosis in rapid cycling and non-rapid cycling bipolar patients does not appear to differ [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31497/abstract/11,13,41\">",
"     11,13,41",
"    </a>",
"    ]. The Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD) study found that a lifetime history of psychotic mood episodes was comparable in rapid cycling and non-rapid cycling patients (39 versus 46 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31497/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The rate of attempted suicide in rapid cycling and non-rapid cycling bipolar disorder is similar [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31497/abstract/5\">",
"     5",
"    </a>",
"    ]. In a meta-analysis of six studies (1171 bipolar patients, including 454 with rapid cycling), a history of attempted suicide was found in a comparable number of rapid cycling and non-rapid cycling patients (35 versus 30 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31497/abstract/8\">",
"     8",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4504928\">",
"    <span class=\"h1\">",
"     COMORBIDITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Comorbid psychiatric and general medical disorders are common in patients with rapid cycling bipolar disorder.",
"   </p>",
"   <p>",
"    Rapid cycling bipolar patients are significantly more likely than non-rapid cycling patients to have a lifetime history of comorbid psychopathology, including [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31497/abstract/5,13\">",
"     5,13",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Anxiety disorders (eg, panic disorder, generalized anxiety disorder, social phobia, and specific phobia)",
"     </li>",
"     <li>",
"      Substance use disorders",
"     </li>",
"     <li>",
"      Attention-deficit hyperactivity disorder &nbsp; &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, impulsivity (evaluated by a rating scale) is greater in rapid cycling bipolar disorder than non-rapid cycling bipolar disorder [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31497/abstract/49\">",
"     49",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    Multiple general medical illnesses are frequently observed in patients with rapid cycling; one study (N = 225) found that the mean number of medical comorbidities was 2.5 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31497/abstract/50\">",
"     50",
"    </a>",
"    ]. Organ systems that are commonly affected include respiratory, musculoskeletal, neurologic,",
"    <span class=\"nowrap\">",
"     endocrine/metabolic,",
"    </span>",
"    and genitourinary [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31497/abstract/51\">",
"     51",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H92694551\">",
"    <span class=\"h1\">",
"     COURSE OF ILLNESS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with bipolar disorder, rapid cycling is generally a transient phenomenon; however, some patients manifest rapid cycling for many consecutive years before it resolves [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31497/abstract/10\">",
"     10",
"    </a>",
"    ]. Once rapid cycling resolves, the risk for a subsequent period of rapid cycling is not known. The persistence of rapid cycling is discussed separately. (See",
"    <a class=\"local\" href=\"#H173673501\">",
"     'Duration'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Bipolar patients who suffer rapid cycling at some point in their course of illness have a poorer long-term prognosis (with more lifetime affective morbidity), compared with non-rapid cycling patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31497/abstract/1,13,27,42\">",
"     1,13,27,42",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A cross-national community study found that the number of lifetime mood episodes was significantly greater in rapid cycling than non-rapid cycling patients (103 versus 28 episodes), as was the number of lifetime years with at least one episode (15 versus 6 years) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/48/31497/abstract/5\">",
"       5",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A study prospectively followed 345 bipolar patients for a mean of 14 years, during which 89 developed rapid cycling at some point [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/48/31497/abstract/12\">",
"       12",
"      </a>",
"      ]. The number of weeks with depressive symptoms was significantly greater in rapid cycling than non-rapid cycling patients (42 versus 30 percent of follow-up weeks).",
"     </li>",
"     <li>",
"      A study prospectively followed 37 rapid cycling and 74 non-rapid cycling bipolar patients for up to five years [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/48/31497/abstract/42\">",
"       42",
"      </a>",
"      ]. During each year of follow-up, the number of recurrent mood episodes was significantly greater in the patients initially classified as rapid cyclers, even after rapid cycling resolved.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    One form of rapid cycling is continuous cycling, which consists of alternating episodes of opposite polarity (major depression on one pole and",
"    <span class=\"nowrap\">",
"     manic/hypomanic/mixed",
"    </span>",
"    episodes on the other pole) that are immediately contiguous with each other or separated by less than eight weeks of remission. These patients may have a poorer prognosis than rapid cycling patients with intermittent periods of euthymia and non-rapid cycling patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31497/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Bipolar patients who at one point experience rapid cycling may recover from bipolar disorder. In a study of 109 bipolar patients with rapid cycling who were followed prospectively for up to 36 years, 33 percent recovered (defined as no recurrent mood episodes for at least one year); the mean duration of recovery was 11 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31497/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H81537325\">",
"    <span class=\"h1\">",
"     ASSESSMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial clinical evaluation of patients with a possible diagnosis of rapid cycling bipolar disorder includes a psychiatric and general medical history, mental status and physical examination, and focused laboratory tests [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31497/abstract/53-55\">",
"     53-55",
"    </a>",
"    ]. The psychiatric history should emphasize the number of major depressive (",
"    <a class=\"graphic graphic_table graphicRef70852 \" href=\"mobipreview.htm?17/21/17756\">",
"     table 3",
"    </a>",
"    ), manic (",
"    <a class=\"graphic graphic_table graphicRef81976 \" href=\"mobipreview.htm?3/53/3932\">",
"     table 1",
"    </a>",
"    ), hypomanic (",
"    <a class=\"graphic graphic_table graphicRef70757 \" href=\"mobipreview.htm?22/39/23164\">",
"     table 2",
"    </a>",
"    ) and mixed (major depression concurrent with mania or hypomania) episodes during the previous 12 months, as well as any previous 12-month period [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31497/abstract/1\">",
"     1",
"    </a>",
"    ]. Patients may have difficulty distinguishing past mood episodes when they are not separated by long intervals of euthymia; interviewing family members may help to determine the number and type of mood episodes that have occurred. The demarcation between separate mood episodes is discussed elsewhere in this topic. (See",
"    <a class=\"local\" href=\"#H16495348\">",
"     'Diagnosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    No self-report instrument is available to screen for rapid cycling or assess response to treatment. Additional information about assessing bipolar patients in general is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/11/19639?source=see_link&amp;anchor=H15#H15\">",
"     \"Bipolar disorder in adults: Epidemiology and diagnosis\", section on 'Evaluation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16495348\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are three subtypes of bipolar disorder that can be diagnosed, depending upon the mood symptoms and episodes that have occurred [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31497/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Bipolar I disorder",
"     </li>",
"     <li>",
"      Bipolar II disorder",
"     </li>",
"     <li>",
"      Bipolar disorder not otherwise specified",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Diagnosis of each bipolar subtype is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/11/19639?source=see_link&amp;anchor=H4#H4\">",
"     \"Bipolar disorder in adults: Epidemiology and diagnosis\", section on 'Clinical manifestations and diagnostic criteria'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The term rapid cycling is used to specify the course of illness in patients with bipolar I disorder or bipolar II disorder, rather than a subtype of bipolar disorder [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31497/abstract/1\">",
"     1",
"    </a>",
"    ]. Any bipolar I or bipolar II patient can develop rapid cycling and then subsequently revert to a non-rapid cycling course [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31497/abstract/40\">",
"     40",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H173673501\">",
"     'Duration'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    According to the American Psychiatric Association's Diagnostic and Statistical Manual, Fourth Edition, Text Revision (DSM-IV-TR), the diagnostic criteria for rapid cycling are [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31497/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      At least four bipolar mood episodes in a 12-month period",
"     </li>",
"     <li>",
"      The episodes meet both the symptom and duration criteria for major depression (",
"      <a class=\"graphic graphic_table graphicRef70852 \" href=\"mobipreview.htm?17/21/17756\">",
"       table 3",
"      </a>",
"      ), mania (",
"      <a class=\"graphic graphic_table graphicRef81976 \" href=\"mobipreview.htm?3/53/3932\">",
"       table 1",
"      </a>",
"      ), hypomania (",
"      <a class=\"graphic graphic_table graphicRef70757 \" href=\"mobipreview.htm?22/39/23164\">",
"       table 2",
"      </a>",
"      ), or mixed episode (major depression concurrent with mania or hypomania); the episodes that occur as part of a rapid cycling pattern are no different from episodes that occur as part of a non-rapid cycling pattern. Mood episodes that are directly caused by substance intoxication (eg, cocaine or corticosteroids) or a general medical disorder do not count toward defining a rapid-cycling pattern.",
"     </li>",
"     <li>",
"      The mood episodes can occur in any order or combination",
"     </li>",
"     <li>",
"      The episodes are demarcated by either",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      A period of partial or full remission for at least two months, or",
"     </li>",
"     <li>",
"      A switch to an episode of opposite polarity. Manic, hypomanic, and mixed episodes are counted as being on the same pole; thus, a switch in polarity involves one of these episodes and an episode of major depression. As an example, a manic episode immediately followed by a mixed episode is counted as only one episode, whereas a switch from mania to major depression counts as two. The time frame for switching poles is less than two months between the point that the patient has remitted from a mood episode on one pole and the point that the patient becomes ill with an episode on the other pole. In some cases the switch occurs suddenly.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although DSM-IV-TR does not include a definition for partial remission, most authorities define it as stabilization of the patient&rsquo;s safety and substantial improvement in the number, intensity, and frequency of psychotic and mood symptoms.",
"   </p>",
"   <p>",
"    Patients who manifest brief mood states in the absence of full-duration mood episodes are classified as bipolar disorder not otherwise specified, without the additional course specifier rapid cycling. Rapid shifts between mood states have been described in case reports as &ldquo;ultra-rapid cycling,&rdquo; in which patients alternate between periods of",
"    <span class=\"nowrap\">",
"     mania/hypomania,",
"    </span>",
"    depression, and euthymia, with each mood state lasting approximately 24 hours [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31497/abstract/56,57\">",
"     56,57",
"    </a>",
"    ]. &ldquo;Ultradian cycling&rdquo; has also been described, consisting of shifts between different mood states (lasting only several hours), occurring within one day [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31497/abstract/57,58\">",
"     57,58",
"    </a>",
"    ]. The mood states seen during ultra-rapid cycling and ultradian cycling do not meet duration criteria for mood episodes as defined in DSM-IV-TR [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31497/abstract/1\">",
"     1",
"    </a>",
"    ]. If these brief mood states meeting symptom criteria but not duration criteria for mood episodes were counted along with full-duration episodes, more bipolar patients would be classified as rapid cyclers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31497/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The World Health Organization's International Classification of Diseases-10th Revision (ICD-10) does not include rapid cycling in its nosology [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31497/abstract/59\">",
"     59",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16496710\">",
"    <span class=\"h2\">",
"     Differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rapid cycling bipolar disorder needs to be distinguished from borderline personality disorder because of differences in treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31497/abstract/10,40\">",
"     10,40",
"    </a>",
"    ]. Rapid switches between mood elevation (manic, hypomanic, or mixed episode) and major depression can occur in rapid cycling, which may resemble the mood lability that occurs in borderline personality disorder [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31497/abstract/10\">",
"     10",
"    </a>",
"    ]. However, the affective instability of borderline patients is generally a reaction to environmental triggers such as perceived rejection or failure, which is typically not the case in rapid cycling patients. In addition, the affect of borderline patients is typically depressed rather than elevated. Borderline personality disorder is also marked by unstable and intense interpersonal relationships, identity disturbance (unstable self-image or sense of self), chronic feelings of emptiness, and frantic efforts to avoid abandonment; these features are not characteristic of rapid cycling bipolar disorder [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31497/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Additional information about the differential diagnosis of bipolar disorder in general is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/11/19639?source=see_link&amp;anchor=H14#H14\">",
"     \"Bipolar disorder in adults: Epidemiology and diagnosis\", section on 'Differential diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (See",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?4/5/4178?source=see_link\">",
"       \"Patient information: Bipolar disorder (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?6/21/6483?source=see_link\">",
"       \"Patient information: Reducing the costs of medicines (The Basics)\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Beyond the Basics topics (See",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?38/55/39796?source=see_link\">",
"       \"Patient information: Bipolar disorder (manic depression) (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?31/61/32726?source=see_link\">",
"       \"Patient information: Reducing the costs of medicines (Beyond the Basics)\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These educational materials can be used as part of psychoeducational psychotherapy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/9/27802?source=see_link&amp;anchor=H21#H21\">",
"     \"Bipolar disorder in adults: Maintenance treatment\", section on 'Psychoeducation'",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p>",
"    The National Institute of Mental Health also has educational material explaining the symptoms, course of illness, and treatment of bipolar disorder in a booklet entitled \"Bipolar Disorder,\" which is available online at the website",
"    <a class=\"external\" href=\"file://www.nimh.nih.gov/health/publications/bipolar-disorder/complete-index.shtml\">",
"     file://www.nimh.nih.gov/health/publications/bipolar-disorder/complete-index.shtml",
"    </a>",
"    or through a toll-free number, 866-615-6464. The web site also provides references, summaries of study results in language intended for the lay public, and information about clinical trials currently recruiting patients.",
"   </p>",
"   <p>",
"    More comprehensive information is provided in many books written for patients and family members, including The Bipolar Disorder Survival Guide: What You and Your Family Need to Know, written by David J. Miklowitz, PhD (published by The Guilford Press, 2002); An Unquiet Mind: A Memoir of Moods and Madness, written by Kay Jamison, PhD (published by Random House, 1995); and Treatment of Bipolar Illness: A Casebook for Clinicians and Patients, by RM Post, MD, and GS Leverich, LCSW (published by Norton Press, 2008).",
"   </p>",
"   <p>",
"    The Depression and Bipolar Support Alliance (",
"    <a class=\"external\" href=\"file://www.dbsalliance.org/\">",
"     file://www.dbsalliance.org",
"    </a>",
"    or 800-826-3632) is a national organization that educates members about bipolar disorder and how to cope with it. Other functions include increasing public awareness of the illness and advocating for more research and services. The organization is administered and maintained by patients and family members, and has local chapters.",
"   </p>",
"   <p>",
"    The National Alliance on Mental Illness (",
"    <a class=\"external\" href=\"file://www.nami.org/\">",
"     file://www.nami.org",
"    </a>",
"    or 800-950-6264) is a similarly structured organization devoted to education, support, and advocacy for patients with any mental illness. Bipolar disorder is one of their priorities.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5068193\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Bipolar disorder is characterized by episodes of mania (",
"      <a class=\"graphic graphic_table graphicRef81976 \" href=\"mobipreview.htm?3/53/3932\">",
"       table 1",
"      </a>",
"      ), hypomania (",
"      <a class=\"graphic graphic_table graphicRef70757 \" href=\"mobipreview.htm?22/39/23164\">",
"       table 2",
"      </a>",
"      ), and major depression (",
"      <a class=\"graphic graphic_table graphicRef70852 \" href=\"mobipreview.htm?17/21/17756\">",
"       table 3",
"      </a>",
"      ), as well as mixed episodes (major depression concurrent with mania or hypomania). (See",
"      <a class=\"local\" href=\"#H87172591\">",
"       'Definitions'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?19/11/19639?source=see_link&amp;anchor=H4#H4\">",
"       \"Bipolar disorder in adults: Epidemiology and diagnosis\", section on 'Clinical manifestations and diagnostic criteria'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Rapid cycling bipolar disorder is diagnosed in patients with four or more mood episodes during a 12-month period. These episodes can occur in any order or combination, and are no different from episodes that occur as part of a non-rapid cycling pattern. Separate mood episodes are demarcated from each other either by a switch from one pole to the other (eg, major depression to mania), or by full or partial remission for at least two months. (See",
"      <a class=\"local\" href=\"#H16495348\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The estimated 12-month prevalence of rapid cycling bipolar disorder in the general population is 0.3 percent. Among bipolar patients seen in clinical settings, approximately 16 to 17 percent have rapid cycling. (See",
"      <a class=\"local\" href=\"#H5068109\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The pathogenesis of rapid cycling bipolar disorder is not known. Although some authorities maintain that antidepressants can trigger and prolong rapid cycling bipolar disorder, this is not established. (See",
"      <a class=\"local\" href=\"#H190200718\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Most authorities think it is arbitrary to use a cut-off of four mood episodes to define rapid cycling bipolar disorder, and conceptualize rapid cycling as one extreme on the spectrum of episode frequency that occurs in bipolar disorder. (See",
"      <a class=\"local\" href=\"#H173673175\">",
"       'Number of mood episodes'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Rapid cycling bipolar disorder is generally a transient phenomenon that can occur at any point in the bipolar patient&rsquo;s course of illness. However, some patients in clinical settings may experience rapid cycling for many years. The sequence of mood episodes observed during rapid cycling varies greatly (",
"      <a class=\"graphic graphic_figure graphicRef72619 \" href=\"mobipreview.htm?8/34/8740\">",
"       figure 1",
"      </a>",
"      ), and the predominant psychopathology is generally depression. Rapid cycling patients are significantly more likely than non-rapid cycling patients to have a lifetime history of comorbid psychopathology. (See",
"      <a class=\"local\" href=\"#H173673501\">",
"       'Duration'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H173673637\">",
"       'Other features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Bipolar patients who suffer rapid cycling at some point in their course of illness have a poorer long-term course of illness, compared with non-rapid cycling patients. (See",
"      <a class=\"local\" href=\"#H92694551\">",
"       'Course of illness'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The initial clinical evaluation of patients with a possible diagnosis of rapid cycling bipolar disorder includes a psychiatric and general medical history, mental status and physical examination, and focused laboratory tests. The psychiatric history should emphasize the number of mood episodes during the previous 12 months, as well as any previous 12-month period. (See",
"      <a class=\"local\" href=\"#H81537325\">",
"       'Assessment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Rapid cycling bipolar disorder needs to be distinguished from borderline personality disorder. (See",
"      <a class=\"local\" href=\"#H16496710\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision, American Psychiatric Association, Washington, DC, 2000.",
"    </li>",
"    <li>",
"     Goodwin FK, Jamison KR. Manic-Depressive Illness: Bipolar Disorders and Recurrent Depression, Second Edition, Oxford University Press, Oxford 2007.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/48/31497/abstract/3\">",
"      Dunner DL, Fieve RR. Clinical factors in lithium carbonate prophylaxis failure. Arch Gen Psychiatry 1974; 30:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/48/31497/abstract/4\">",
"      Tondo L, Hennen J, Baldessarini RJ. Rapid-cycling bipolar disorder: effects of long-term treatments. Acta Psychiatr Scand 2003; 108:4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/48/31497/abstract/5\">",
"      Lee S, Tsang A, Kessler RC, et al. Rapid-cycling bipolar disorder: cross-national community study. Br J Psychiatry 2010; 196:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/48/31497/abstract/6\">",
"      Merikangas KR, Akiskal HS, Angst J, et al. Lifetime and 12-month prevalence of bipolar spectrum disorder in the National Comorbidity Survey replication. Arch Gen Psychiatry 2007; 64:543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/48/31497/abstract/7\">",
"      Seedat S, Scott KM, Angermeyer MC, et al. Cross-national associations between gender and mental disorders in the World Health Organization World Mental Health Surveys. Arch Gen Psychiatry 2009; 66:785.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/48/31497/abstract/8\">",
"      Kupka RW, Luckenbaugh DA, Post RM, et al. Rapid and non-rapid cycling bipolar disorder: a meta-analysis of clinical studies. J Clin Psychiatry 2003; 64:1483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/48/31497/abstract/9\">",
"      Cruz N, Vieta E, Comes M, et al. Rapid-cycling bipolar I disorder: course and treatment outcome of a large sample across Europe. J Psychiatr Res 2008; 42:1068.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/48/31497/abstract/10\">",
"      Bauer M, Beaulieu S, Dunner DL, et al. Rapid cycling bipolar disorder--diagnostic concepts. Bipolar Disord 2008; 10:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/48/31497/abstract/11\">",
"      Schneck CD, Miklowitz DJ, Calabrese JR, et al. Phenomenology of rapid-cycling bipolar disorder: data from the first 500 participants in the Systematic Treatment Enhancement Program. Am J Psychiatry 2004; 161:1902.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/48/31497/abstract/12\">",
"      Coryell W, Solomon D, Turvey C, et al. The long-term course of rapid-cycling bipolar disorder. Arch Gen Psychiatry 2003; 60:914.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/48/31497/abstract/13\">",
"      Kupka RW, Luckenbaugh DA, Post RM, et al. Comparison of rapid-cycling and non-rapid-cycling bipolar disorder based on prospective mood ratings in 539 outpatients. Am J Psychiatry 2005; 162:1273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/48/31497/abstract/14\">",
"      McGuffin P, Rijsdijk F, Andrew M, et al. The heritability of bipolar affective disorder and the genetic relationship to unipolar depression. Arch Gen Psychiatry 2003; 60:497.",
"     </a>",
"    </li>",
"    <li>",
"     Lohoff FW, Berrettini WH. Genetics of bipolar disorder. In: Bipolar Disorder: Clinical and Neurobiological Foundations, Yatham LN, Maj M.  (Eds), Wiley-Blackwell, West Sussex, UK 2010. p.110.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/48/31497/abstract/16\">",
"      Fisfalen ME, Schulze TG, DePaulo JR Jr, et al. Familial variation in episode frequency in bipolar affective disorder. Am J Psychiatry 2005; 162:1266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/48/31497/abstract/17\">",
"      Kirov G, Murphy KC, Arranz MJ, et al. Low activity allele of catechol-O-methyltransferase gene associated with rapid cycling bipolar disorder. Mol Psychiatry 1998; 3:342.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/48/31497/abstract/18\">",
"      Sj&ouml;holm LK, Backlund L, Cheteh EH, et al. CRY2 is associated with rapid cycling in bipolar disorder patients. PLoS One 2010; 5:e12632.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/48/31497/abstract/19\">",
"      Green EK, Raybould R, Macgregor S, et al. Genetic variation of brain-derived neurotrophic factor (BDNF) in bipolar disorder: case-control study of over 3000 individuals from the UK. Br J Psychiatry 2006; 188:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/48/31497/abstract/20\">",
"      M&uuml;ller DJ, de Luca V, Sicard T, et al. Brain-derived neurotrophic factor (BDNF) gene and rapid-cycling bipolar disorder: family-based association study. Br J Psychiatry 2006; 189:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/48/31497/abstract/21\">",
"      Cusin C, Serretti A, Lattuada E, et al. Influence of 5-HTTLPR and TPH variants on illness time course in mood disorders. J Psychiatr Res 2001; 35:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/48/31497/abstract/22\">",
"      Rousseva A, Henry C, van den Bulke D, et al. Antidepressant-induced mania, rapid cycling and the serotonin transporter gene polymorphism. Pharmacogenomics J 2003; 3:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/48/31497/abstract/23\">",
"      Narita K, Suda M, Takei Y, et al. Volume reduction of ventromedial prefrontal cortex in bipolar II patients with rapid cycling: a voxel-based morphometric study. Prog Neuropsychopharmacol Biol Psychiatry 2011; 35:439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/48/31497/abstract/24\">",
"      Blumberg HP, Krystal JH, Bansal R, et al. Age, rapid-cycling, and pharmacotherapy effects on ventral prefrontal cortex in bipolar disorder: a cross-sectional study. Biol Psychiatry 2006; 59:611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/48/31497/abstract/25\">",
"      Ghaemi SN. Treatment of rapid-cycling bipolar disorder: are antidepressants mood destabilizers? Am J Psychiatry 2008; 165:300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/48/31497/abstract/26\">",
"      Goodwin GM, Consensus Group of the British Association for Psychopharmacology. Evidence-based guidelines for treating bipolar disorder: revised second edition--recommendations from the British Association for Psychopharmacology. J Psychopharmacol 2009; 23:346.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/48/31497/abstract/27\">",
"      Coryell W. Rapid cycling bipolar disorder: clinical characteristics and treatment options. CNS Drugs 2005; 19:557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/48/31497/abstract/28\">",
"      Bauer M, Rasgon N, Grof P, et al. Do antidepressants influence mood patterns? A naturalistic study in bipolar disorder. Eur Psychiatry 2006; 21:262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/48/31497/abstract/29\">",
"      Licht RW, Gijsman H, Nolen WA, Angst J. Are antidepressants safe in the treatment of bipolar depression? A critical evaluation of their potential risk to induce switch into mania or cycle acceleration. Acta Psychiatr Scand 2008; 118:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/48/31497/abstract/30\">",
"      Schneck CD, Miklowitz DJ, Miyahara S, et al. The prospective course of rapid-cycling bipolar disorder: findings from the STEP-BD. Am J Psychiatry 2008; 165:370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/48/31497/abstract/31\">",
"      Coryell W, Endicott J, Keller M. Rapidly cycling affective disorder. Demographics, diagnosis, family history, and course. Arch Gen Psychiatry 1992; 49:126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/48/31497/abstract/32\">",
"      Tohen M, Vieta E, Calabrese J, et al. Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression. Arch Gen Psychiatry 2003; 60:1079.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/48/31497/abstract/33\">",
"      Sachs GS, Nierenberg AA, Calabrese JR, et al. Effectiveness of adjunctive antidepressant treatment for bipolar depression. N Engl J Med 2007; 356:1711.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/48/31497/abstract/34\">",
"      Ghaemi SN, Wingo AP, Filkowski MA, Baldessarini RJ. Long-term antidepressant treatment in bipolar disorder: meta-analyses of benefits and risks. Acta Psychiatr Scand 2008; 118:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/48/31497/abstract/35\">",
"      Altshuler LL, Post RM, Hellemann G, et al. Impact of antidepressant continuation after acute positive or partial treatment response for bipolar depression: a blinded, randomized study. J Clin Psychiatry 2009; 70:450.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/48/31497/abstract/36\">",
"      Rhoades HM, Overall JE. The semistructured BPRS interview and rating guide. Psychopharmacol Bull 1988; 24:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/48/31497/abstract/37\">",
"      Young RC, Biggs JT, Ziegler VE, Meyer DA. A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry 1978; 133:429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/48/31497/abstract/38\">",
"      Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med 2001; 16:606.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/48/31497/abstract/39\">",
"      Grunze H, Kasper S, Goodwin G, et al. The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders, part III: maintenance treatment. World J Biol Psychiatry 2004; 5:120.",
"     </a>",
"    </li>",
"    <li>",
"     National Institute for Health and Clinical Excellence. Bipolar disorder: The management of bipolar disorder in adults, children and adolescents, in primary and secondary care.",
"National Clinical Practice Guideline Number 38, 2006. file://www.nice.org.uk/ (Accessed on April 26, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/48/31497/abstract/41\">",
"      Bauer MS, Calabrese J, Dunner DL, et al. Multisite data reanalysis of the validity of rapid cycling as a course modifier for bipolar disorder in DSM-IV. Am J Psychiatry 1994; 151:506.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/48/31497/abstract/42\">",
"      Maj M, Magliano L, Pirozzi R, et al. Validity of rapid cycling as a course specifier for bipolar disorder. Am J Psychiatry 1994; 151:1015.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/48/31497/abstract/43\">",
"      Maj M, Pirozzi R, Formicola AM, Tortorella A. Reliability and validity of four alternative definitions of rapid-cycling bipolar disorder. Am J Psychiatry 1999; 156:1421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/48/31497/abstract/44\">",
"      Koukopoulos A, Sani G, Koukopoulos AE, et al. Duration and stability of the rapid-cycling course: a long-term personal follow-up of 109 patients. J Affect Disord 2003; 73:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/48/31497/abstract/45\">",
"      Schneider AL, Wilcox CS. Divalproate augmentation in lithium-resistant rapid cycling mania in four geriatric patients. J Affect Disord 1998; 47:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/48/31497/abstract/46\">",
"      Camus V, de Mendon&ccedil;a Lima CA, Antonioli D, Wertheimer J. Rapid-cycling affective disorder in the elderly: clinical subtype or specific course of manic-depressive illness? J Geriatr Psychiatry Neurol 1997; 10:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/48/31497/abstract/47\">",
"      Judd LL, Akiskal HS, Schettler PJ, et al. The long-term natural history of the weekly symptomatic status of bipolar I disorder. Arch Gen Psychiatry 2002; 59:530.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/48/31497/abstract/48\">",
"      Judd LL, Akiskal HS, Schettler PJ, et al. A prospective investigation of the natural history of the long-term weekly symptomatic status of bipolar II disorder. Arch Gen Psychiatry 2003; 60:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/48/31497/abstract/49\">",
"      Etain B, Mathieu F, Liquet S, et al. Clinical features associated with trait-impulsiveness in euthymic bipolar disorder patients. J Affect Disord 2013; 144:240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/48/31497/abstract/50\">",
"      Kemp DE, Gao K, Chan PK, et al. Medical comorbidity in bipolar disorder: relationship between illnesses of the endocrine/metabolic system and treatment outcome. Bipolar Disord 2010; 12:404.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/48/31497/abstract/51\">",
"      Kemp DE, Gao K, Ganocy SJ, et al. Medical and substance use comorbidity in bipolar disorder. J Affect Disord 2009; 116:64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/48/31497/abstract/52\">",
"      Maj M, Pirozzi R, Magliano L, Bartoli L. The prognostic significance of \"switching\" in patients with bipolar disorder: a 10-year prospective follow-up study. Am J Psychiatry 2002; 159:1711.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/48/31497/abstract/53\">",
"      Work Group on Psychiatric Evaluation, American Psychiatric Association Steering Committee on Practice Guidlines. Psychiatric evaluation of adults. Second edition. American Psychiatric Association. Am J Psychiatry 2006; 163:3.",
"     </a>",
"    </li>",
"    <li>",
"     American Psychiatric Association Practice Guideline for the Psychiatric Evaluation of Adults, Second Edition, 2006. file://www.psych.org/MainMenu/PsychiatricPractice/PracticeGuidelines_1.aspx (Accessed on July 18, 2011).",
"    </li>",
"    <li>",
"     Freudenreich O, Nejad SH, Francis A, Fricchione GL. Psychosis, mania, and catatonia. In: Textbook of Psychosomatic Medicine: Psychiatric Care of the Medically Ill, Second Edition, Levenson JL.  (Ed), American Psychiatric Publishing, Washington, DC 2011. p.219.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/48/31497/abstract/56\">",
"      Alarcon RD. Rapid cycling affective disorders: a clinical review. Compr Psychiatry 1985; 26:522.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/48/31497/abstract/57\">",
"      Kramlinger KG, Post RM. Ultra-rapid and ultradian cycling in bipolar affective illness. Br J Psychiatry 1996; 168:314.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/48/31497/abstract/58\">",
"      B&uuml;rgy M. Successful treatment of ultradian or ultra-ultra-rapid cycling: a case report. J Affect Disord 2011; 133:655.",
"     </a>",
"    </li>",
"    <li>",
"     The ICD-10 Classification of Mental and Behavioural Disorders: Clinical Descriptions and Diagnostic Guidelines. World Health Organization. file://www.who.int/classifications/icd/en/ (Accessed on October 31, 2011).",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 15249 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-61.234.146.186-6C4A3AC97D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_48_31497=[""].join("\n");
var outline_f30_48_31497=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H5068193\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5068102\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H87172591\">",
"      DEFINITIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5068109\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1412757\">",
"      General population",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1412771\">",
"      - Sociodemographic and clinical correlates",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1412764\">",
"      Patients with bipolar disorder",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H190200559\">",
"      Functional impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H190200718\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H190200740\">",
"      Antidepressants",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5068116\">",
"      CLINICAL MANIFESTATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H173673175\">",
"      Number of mood episodes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H173673501\">",
"      Duration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H173673637\">",
"      Other features",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4504928\">",
"      COMORBIDITY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H92694551\">",
"      COURSE OF ILLNESS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H81537325\">",
"      ASSESSMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16495348\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16496710\">",
"      Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5068193\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PSYCH/15249\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PSYCH/15249|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?8/34/8740\" title=\"figure 1\">",
"      Variability in presentation of rapid cycling bipolar disorder",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PSYCH/15249|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?3/53/3932\" title=\"table 1\">",
"      DSM-IV-TR diagnostic criteria for mania",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?22/39/23164\" title=\"table 2\">",
"      DSM-IV-TR diagnostic criteria for hypomania",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?17/21/17756\" title=\"table 3\">",
"      DSM-IV-TR diagnostic criteria for major depression",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?14/12/14541\" title=\"table 4\">",
"      PHQ-9 questionnaire",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/11/19639?source=related_link\">",
"      Bipolar disorder in adults: Epidemiology and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/9/27802?source=related_link\">",
"      Bipolar disorder in adults: Maintenance treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/3/44088?source=related_link\">",
"      Bipolar disorder in adults: Pharmacotherapy for acute depression",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/8/38026?source=related_link\">",
"      Bipolar disorder in adults: Pharmacotherapy for acute mania, mixed episodes, and hypomania",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?4/5/4178?source=related_link\">",
"      Patient information: Bipolar disorder (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?38/55/39796?source=related_link\">",
"      Patient information: Bipolar disorder (manic depression) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?31/61/32726?source=related_link\">",
"      Patient information: Reducing the costs of medicines (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?6/21/6483?source=related_link\">",
"      Patient information: Reducing the costs of medicines (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/14/42216?source=related_link\">",
"      Rapid cycling bipolar disorder in adults: Treatment of major depression",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/44/41673?source=related_link\">",
"      Rapid cycling bipolar disorder in adults: Treatment of mania, hypomania, and mixed episodes",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f30_48_31498="Management of refractory discoid lupus and subacute cutaneous lupus";
var content_f30_48_31498=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Management of refractory discoid lupus and subacute cutaneous lupus",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/48/31498/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/48/31498/contributors\">",
"     Jennie Clarke, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/48/31498/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/48/31498/contributors\">",
"     Jeffrey Callen, MD, FACP, FAAD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/48/31498/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/48/31498/contributors\">",
"     Abena O Ofori, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?30/48/31498/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 3, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H14890783\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Discoid lupus erythematosus (DLE) and subacute cutaneous lupus erythematosus (SCLE) are variants of cutaneous lupus erythematosus (LE) that may occur independently or as manifestations of systemic lupus erythematosus. DLE most commonly occurs on the head and is characterized by well-defined inflammatory plaques that evolve into atrophic, disfiguring scars (",
"    <a class=\"graphic graphic_picture graphicRef64844 graphicRef75833 \" href=\"mobipreview.htm?17/33/17945\">",
"     picture 1A-B",
"    </a>",
"    ). SCLE typically presents with erythematous, scaly papules or annular plaques on the neck, upper trunk, and arms (",
"    <a class=\"graphic graphic_picture graphicRef66580 graphicRef55903 \" href=\"mobipreview.htm?39/29/40407\">",
"     picture 2A-B",
"    </a>",
"    ). The symptomatic and disfiguring nature of DLE and SCLE underlies the need for appropriate treatment.",
"   </p>",
"   <p>",
"    Most patients with DLE or SCLE will respond to conservative therapy with topical agents and antimalarial drugs; however, when the response to these interventions is inadequate, alternative immunomodulating or immunosuppressive drugs must be utilized. The management of patients with refractory DLE and SCLE will be discussed here; the initial management of these disorders and the clinical manifestations of DLE and SCLE are reviewed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/19/314?source=see_link\">",
"     \"Initial management of discoid lupus and subacute cutaneous lupus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/33/36378?source=see_link\">",
"     \"Mucocutaneous manifestations of systemic lupus erythematosus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1087099\">",
"    <span class=\"h1\">",
"     APPROACH TO REFRACTORY DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;For most patients with cutaneous LE, strict photoprotection combined with topical or intralesional corticosteroids, topical calcineurin inhibitors, or systemic antimalarial agents results in satisfactory improvement. When disease is refractory to these interventions, other systemic agents are utilized. The adverse effects of many of these drugs limit their use to the subset of patients who fail to respond to conventional therapy.",
"   </p>",
"   <p>",
"    Data on the efficacy of treatments for refractory DLE and SCLE primarily are limited to small open-label studies, retrospective reviews, case series, and case reports. The scarcity of high quality studies stems from a lack of pharmaceutical, governmental, and foundational support for large, multicenter, controlled trials in cutaneous LE, as well as the relative rarity of refractory cutaneous LE. &nbsp;",
"   </p>",
"   <p>",
"    In addition, the historical absence of standardized objective measures of disease activity in cutaneous LE has made it difficult to systematically interpret the results of much of the published literature [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31498/abstract/1\">",
"     1",
"    </a>",
"    ]. In 2005, the Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) was developed and validated as a tool to assess disease activity and skin damage in cutaneous LE [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31498/abstract/2\">",
"     2",
"    </a>",
"    ]. The CLASI is now being used in a number of clinical trials, and should improve the quality and applicability of data from studies of cutaneous LE [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31498/abstract/3\">",
"     3",
"    </a>",
"    ]. A revised version of CLASI has also been proposed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31498/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32666738\">",
"    <span class=\"h2\">",
"     Choice of therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with DLE or SCLE who have failed topical, intralesional, and antimalarial therapy can be treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    , systemic retinoids,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    mofetil, or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/59/32688?source=see_link\">",
"     dapsone",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31498/abstract/5\">",
"     5",
"    </a>",
"    ]. Among these agents, methotrexate and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/1/39958?source=see_link\">",
"     acitretin",
"    </a>",
"    have the strongest evidence for efficacy for in the treatment of DLE and SCLE. In general, we favor methotrexate based upon the data supporting the use of this agent, as well as reports of patients in whom periods of disease remission occurred following the discontinuation of methotrexate therapy. Systemic retinoids (acitretin and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/62/1000?source=see_link\">",
"     isotretinoin",
"    </a>",
"    ) are much more expensive than methotrexate, and in our experience, relapses occur quickly following discontinuation of these drugs. (See",
"    <a class=\"local\" href=\"#H32666692\">",
"     'First-line agents'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The ability of patients to tolerate treatments also influences the selection of the most appropriate medication.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     Methotrexate",
"    </a>",
"    can cause serious toxicity in patients with renal insufficiency or preexisting liver disease. Although methotrexate,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    mofetil (MMF), and systemic retinoids are all teratogenic,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/1/39958?source=see_link\">",
"     acitretin",
"    </a>",
"    is an unfavorable choice for women of child-bearing potential due to the long period during which women must abstain from pregnancy following treatment with the drug (three years).",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/59/32688?source=see_link\">",
"     Dapsone",
"    </a>",
"    cannot be given to patients with sulfonamide allergies and must be used with caution in patients with G6PD deficiency.",
"   </p>",
"   <p>",
"    When one or more of the above agents is unsuccessful, more aggressive therapy to induce disease remission should be considered.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/62/29673?source=see_link\">",
"     Thalidomide",
"    </a>",
"    is highly effective for cutaneous LE, but it is the potential for serious adverse effects, including teratogenicity and a relatively high risk of peripheral neuropathy, that keeps thalidomide from being used as a first line agent for refractory cutaneous LE. Thalidomide should only be used in patients who comprehend the risks associated with this drug. Intravenous immunoglobulin (IVIG) has also been effective as a remission-inducing agent, particularly for SCLE. Improvement following IVIG generally is short-lived, and treatment with IVIG is expensive. (See",
"    <a class=\"local\" href=\"#H1088110\">",
"     'Remission-inducing agents'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    A number of other treatments, such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    , and other immunomodulatory agents, have also been used in refractory DLE and SCLE. However, the evidence for the efficacy of these drugs is limited and the range of adverse effects is wide, delegating the use of these agents to patients who fail to respond to the other therapies for refractory disease. Clofazimine has also been used for the treatment of refractory cutaneous LE, but the availability of this drug is limited. (See",
"    <a class=\"local\" href=\"#H10482853\">",
"     'Other agents'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32666745\">",
"    <span class=\"h2\">",
"     Systemic glucocorticoids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because of the chronic nature of cutaneous LE, the existence of only limited evidence for the efficacy of systemic glucocorticoids [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31498/abstract/6,7\">",
"     6,7",
"    </a>",
"    ], and the numerous potential adverse effects of long term therapy with systemic glucocorticoids, these drugs generally are not recommended for the treatment of DLE and SCLE [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31498/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32666692\">",
"    <span class=\"h1\">",
"     FIRST-LINE AGENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     Methotrexate",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/1/39958?source=see_link\">",
"     acitretin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/62/1000?source=see_link\">",
"     isotretinoin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    mofetil, and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/59/32688?source=see_link\">",
"     dapsone",
"    </a>",
"    can be effective treatments for patients with DLE or SCLE that is refractory to conventional therapy. (See",
"    <a class=\"local\" href=\"#H32666738\">",
"     'Choice of therapy'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1086886\">",
"    <span class=\"h2\">",
"     Methotrexate",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     Methotrexate",
"    </a>",
"    is a",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/61/9174?source=see_link\">",
"     folic acid",
"    </a>",
"    antagonist that has been used since the 1960s for systemic lupus erythematosus. The drug has also been shown to be effective for patients with cutaneous disease. Proposed mechanisms for the therapeutic properties of methotrexate in connective tissue diseases include anti-inflammatory effects secondary to increased production of adenosine, inhibitory action on lymphocytes and neutrophils, and suppression of antibody production [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31498/abstract/9-11\">",
"     9-11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1087166\">",
"    <span class=\"h3\">",
"     Efficacy and administration",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    was beneficial for cutaneous LE in a six-month randomized trial in which 37 patients with systemic lupus erythematosus were treated with either methotrexate (15 to 20",
"    <span class=\"nowrap\">",
"     mg/week)",
"    </span>",
"    or placebo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31498/abstract/12\">",
"     12",
"    </a>",
"    ]. Compared with the patients who were given placebo, those who took methotrexate were less likely to have signs of active cutaneous LE (malar rash or DLE) at the end of the trial. The percentage of patients with cutaneous LE decreased from 60 to 16 percent in the group treated with methotrexate, but increased from 76 to 84 percent in the placebo group. The authors did not distinguish between the response rates in patients with malar rash versus DLE.",
"   </p>",
"   <p>",
"    The use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    specifically for refractory DLE and SCLE is supported by the results of retrospective studies and case reports [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31498/abstract/9,13-16\">",
"     9,13-16",
"    </a>",
"    ]. In one retrospective study, 43 patients with cutaneous LE that was refractory to other systemic agents (including 16 subjects with SCLE and 12 subjects with DLE) were treated with 7.5 to 25",
"    <span class=\"nowrap\">",
"     mg/week",
"    </span>",
"    of oral or intravenous methotrexate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31498/abstract/15\">",
"     15",
"    </a>",
"    ]. All except one patient exhibited improvement in skin lesions, with the best clinical improvement noted in patients with SCLE or localized DLE. Another retrospective review of 12 patients with various types of cutaneous LE found similar success with methotrexate (10 to 25",
"    <span class=\"nowrap\">",
"     mg/week)",
"    </span>",
"    in refractory disease; complete or partial responses occurred in 9 out of the 10 patients with DLE OR SCLE [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31498/abstract/16\">",
"     16",
"    </a>",
"    ]. Five of the patients with cutaneous LE who responded to treatment also had long lasting remissions after cessation of methotrexate therapy.",
"   </p>",
"   <p>",
"    Typical doses of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    for DLE or SCLE range from 10 to 25 mg per week. At the start of therapy, a test dose of 5 to 10 mg followed by a complete blood count and liver function tests five to six days later is given to assess patient tolerability to the drug [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31498/abstract/17\">",
"     17",
"    </a>",
"    ]. Methotrexate can be administered orally, intramuscularly, subcutaneously, or intravenously.",
"   </p>",
"   <p>",
"    Improvement with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    is rapid, generally becoming evident within the first two to four weeks of therapy. Lesion clearance occurs at an average of six to eight weeks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31498/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1087357\">",
"    <span class=\"h3\">",
"     Adverse effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adverse effects of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    include gastrointestinal upset, oral ulcers, bone marrow suppression, hepatotoxicity, pulmonary fibrosis, and renal toxicity. Daily",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/61/9174?source=see_link\">",
"     folic acid",
"    </a>",
"    supplementation may lessen the severity of gastrointestinal upset and oral ulceration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31498/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Renal insufficiency increases the risk for toxicity, and the use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    should be carefully considered in elderly patients and those with renal disease. Dose adjustments are necessary when methotrexate is required in the setting of renal insufficiency. Alcohol abuse and preexisting liver disease are additional relative contraindications for methotrexate therapy. Methotrexate is teratogenic and should be avoided in women for one to three cycles preceding pregnancy, and in men for three months prior to an attempt to conceive. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/59/38842?source=see_link&amp;anchor=H17#H17\">",
"     \"Use of antiinflammatory and immunosuppressive drugs in rheumatic diseases during pregnancy and lactation\", section on 'Methotrexate'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Monitoring for hepatic, hematologic, and renal compromise before and during therapy is warranted in all patients treated with MTX. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/61/11223?source=see_link\">",
"     \"Major side effects of low-dose methotrexate\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/24/32134?source=see_link&amp;anchor=H2#H2\">",
"     \"Hepatotoxicity associated with chronic oral methotrexate for nonmalignant disease\", section on 'Hepatotoxicity'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/6/40042?source=see_link&amp;anchor=H32#H32\">",
"     \"Treatment of psoriasis\", section on 'Hepatotoxicity and liver biopsy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14890797\">",
"    <span class=\"h2\">",
"     Systemic retinoids",
"    </span>",
"    &nbsp;&mdash;&nbsp;The systemic retinoids",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/1/39958?source=see_link\">",
"     acitretin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/62/1000?source=see_link\">",
"     isotretinoin",
"    </a>",
"    , and etretinate can be effective for the treatment of DLE and SCLE [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31498/abstract/19-26\">",
"     19-26",
"    </a>",
"    ]. Knowledge of the anti-inflammatory properties of retinoids and the beneficial effects of these drugs on epidermal keratinization prompted the use of these agents in cutaneous LE. Retinoids may be particularly useful in treating SCLE or hypertrophic forms of DLE [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31498/abstract/21,22,27,28\">",
"     21,22,27,28",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1087401\">",
"    <span class=\"h3\">",
"     Efficacy and administration",
"    </span>",
"    &nbsp;&mdash;&nbsp;The aromatic retinoid etretinate was the first systemic retinoid studied for cutaneous LE. In an open-label study of 19 patients with cutaneous LE (including 11 patients with DLE and 7 patients with SCLE), 7 patients (64 percent) with DLE and 4 patients (57 percent) with SCLE obtained excellent or good responses to etretinate within two to six weeks of treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31498/abstract/20\">",
"     20",
"    </a>",
"    ]. The best responses were seen in males with DLE.",
"   </p>",
"   <p>",
"    Etretinate was removed from the United States market in 1998 due concern over its prolonged elimination half life (120 days). It was replaced by its metabolite",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/1/39958?source=see_link\">",
"     acitretin",
"    </a>",
"    , which was effective in treating cutaneous LE in a 12-week pilot study of 14 patients with DLE and 6 patients SCLE. All patients with SCLE, and 9 out of the 14 patients with DLE, achieved complete clearing or marked reduction of lesions by the end of the study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31498/abstract/21\">",
"     21",
"    </a>",
"    ]. Seven patients who previously had not responded well to antimalarials or systemic glucocorticoids were among the responders to acitretin.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/1/39958?source=see_link\">",
"     Acitretin",
"    </a>",
"    (50",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    was subsequently compared to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/26/2471?source=see_link\">",
"     hydroxychloroquine",
"    </a>",
"    (400",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    in an eight-week randomized trial of 58 patients with DLE OR SCLE, and was determined to have similar efficacy as hydroxychloroquine. Complete clearing or marked improvement occurred in 46 percent of patients treated with acitretin and 50 percent of patients treated with hydroxychloroquine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31498/abstract/24\">",
"     24",
"    </a>",
"    ]. Seven patients who had previously failed antimalarial therapy were included in the acitretin group (n = 28); however, the authors did not report response rates specific for this group. Adverse effects were more frequent with acitretin therapy.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/62/1000?source=see_link\">",
"     Isotretinoin",
"    </a>",
"    has a shorter elimination half-life than",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/1/39958?source=see_link\">",
"     acitretin",
"    </a>",
"    and etretinate, and favorable responses have been documented in patients with DLE and SCLE in an open label study and case reports [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31498/abstract/23,25,26\">",
"     23,25,26",
"    </a>",
"    ]. In the open label study, 8 out of 10 patients with SCLE or DLE that was refractory to sunscreens, topical corticosteroids, and antimalarials completed a 16-week course of isotretinoin therapy (80",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31498/abstract/23\">",
"     23",
"    </a>",
"    ]. All eight patients achieved a response designated as excellent. Two patients were lost to follow-up prior to the first two-week follow-up visit.",
"   </p>",
"   <p>",
"    When used in the treatment of DLE,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/1/39958?source=see_link\">",
"     acitretin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/62/1000?source=see_link\">",
"     isotretinoin",
"    </a>",
"    usually are prescribed in doses of 0.2 to 1.0",
"    <span class=\"nowrap\">",
"     mg/kg/day",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31498/abstract/5\">",
"     5",
"    </a>",
"    ]. The response to retinoid therapy usually is rapid, occurring within the first two to six weeks of treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31498/abstract/20,21,25\">",
"     20,21,25",
"    </a>",
"    ]. However, our clinical experiences and that of others indicate that relapses often occur quickly once the drug is stopped [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31498/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Improvement in DLE and SCLE with oral",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/45/25299?source=see_link\">",
"     alitretinoin",
"    </a>",
"    (30 mg per day) has been reported in a few patients who failed treatment with a variety of other therapies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31498/abstract/29\">",
"     29",
"    </a>",
"    ]. Further study is necessary to evaluate the efficacy and safety of alitretinoin when used for cutaneous lupus. Oral alitretinoin is not commercially available in the United States.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1087464\">",
"    <span class=\"h3\">",
"     Adverse effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common side effects of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/62/1000?source=see_link\">",
"     isotretinoin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/1/39958?source=see_link\">",
"     acitretin",
"    </a>",
"    include hypertriglyceridemia and xerosis, both of which resolve with drug discontinuation. Elevated transaminases, skeletal hyperostosis, and, rarely, leukopenia may also occur with systemic retinoids.",
"   </p>",
"   <p>",
"    Retinoids are potent teratogens and must be used with caution in females of child-bearing age. Although",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/1/39958?source=see_link\">",
"     acitretin",
"    </a>",
"    has a shorter half life than etretinate (two days), it can be reversely metabolized to etretinate, thereby prolonging the risk for teratogenicity. Due to its short elimination half-life,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/62/1000?source=see_link\">",
"     isotretinoin",
"    </a>",
"    is a better choice for female patients of child-bearing potential; strict contraceptive practices must be adhered to during and for one month after cessation of isotretinoin. Three years of strict pregnancy prevention is necessary following the cessation of acitretin therapy. (See",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/1/39958?source=see_link\">",
"     \"Acitretin: Drug information\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/42/22184?source=see_link&amp;anchor=H7#H7\">",
"     \"Oral isotretinoin therapy for acne vulgaris\", section on 'Isotretinoin safety'",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/62/1000?source=see_link\">",
"     \"Isotretinoin: Drug information\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10481559\">",
"    <span class=\"h2\">",
"     Mycophenolate mofetil",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/29/4569?source=see_link\">",
"     Mycophenolate",
"    </a>",
"    mofetil (MMF) is an immunosuppressant that reversibly inhibits inosine monophosphate dehydrogenase, an enzyme necessary for de novo purine synthesis. Because it preferentially targets cells that are dependent on de novo purine synthesis for DNA and RNA production such as B and T cells, it has a more favorable toxicity profile than many other immunosuppressants.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10481566\">",
"    <span class=\"h3\">",
"     Efficacy and administration",
"    </span>",
"    &nbsp;&mdash;&nbsp;Evidence supporting the use of MMF for SCLE and DLE is limited to an open-label study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31498/abstract/30\">",
"     30",
"    </a>",
"    ], a retrospective study, and case reports [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31498/abstract/31-34\">",
"     31-34",
"    </a>",
"    ]. In the open label study, 10 patients with SCLE that was refractory to topical corticosteroids or antimalarials were treated with MMF (1440",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    for three months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31498/abstract/30\">",
"     30",
"    </a>",
"    ]. Reductions in disease activity were statistically significant (CLASI decreased from 10.8&plusmn;6.0 to 2.9&plusmn;2.6) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31498/abstract/30\">",
"     30",
"    </a>",
"    ]. In the retrospective study, the addition of MMF to existing treatment regimens led to at least partial disease improvement in all of 24 women with cutaneous lupus refractory to antimalarial therapy who were treated with MMF for at least three months (19 with DLE, 3 with SCLE, 1 with",
"    <span class=\"nowrap\">",
"     DLE/SCLE",
"    </span>",
"    overlap, and 1 with tumid lupus erythematosus) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31498/abstract/35\">",
"     35",
"    </a>",
"    ]. Final doses ranged from 1500 to 3500",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    (average final dose 2750",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    and the mean time to initial treatment response was 2.76 months.",
"   </p>",
"   <p>",
"    In contrast, a retrospective study of seven patients with a variety of skin manifestations of systemic lupus erythematosus (including three patients with DLE and one patient with SCLE) who failed to improve with or tolerate other systemic therapies found that MMF (2000 to 3000",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    was poorly effective in treating skin disease; five out of seven patients did not respond to treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31498/abstract/36\">",
"     36",
"    </a>",
"    ]. One of the two patients who had a partial response to treatment was a patient with DLE who responded initially, but subsequently experienced a disease flare during treatment. The other responder was a patient with urticarial vasculitis.",
"   </p>",
"   <p>",
"    MMF typically is given in dosages of 1 to 3 grams per day [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31498/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10481573\">",
"    <span class=\"h3\">",
"     Adverse effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although MMF is generally well tolerated, nausea, vomiting, and diarrhea are the most common adverse reactions. Administering the drug in two or three divided doses during the day may help to minimize gastrointestinal symptoms. Reversible cytopenias and teratogenicity are additional side effects of MMF. An increased risk of malignancy has been postulated but has not been definitively demonstrated to date. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/50/2855?source=see_link\">",
"     \"Mycophenolate mofetil: Pharmacology and adverse effects when used in the treatment of rheumatic diseases\"",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/29/4569?source=see_link\">",
"     \"Mycophenolate: Drug information\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14890811\">",
"    <span class=\"h2\">",
"     Dapsone",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/59/32688?source=see_link\">",
"     Dapsone",
"    </a>",
"    has variable efficacy in the treatment of DLE and SCLE. Like other sulfonamide drugs, its antimicrobial action occurs via inhibition of the",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/61/9174?source=see_link\">",
"     folic acid",
"    </a>",
"    pathway. The mechanisms underlying its anti-inflammatory properties are less clear, but the efficacy of dapsone in cutaneous disease primarily has been linked to inhibitory effects on neutrophil-mediated tissue damage and neutrophil migration. Concordantly, in clinical practice dapsone has been most useful in treating skin conditions characterized by prominent neutrophilic infiltrates.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1087479\">",
"    <span class=\"h3\">",
"     Efficacy and administration",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/59/32688?source=see_link\">",
"     Dapsone",
"    </a>",
"    therapy can result in dramatic improvement in patients with bullous lupus erythematosus, a variant of cutaneous LE that presents with neutrophilic infiltrates on biopsy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31498/abstract/37-39\">",
"     37-39",
"    </a>",
"    ]. Although neutrophils are not a prominent feature in the histopathology of DLE and SCLE, dapsone is effective for some patients.",
"   </p>",
"   <p>",
"    Evidence for the efficacy of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/59/32688?source=see_link\">",
"     dapsone",
"    </a>",
"    in the treatment of SCLE is limited to case reports [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31498/abstract/40-44\">",
"     40-44",
"    </a>",
"    ], but successful use of dapsone in DLE has been documented in a pilot study and retrospective review. In the pilot study, 16 patients with DLE were given dapsone (100",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    for 6 to 16 weeks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31498/abstract/45\">",
"     45",
"    </a>",
"    ]. At the end of the study, four patients (25 percent) were noted to have appreciable improvement in skin disease; moderate improvement occurred in an additional four patients. A separate review of the records of 33 patients with DLE who were treated with dapsone revealed excellent improvement in eight patients (24 percent), and partial effect in another eight subjects [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31498/abstract/46\">",
"     46",
"    </a>",
"    ]. The excellent responders included two out of six patients who were treated simultaneously with dapsone and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/26/2471?source=see_link\">",
"     hydroxychloroquine",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    Therapeutic dosages of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/59/32688?source=see_link\">",
"     dapsone",
"    </a>",
"    range from 25 to 200 mg daily. Treatment is initiated with low doses and the dosage is gradually increased while closely monitoring hematologic parameters [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31498/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1087486\">",
"    <span class=\"h3\">",
"     Adverse effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adverse effects of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/59/32688?source=see_link\">",
"     dapsone",
"    </a>",
"    include hemolysis and methemoglobinemia. All patients develop some degree of hemolysis, but those with glucose-6-phosphate dehydrogenase (G6PD) deficiency are more likely to develop substantial hemolysis. Methemoglobinemia is dose-dependent and is independent of G6PD status.",
"   </p>",
"   <p>",
"    Idiosyncratic adverse reactions to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/59/32688?source=see_link\">",
"     dapsone",
"    </a>",
"    include peripheral neuropathy, agranulocytosis, and dapsone hypersensitivity syndrome. Agranulocytosis may occur as early as three weeks into therapy and almost always occurs within the first 12 weeks of treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31498/abstract/47\">",
"     47",
"    </a>",
"    ]. Patients may present with fevers, pharyngitis, or, less commonly, signs of sepsis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31498/abstract/48\">",
"     48",
"    </a>",
"    ]. Fever, a morbilliform skin eruption, and hepatitis are features of the hypersensitivity syndrome. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/17/41241?source=see_link&amp;anchor=H10#H10\">",
"     \"Drug eruptions\", section on 'Hypersensitivity syndrome'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1088110\">",
"    <span class=\"h1\">",
"     REMISSION-INDUCING AGENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients who fail treatment with one or more of the agents reviewed above,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/62/29673?source=see_link\">",
"     thalidomide",
"    </a>",
"    or IVIG can be used in an attempt to attain disease control. The potential adverse effects of these drugs make them most useful as short-term remission-inducing agents, which can be followed by maintenance treatment with conventional therapies or other systemic medications for refractory cutaneous LE. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/19/314?source=see_link\">",
"     \"Initial management of discoid lupus and subacute cutaneous lupus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1087851\">",
"    <span class=\"h2\">",
"     Thalidomide",
"    </span>",
"    &nbsp;&mdash;&nbsp;First synthesized as a sedative agent in 1954,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/62/29673?source=see_link\">",
"     thalidomide",
"    </a>",
"    has had a tumultuous history. After the first description in 1961 of its association with phocomelia in infants born to mothers who had taken the drug during pregnancy, it was withdrawn from the pharmaceutical market worldwide in 1962. Despite these potential adverse effects, thalidomide can be highly effective for DLE and SCLE.",
"   </p>",
"   <p>",
"    The mechanism of action of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/62/29673?source=see_link\">",
"     thalidomide",
"    </a>",
"    in cutaneous LE is incompletely understood, but is thought to involve the inhibition of TNF-alpha and the suppression of UVB induced keratinocyte apoptosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31498/abstract/49\">",
"     49",
"    </a>",
"    ]. The detection of elevated levels of TNF-alpha in lesions of SCLE supports the theory that suppression of TNF-alpha is at least partially responsible for the efficacy of thalidomide for cutaneous LE [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31498/abstract/50\">",
"     50",
"    </a>",
"    ]. However, drugs that inhibit TNF-alpha have also been implicated in the induction of lupus-like cutaneous and systemic disease. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/4/2120?source=see_link&amp;anchor=H11#H11\">",
"     \"Tumor necrosis factor-alpha inhibitors: Induction of antibodies, autoantibodies, and autoimmune diseases\", section on 'Autoimmune diseases'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other potential mechanisms of action of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/62/29673?source=see_link\">",
"     thalidomide",
"    </a>",
"    include modulation of lymphocyte proliferation, cytokine production, neutrophil chemotaxis, and angiogenesis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31498/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1088126\">",
"    <span class=\"h3\">",
"     Efficacy and administration",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no randomized trials of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/62/29673?source=see_link\">",
"     thalidomide",
"    </a>",
"    for DLE or SCLE. However, a review summarizing the results of eight case series (171 patients in total) found that thalidomide therapy was highly effective for cutaneous LE. Complete responses occurred in 63 percent of patients with DLE and 59 percent of patients with SCLE. Partial responses to treatment were observed in 27 percent and 24 percent of patients, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31498/abstract/51\">",
"     51",
"    </a>",
"    ]. Of note, patients who were simultaneously treated with other therapies for cutaneous LE were not excluded in the review.",
"   </p>",
"   <p>",
"    A subsequent study that utilized retrospectively-assessed CLASI scores to evaluate the response to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/62/29673?source=see_link\">",
"     thalidomide",
"    </a>",
"    (&le;100 mg per day) in 60 patients with refractory cutaneous lupus (42 percent with DLE, 30 percent with SCLE) also supported the efficacy of this agent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31498/abstract/52\">",
"     52",
"    </a>",
"    ]. The patients were treated for a mean of six months and were followed for an average of eight years. Improvement occurred in 58 of the 59 patients who tolerated thalidomide, and complete responses were achieved in 50 patients (85 percent). Long-term disease clearance was more likely to occur in SCLE than DLE; lesions recurred in 25 versus 87 percent of patients with DLE and SCLE, respectively, following the cessation of therapy. All patients who relapsed responded to the reintroduction of thalidomide.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/62/29673?source=see_link\">",
"     Thalidomide",
"    </a>",
"    has a quick onset of action; responses to thalidomide generally begin within the first month of treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31498/abstract/52\">",
"     52",
"    </a>",
"    ]. Thalidomide should be initiated at doses of 50 to 100",
"    <span class=\"nowrap\">",
"     mg/day,",
"    </span>",
"    and the dose should be tapered to the lowest effective dose after clinical improvement is attained [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31498/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although the development of adverse effects, particularly peripheral neuropathy, limits long term treatment with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/62/29673?source=see_link\">",
"     thalidomide",
"    </a>",
"    in many patients, relapse often occurs within three to four months if therapy is discontinued [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31498/abstract/51,52\">",
"     51,52",
"    </a>",
"    ]. Thus, thalidomide is frequently used as a therapeutic bridge while awaiting the onset of other systemic agents. In patients who tolerate thalidomide and cannot be transitioned to other effective therapies, thalidomide (25 to 50",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    or less) can be given as maintenance therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31498/abstract/51\">",
"     51",
"    </a>",
"    ]. In our clinical experience, some patients can maintain improvement on doses as low as 25 or 50 mg every three days. These patients should be monitored closely for adverse effects. (See",
"    <a class=\"local\" href=\"#H1088133\">",
"     'Adverse effects'",
"    </a>",
"    below.) &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1088133\">",
"    <span class=\"h3\">",
"     Adverse effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Careful patient selection and conscientious monitoring must occur with the use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/62/29673?source=see_link\">",
"     thalidomide",
"    </a>",
"    . The most well known and most serious toxicity of thalidomide is teratogenicity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31498/abstract/51\">",
"     51",
"    </a>",
"    ]. In the United States, thalidomide can only be prescribed through the",
"    <a class=\"external\" href=\"file://www.thalomid.com/steps_program.aspx\">",
"     System for Thalidomide Education and Prescribing Safety (S.T.E.P.S.&reg;) program",
"    </a>",
"    (",
"    <a class=\"external\" href=\"file://www.thalomid.com/steps_program.aspx\">",
"     file://www.thalomid.com/steps_program.aspx",
"    </a>",
"    ), a registration and monitoring program for the safe use of thalidomide [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31498/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Peripheral neuropathy is another serious adverse effect associated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/62/29673?source=see_link\">",
"     thalidomide",
"    </a>",
"    . Sensory neuropathy typically precedes motor neuropathy. It is unclear whether the risk for this side effect is dose-dependent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31498/abstract/54-56\">",
"     54-56",
"    </a>",
"    ], and estimates for the risk for peripheral neuropathy vary widely [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31498/abstract/51,52,54-58\">",
"     51,52,54-58",
"    </a>",
"    ]. One prospective study of patients with cutaneous LE reported the development of neuropathy in 10 out of 14 patients (71 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31498/abstract/55\">",
"     55",
"    </a>",
"    ]. If symptoms of neuropathy develop, the dose of thalidomide should be decreased [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31498/abstract/51\">",
"     51",
"    </a>",
"    ]. If symptoms persist one month after dose-reduction, thalidomide should be discontinued.",
"   </p>",
"   <p>",
"    Guidelines in the",
"    <a class=\"external\" href=\"file://www.thalomid.com/steps_program.aspx\">",
"     S.T.E.P.S.&reg; program",
"    </a>",
"    recommend that nerve conduction studies should also be performed at baseline and every six months thereafter. However, since symptoms of neuropathy may occur in patients with normal nerve conduction studies, this test should be used only as an adjunct to clinical assessment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31498/abstract/51\">",
"     51",
"    </a>",
"    ]. As noted above,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/62/29673?source=see_link\">",
"     thalidomide",
"    </a>",
"    should be reduced or discontinued in patients who develop symptoms of neuropathy. The package label for thalidomide states that it is contraindicated in patients with preexisting peripheral neuropathy.",
"   </p>",
"   <p>",
"    Other side effects of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/62/29673?source=see_link\">",
"     thalidomide",
"    </a>",
"    include thrombosis, sedation, constipation, endocrine dysfunction, and neutropenia. Treatment with thalidomide should be considered carefully in patients with other risk factors for venous thrombosis. &nbsp;(See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/57/29594?source=see_link\">",
"     \"Thrombotic complications following treatment of multiple myeloma with thalidomide and its analogues\"",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/62/29673?source=see_link\">",
"     \"Thalidomide: Drug information\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10482425\">",
"    <span class=\"h3\">",
"     Lenalidomide",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/25/16793?source=see_link\">",
"     Lenalidomide",
"    </a>",
"    is a",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/62/29673?source=see_link\">",
"     thalidomide",
"    </a>",
"    derivative that is a far more potent inhibitor of TNF-alpha. This drug has a lower frequency of sedation, constipation, and neuropathy than thalidomide.",
"   </p>",
"   <p>",
"    Beneficial effects of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/25/16793?source=see_link\">",
"     lenalidomide",
"    </a>",
"    in refractory cutaneous LE have been reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31498/abstract/59-61\">",
"     59-61",
"    </a>",
"    ]. In an open-label study in which 15 women with refractory cutaneous lupus (including 9 with DLE and 2 with SCLE) were treated with lenalidomide (initially 5 mg per day and increased to 10 mg per day if no improvement), 12 patients achieved complete responses (CLASI score = 0), including four who previously failed",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/62/29673?source=see_link\">",
"     thalidomide",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31498/abstract/61\">",
"     61",
"    </a>",
"    ]. The remaining patients included two patients with DLE who achieved only partial improvement (at least 50 percent improvement in CLASI score), and one patient with DLE who was withdrawn from the study due to poor gastrointestinal tolerance of the drug. The patients with DLE and SCLE who achieved complete responses did so within a mean of six weeks (range 2 to 12 weeks), and the median length of treatment for all patients was 11 months. Relapses were common after the tapering or cessation of therapy.",
"   </p>",
"   <p>",
"    In a smaller, six-week, open-label study, at least a four-point reduction in CLASI score occurred in four of five patients (three with DLE and one with a mixed presentation of SCLE and tumid lupus erythematosus) who were treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/25/16793?source=see_link\">",
"     lenalidomide",
"    </a>",
"    (5 mg per day), including two who had previously failed",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/62/29673?source=see_link\">",
"     thalidomide",
"    </a>",
"    therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31498/abstract/60\">",
"     60",
"    </a>",
"    ]. Of note, one of the responders with DLE developed symptoms of systemic lupus erythematosus during treatment, an event that the authors postulated may have been a side effect of lenalidomide therapy. However, none of the patients in the larger open-label study experienced a similar event [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31498/abstract/61\">",
"     61",
"    </a>",
"    ]. Additional studies are necessary to determine the role of lenalidomide in the treatment of cutaneous LE.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14890853\">",
"    <span class=\"h2\">",
"     IVIG",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intravenous immunoglobulin (IVIG) is a product derived from the pooled plasma of tens of thousands of donors that provides a vast array of immunoregulatory substances. The exact mechanisms of action of IVIG in the treatment of autoimmune disorders remain unknown. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/11/28857?source=see_link&amp;anchor=H9#H9\">",
"     \"General principles in the use of immune globulin\", section on 'Autoimmune disorders'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32666583\">",
"    <span class=\"h3\">",
"     Efficacy and administration",
"    </span>",
"    &nbsp;&mdash;&nbsp;Data are limited on the use of IVIG for DLE and SCLE. The efficacy of IVIG was evaluated in an uncontrolled study of 12 patients with cutaneous LE that was refractory to other systemic therapies (including five patients with disseminated DLE and five patients with SCLE) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31498/abstract/62\">",
"     62",
"    </a>",
"    ]. Subjects were given a total of two doses of 1",
"    <span class=\"nowrap\">",
"     g/kg",
"    </span>",
"    of IVIG on consecutive days followed by 400",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    monthly for up to six months. After treatment, five patients (42 percent) had more than 75 percent improvement in skin lesions and two patients (17 percent) exhibited partial responses (50 to 75 percent improvement in skin lesions). Overall, patients with SCLE exhibited greater degrees of improvement than those with DLE, and relapse was common after the discontinuation of therapy. Several case reports also have supported in the efficacy of IVIG for SCLE that had been refractory to other therapies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31498/abstract/63-65\">",
"     63-65",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In contrast, in a 12-month open-label study of IVIG in seven patients with cutaneous LE (including five patients with systemic lupus erythematosus manifesting as malar rash and oral ulcers and two patients with SCLE), monthly infusions of IVIG at a dose of 300",
"    <span class=\"nowrap\">",
"     mg/kg/day",
"    </span>",
"    for five days were associated with no change in disease activity in the patients with systemic lupus and worsening of disease in those with SCLE [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31498/abstract/66\">",
"     66",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Dosing regimens for IVIG vary, although it is often administered at a dose of 2",
"    <span class=\"nowrap\">",
"     g/kg",
"    </span>",
"    every four to eight weeks depending upon response [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31498/abstract/63,65\">",
"     63,65",
"    </a>",
"    ]. Although responses are prompt, they are typically short lived, necessitating repeated infusions to maintain benefit. Some patients may fail to respond to subsequent courses of therapy after relapse [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31498/abstract/62\">",
"     62",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Because of the high cost of this agent and high likelihood for relapse it should be reserved for attempting to gain rapid control of severe, refractory disease while initiating other long term therapies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32666590\">",
"    <span class=\"h3\">",
"     Adverse effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adverse events following IVIG infusion include hypersensitivity reactions, headache, vasculitis, aseptic meningitis, renal failure, myocardial infarction, and thrombosis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/32/38409?source=see_link\">",
"     \"Intravenous immune globulin: Adverse effects\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10482853\">",
"    <span class=\"h1\">",
"     OTHER AGENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple other medications have been used for SCLE and DLE. With the exception of clofazimine, data supporting these therapies is limited.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14536481\">",
"    <span class=\"h2\">",
"     Clofazimine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clofazimine is an antimycobacterial agent that also possesses antiinflammatory and immunosuppressive properties. This drug has been used in the treatment of infectious, inflammatory, and granulomatous diseases of the skin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31498/abstract/67\">",
"     67",
"    </a>",
"    ]. Due to concern for the induction antimicrobial resistance that could compromise the treatment of Hansen&rsquo;s disease and multi-drug resistant tuberculosis, the use of clofazimine is restricted in many countries, including the United States [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31498/abstract/68,69\">",
"     68,69",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a six-month randomized trial, 33 patients with both systemic lupus erythematosus and cutaneous LE (malar rash, DLE, or SCLE) were treated with either clofazimine (100",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/54/25447?source=see_link\">",
"     chloroquine",
"    </a>",
"    (250",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31498/abstract/70\">",
"     70",
"    </a>",
"    ]. At the end of the study, 19 percent of patients treated with clofazimine and 41 percent of patients treated with chloroquine achieved a complete response. However, the difference in efficacy between the two agents was not statistically significant. The trial did not distinguish between response rates in DLE versus SCLE. Of note, five patients in the clofazimine group experienced a flare of systemic lupus during treatment. It was unclear whether clofazimine was a contributing factor, and the authors advised against the use of clofazimine in patients with systemic lupus erythematosus.",
"   </p>",
"   <p>",
"    The efficacy of clofazimine was also investigated in an uncontrolled study of 26 patients with DLE, many of whom had failed",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/54/25447?source=see_link\">",
"     chloroquine",
"    </a>",
"    and other treatments [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31498/abstract/71\">",
"     71",
"    </a>",
"    ]. Most patients were treated with 100 or 200",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    for three to six months. Disease remission occurred in 17 out of 26 patients (65 percent), and six patients remained in remission two to five months after treatment was discontinued.",
"   </p>",
"   <p>",
"    A common adverse effect of clofazimine is an orange-pink discoloration of the skin that begins within the first few weeks of treatment and resolves a few months after the end of therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31498/abstract/72\">",
"     72",
"    </a>",
"    ]. Discoloration of body fluids (eg, sweat, tears, sputum, urine, and feces) may also occur. Other potential risks include acquired ichthyosis, gastrointestinal distress, and elevations of transaminases. Rarely, particularly with doses greater than 100",
"    <span class=\"nowrap\">",
"     mg/day,",
"    </span>",
"    deposition of crystals within the small intestine can lead to a severe or fatal enteropathy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31498/abstract/67\">",
"     67",
"    </a>",
"    ]. Other infrequent side effects include splenic infarction and eosinophilic enteritis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32666318\">",
"    <span class=\"h2\">",
"     Azathioprine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Successful treatment of DLE and SCLE with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    has been reported. In an open-label study, four patients with refractory SCLE and two patients with refractory DLE were treated with azathioprine (100 to 150",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    (20 to 30",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31498/abstract/73\">",
"     73",
"    </a>",
"    ]. One patient with SCLE had an excellent response with near clearing of skin lesions and a decreased oral prednisone requirement; two additional patients with SCLE exhibited partial responses. Adverse effects led to the discontinuation of therapy in two patients, and one patient with severe, erosive palmar DLE failed to respond to therapy. However, several case reports have supported the use of azathioprine in patients with extensive or recalcitrant DLE [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31498/abstract/74-76\">",
"     74-76",
"    </a>",
"    ]. Improvement with azathioprine usually occurs within one to two months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31498/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Adverse effects of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    include bone marrow suppression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31498/abstract/77\">",
"     77",
"    </a>",
"    ], gastrointestinal upset [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31498/abstract/78-80\">",
"     78-80",
"    </a>",
"    ], hepatitis, and abnormal liver function tests [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31498/abstract/77,81\">",
"     77,81",
"    </a>",
"    ]. The risk of myelosuppression may be related to thiopurine methyltransferase activity (TPMT), an enzyme involved in the metabolism of azathioprine. Assessment of the TPMT enzyme activity should be performed prior to initiating AZA therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31498/abstract/82\">",
"     82",
"    </a>",
"    ]. Most patients with cutaneous LE and normal TPMT activity are treated with 1 to 2.5",
"    <span class=\"nowrap\">",
"     mg/kg/day",
"    </span>",
"    of azathioprine. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/32/22026?source=see_link&amp;anchor=H6#H6\">",
"     \"Overview of pharmacogenomics\", section on 'Thiopurine methyltransferase'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    An increased incidence of lymphoproliferative malignancies has been reported in patients with rheumatoid arthritis treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31498/abstract/83,84\">",
"     83,84",
"    </a>",
"    ]; however, it has not been proven that a similar risk occurs in patients treated with azathioprine for cutaneous LE. One retrospective study (n = 358) that compared the incidence of lymphoma in patients with systemic lupus erythematosus who were treated with azathioprine versus those who had not received the drug found no significant difference in the risk for lymphoma or other malignancies between the two groups [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31498/abstract/85\">",
"     85",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14890860\">",
"    <span class=\"h2\">",
"     Rituximab",
"    </span>",
"    &nbsp;&mdash;&nbsp;Originally approved in 1997 for the treatment of non-Hodgkin&rsquo;s lymphoma,",
"    <strong>",
"    </strong>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    is a chimeric monoclonal antibody specific for human CD20, a membrane associated glycoprotein highly expressed on the surface of pre-B cells and resting and activated mature B lymphocytes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31498/abstract/86\">",
"     86",
"    </a>",
"    ]. The binding of rituximab to CD20 results in B cell death [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31498/abstract/86\">",
"     86",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Two case reports document improvement in severe, refractory SCLE with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31498/abstract/87,88\">",
"     87,88",
"    </a>",
"    ]. In one patient, a single cycle of rituximab (375",
"    <span class=\"nowrap\">",
"     mg/m2",
"    </span>",
"    weekly for four weeks) led to an 11 month remission followed by a flare that necessitated retreatment with another cycle. Improvement was maintained with rituximab infusions every eight weeks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31498/abstract/87\">",
"     87",
"    </a>",
"    ]. In the second report, two weekly doses of rituximab (1000",
"    <span class=\"nowrap\">",
"     mg/dose)",
"    </span>",
"    led to near complete clearance of SCLE lesions, discontinuation of systemic corticosteroids, and sustained improvement for at least six months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31498/abstract/88\">",
"     88",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although generally well tolerated, the adverse effects of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    include infections, nausea, serum sickness-like reactions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31498/abstract/89\">",
"     89",
"    </a>",
"    ], and infusion-related events including hypotension, fevers, and rigors. A boxed warning has been mandated by the US Food and Drug Administration (FDA) due to reports of fatalities from infusion reactions, severe mucocutaneous reactions, and progressive multifocal leukoencephalopathy due to JC virus in patients treated with rituximab. (See",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     \"Rituximab: Drug information\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     Rituximab",
"    </a>",
"    should be considered only for patients with severe, extensive, cutaneous LE that has failed to respond to other therapies for refractory disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14538552\">",
"    <span class=\"h2\">",
"     Gold",
"    </span>",
"    &nbsp;&mdash;&nbsp;The antiinflammatory properties of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?30/47/31476?source=see_link\">",
"     auranofin",
"    </a>",
"    (oral gold) have been useful in cutaneous LE. Auranofin was an effective therapy in a series of 23 patients with DLE that was refractory to other treatments; four patients (17 percent) achieved complete resolution of skin disease, and partial improvement occurred in 15 patients (65 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31498/abstract/90\">",
"     90",
"    </a>",
"    ]. Gold is no longer used by most clinicians due to its multiple side effects, including gastrointestinal distress, headache, pruritus, rash, and hematologic or renal abnormalities [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31498/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10482774\">",
"    <span class=\"h2\">",
"     Cyclosporine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     Cyclosporine",
"    </a>",
"    exerts its immunosuppressive effects via the inhibition of IL-2 and other cytokines. Combination therapy with cyclosporine and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/26/2471?source=see_link\">",
"     hydroxychloroquine",
"    </a>",
"    was effective in improving skin lesions in a patient with SCLE and generalized lichen planus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31498/abstract/91\">",
"     91",
"    </a>",
"    ]. However, in other reports, cyclosporine failed to induce improvement in patients with DLE that was refractory to other therapies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31498/abstract/92,93\">",
"     92,93",
"    </a>",
"    ]. DLE has also occurred during treatment with cyclosporine for other disorders in patients without a history of cutaneous LE [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31498/abstract/94,95\">",
"     94,95",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/27/28090?source=see_link\">",
"     \"Pharmacology and side effects of cyclosporine and tacrolimus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10482781\">",
"    <span class=\"h2\">",
"     Cyclophosphamide",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     Cyclophosphamide",
"    </a>",
"    is an alkylating agent and a potent immunosuppressant. In one open-label study of cyclophosphamide in nine patients with SCLE or DLE, five patients obtained complete remission, three had partial responses, and one patient did not respond [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31498/abstract/96\">",
"     96",
"    </a>",
"    ]. Because of the serious toxicities associated with its use, the rheumatologic use of cyclophosphamide is typically limited to the treatment of life or organ threatening disease. Cyclophosphamide should not be used solely for the treatment of cutaneous LE. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/40/16008?source=see_link\">",
"     \"General principles of the use of cyclophosphamide in rheumatic and renal disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14534301\">",
"    <span class=\"h2\">",
"     Leflunomide",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/36/19015?source=see_link\">",
"     Leflunomide",
"    </a>",
"    is a unique immunomodulating agent; its major mechanism of action involves the inhibition of the synthesis of the pyrimidine, ribonucleotide uridine monophosphate pyrimidine (rUMP). It is approved by the US FDA for the treatment of rheumatoid arthritis, and has been used successfully in some patients with systemic lupus erythematosus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31498/abstract/97,98\">",
"     97,98",
"    </a>",
"    ]. Although one case report documents improvement of SCLE with leflunomide therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31498/abstract/99\">",
"     99",
"    </a>",
"    ], many more reports document the onset of drug-induced SCLE or worsening of SCLE with this agent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31498/abstract/99-105\">",
"     99-105",
"    </a>",
"    ]. In the absence of additional evidence documenting efficacy in cutaneous LE, we do not recommend its use for SCLE and DLE. (See",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/36/19015?source=see_link\">",
"     \"Leflunomide: Drug information\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16532555\">",
"    <span class=\"h2\">",
"     Additional therapies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other therapies that have been used in the treatment of cutaneous LE include",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/46/742?source=see_link\">",
"     ustekinumab",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31498/abstract/106\">",
"     106",
"    </a>",
"    ], apremilast [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31498/abstract/107\">",
"     107",
"    </a>",
"    ],",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/48/35594?source=see_link\">",
"     phenytoin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31498/abstract/108\">",
"     108",
"    </a>",
"    ],",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/28/8647?source=see_link\">",
"     sulfasalazine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31498/abstract/109-111\">",
"     109-111",
"    </a>",
"    ],",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/61/26583?source=see_link\">",
"     cefuroxime",
"    </a>",
"    axetil [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31498/abstract/112\">",
"     112",
"    </a>",
"    ],",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/0/26629?source=see_link\">",
"     danazol",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31498/abstract/113,114\">",
"     113,114",
"    </a>",
"    ], and extracorporeal photophoresis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31498/abstract/115-117\">",
"     115-117",
"    </a>",
"    ]. Despite reports of efficacy in cutaneous LE, phenytoin and sulfasalazine also have been associated with the development of drug-induced lupus. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/32/28168?source=see_link\">",
"     \"Drug-induced lupus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Photodynamic therapy was reported to be effective in one patient with DLE that was refractory to topical and antimalarial therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31498/abstract/118\">",
"     118",
"    </a>",
"    ]; however, photodynamic therapy was not useful in two patients with refractory DLE in another report [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31498/abstract/119\">",
"     119",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10482982\">",
"    <span class=\"h1\">",
"     INVESTIGATIONAL THERAPY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16532635\">",
"    <span class=\"h2\">",
"     R-salbutamol",
"    </span>",
"    &nbsp;&mdash;&nbsp;R-salbutamol is an antiinflammatory agent that inhibits T-cell production of the proinflammatory cytokines IL-2 and interferon-gamma. After the authors of a pilot study investigating a topical formulation of R-salbutamol reported at least moderate clinical improvement in four out of four patients with treatment-resistant SCLE and two out of five patients with treatment-resistant DLE [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31498/abstract/120\">",
"     120",
"    </a>",
"    ], a randomized trial (n=37) was developed to evaluate the efficacy of the drug in DLE [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/48/31498/abstract/121\">",
"     121",
"    </a>",
"    ]. Although the randomized trial found no significant difference in the primary outcome measure (change in modified CLASI score) between R-salbutamol and placebo, significantly greater improvement was noted in specific lesions characteristics, such as scaling or hypertrophy, pain, itching, induration, and lesion size. Further studies are necessary to investigate efficacy and safety of R-salbutamol for cutaneous LE.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?16/5/16466?source=see_link\">",
"       \"Patient information: Discoid lupus (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14890874\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Most patients with discoid lupus erythematosus (DLE) and subacute cutaneous lupus erythematosus (SCLE) respond well to treatment with photoprotection, topical medications, and systemic antimalarial drugs. Patients who fail to respond to these agents can be treated with alternative systemic therapies. These drugs have a wide range of potential adverse effects and should be prescribed with caution. (See",
"      <a class=\"local\" href=\"#H1087099\">",
"       'Approach to refractory disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The decision of which agent to use for the treatment of refractory cutaneous lupus erythematosus (LE) should be based upon drug efficacy, assessment of the patient&rsquo;s comorbidities, and consideration of the drug&rsquo;s potential adverse effects. For some patients, cost may also be a factor. (See",
"      <a class=\"local\" href=\"#H32666738\">",
"       'Choice of therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with DLE and SCLE who fail treatment with conventional therapy, we suggest treatment with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      before other systemic agents for refractory disease (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Methotrexate has been shown to be efficacious for refractory cutaneous LE, can be used for long-term therapy, and is relatively inexpensive. For patients who cannot tolerate methotrexate, or do not respond to this drug, additional treatment options include systemic retinoids,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?4/29/4569?source=see_link\">",
"       mycophenolate",
"      </a>",
"      mofetil, and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/59/32688?source=see_link\">",
"       dapsone",
"      </a>",
"      . (See",
"      <a class=\"local\" href=\"#H32666692\">",
"       'First-line agents'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Both",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      and systemic retinoids are categorized as pregnancy class X drugs, and women must abstain from pregnancy for three years following treatment with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/1/39958?source=see_link\">",
"       acitretin",
"      </a>",
"      . In general, acitretin should be avoided in women of child-bearing potential. (See",
"      <a class=\"local\" href=\"#H1087357\">",
"       'Adverse effects'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H1087464\">",
"       'Adverse effects'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Some patients fail to improve with first-line therapies for refractory cutaneous LE, and may require more aggressive therapies to induce remission. For patients who fail to improve with first-line therapies for refractory cutaneous LE, we suggest treatment with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?28/62/29673?source=see_link\">",
"       thalidomide",
"      </a>",
"      (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). IVIG is another therapeutic option for inducing remission in patients with refractory cutaneous LE. (See",
"      <a class=\"local\" href=\"#H1088110\">",
"       'Remission-inducing agents'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients treated with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?28/62/29673?source=see_link\">",
"       thalidomide",
"      </a>",
"      should be well-informed of the potential adverse effects of the drug, and should be willing to comply with recommendations to ensure the safe use of thalidomide. Thalidomide is a potent teratogen, and in the United States, both clinicians and patients must register in the",
"      <a class=\"external\" href=\"file://www.thalomid.com/steps_program.aspx\">",
"       S.T.E.P.S.&reg; program",
"      </a>",
"      prior to the initiation of therapy. Patients treated with the drug also should be monitored closely for the development of peripheral neuropathy. (See",
"      <a class=\"local\" href=\"#H1087851\">",
"       'Thalidomide'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/48/31498/abstract/1\">",
"      Jessop S, Whitelaw DA, Delamere FM. Drugs for discoid lupus erythematosus. Cochrane Database Syst Rev 2009; :CD002954.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/48/31498/abstract/2\">",
"      Albrecht J, Taylor L, Berlin JA, et al. The CLASI (Cutaneous Lupus Erythematosus Disease Area and Severity Index): an outcome instrument for cutaneous lupus erythematosus. J Invest Dermatol 2005; 125:889.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/48/31498/abstract/3\">",
"      Jolly M, Kazmi N, Mikolaitis RA, et al. Validation of the Cutaneous Lupus Disease Area and Severity Index (CLASI) using physician- and patient-assessed health outcome measures. J Am Acad Dermatol 2013; 68:618.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/48/31498/abstract/4\">",
"      Kuhn A, Meuth AM, Bein D, et al. Revised Cutaneous Lupus Erythematosus Disease Area and Severity Index (RCLASI): a modified outcome instrument for cutaneous lupus erythematosus. Br J Dermatol 2010; 163:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/48/31498/abstract/5\">",
"      Kuhn A, Ruland V, Bonsmann G. Cutaneous lupus erythematosus: update of therapeutic options part II. J Am Acad Dermatol 2011; 65:e195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/48/31498/abstract/6\">",
"      Miettunen PM, Bruecks A, Remington T. Dramatic response of scarring scalp discoid lupus erythematosus (DLE) to intravenous methylprednisolone, oral corticosteroids, and hydroxychloroquine in a 5-year-old child. Pediatr Dermatol 2009; 26:338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/48/31498/abstract/7\">",
"      Goldberg JW, Lidsky MD. Pulse methylprednisolone therapy for persistent subacute cutaneous lupus. Arthritis Rheum 1984; 27:837.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/48/31498/abstract/8\">",
"      Callen JP. Management of \"refractory\" skin disease in patients with lupus erythematosus. Best Pract Res Clin Rheumatol 2005; 19:767.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/48/31498/abstract/9\">",
"      Kuhn A, Specker C, Ruzicka T, Lehmann P. Methotrexate treatment for refractory subacute cutaneous lupus erythematosus. J Am Acad Dermatol 2002; 46:600.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/48/31498/abstract/10\">",
"      Genestier L, Paillot R, Quemeneur L, et al. Mechanisms of action of methotrexate. Immunopharmacology 2000; 47:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/48/31498/abstract/11\">",
"      B&ouml;hm I. Decrease of B-cells and autoantibodies after low-dose methotrexate. Biomed Pharmacother 2003; 57:278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/48/31498/abstract/12\">",
"      Carneiro JR, Sato EI. Double blind, randomized, placebo controlled clinical trial of methotrexate in systemic lupus erythematosus. J Rheumatol 1999; 26:1275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/48/31498/abstract/13\">",
"      B&ouml;hm L, Uerlich M, Bauer R. Rapid improvement of subacute cutaneous lupus erythematosus with low-dose methotrexate. Dermatology 1997; 194:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/48/31498/abstract/14\">",
"      Malcangi G, Brandozzi G, Giangiacomi M, et al. Bullous SLE: response to methotrexate and relationship with disease activity. Lupus 2003; 12:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/48/31498/abstract/15\">",
"      Wenzel J, Br&auml;hler S, Bauer R, et al. Efficacy and safety of methotrexate in recalcitrant cutaneous lupus erythematosus: results of a retrospective study in 43 patients. Br J Dermatol 2005; 153:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/48/31498/abstract/16\">",
"      Boehm IB, Boehm GA, Bauer R. Management of cutaneous lupus erythematosus with low-dose methotrexate: indication for modulation of inflammatory mechanisms. Rheumatol Int 1998; 18:59.",
"     </a>",
"    </li>",
"    <li>",
"     Callen, JP, Kulp-Shorten, CL, Wolverton, SE. Methotrexate. In: Comprehensive dermatologic drug therapy, 2nd ed, Wolverton (Ed), Elsevier Inc., Philadelphia 2007. p.163.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/48/31498/abstract/18\">",
"      Ortiz Z, Shea B, Suarez-Almazor ME, et al. The efficacy of folic acid and folinic acid in reducing methotrexate gastrointestinal toxicity in rheumatoid arthritis. A metaanalysis of randomized controlled trials. J Rheumatol 1998; 25:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/48/31498/abstract/19\">",
"      Shimizu S, Yasui C, Kawasaki H, Tsuchiya K. Dramatic efficacy of oral aromatic retinoid in long-standing hypertrophic lupus erythematosus. Acta Derm Venereol 2004; 84:491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/48/31498/abstract/20\">",
"      Ruzicka T, Meurer M, Braun-Falco O. Treatment of cutaneous lupus erythematosus with etretinate. Acta Derm Venereol 1985; 65:324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/48/31498/abstract/21\">",
"      Ruzicka T, Meurer M, Bieber T. Efficiency of acitretin in the treatment of cutaneous lupus erythematosus. Arch Dermatol 1988; 124:897.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/48/31498/abstract/22\">",
"      Al-Mutairi N, Rijhwani M, Nour-Eldin O. Hypertrophic lupus erythematosus treated successfully with acitretin as monotherapy. J Dermatol 2005; 32:482.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/48/31498/abstract/23\">",
"      Newton RC, Jorizzo JL, Solomon AR Jr, et al. Mechanism-oriented assessment of isotretinoin in chronic or subacute cutaneous lupus erythematosus. Arch Dermatol 1986; 122:170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/48/31498/abstract/24\">",
"      Ruzicka T, Sommerburg C, Goerz G, et al. Treatment of cutaneous lupus erythematosus with acitretin and hydroxychloroquine. Br J Dermatol 1992; 127:513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/48/31498/abstract/25\">",
"      Shornick JK, Formica N, Parke AL. Isotretinoin for refractory lupus erythematosus. J Am Acad Dermatol 1991; 24:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/48/31498/abstract/26\">",
"      Furner BB. Subacute cutaneous lupus erythematosus response to isotretinoin. Int J Dermatol 1990; 29:587.",
"     </a>",
"    </li>",
"    <li>",
"     Grupper, CH, Barretti, B. Lupus erythematosus and etretinate. In: Retinoid Therapy: A review of clinical and laboratory research, Cunliffe, WJ, Miller, AJ (Eds), Springer-Verlag, New York 1984. p.73.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/48/31498/abstract/28\">",
"      Green SG, Piette WW. Successful treatment of hypertrophic lupus erythematosus with isotretinoin. J Am Acad Dermatol 1987; 17:364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/48/31498/abstract/29\">",
"      Kuhn A, Patsinakidis N, Luger T. Alitretinoin for cutaneous lupus erythematosus. J Am Acad Dermatol 2012; 67:e123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/48/31498/abstract/30\">",
"      Kreuter A, Tomi NS, Weiner SM, et al. Mycophenolate sodium for subacute cutaneous lupus erythematosus resistant to standard therapy. Br J Dermatol 2007; 156:1321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/48/31498/abstract/31\">",
"      Goyal S, Nousari HC. Treatment of resistant discoid lupus erythematosus of the palms and soles with mycophenolate mofetil. J Am Acad Dermatol 2001; 45:142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/48/31498/abstract/32\">",
"      Hanjani NM, Nousari CH. Mycophenolate mofetil for the treatment of cutaneous lupus erythematosus with smoldering systemic involvement. Arch Dermatol 2002; 138:1616.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/48/31498/abstract/33\">",
"      Schanz S, Ulmer A, Rassner G, Fierlbeck G. Successful treatment of subacute cutaneous lupus erythematosus with mycophenolate mofetil. Br J Dermatol 2002; 147:174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/48/31498/abstract/34\">",
"      Sadlier M, Kirby B, Lally A. Mycophenolate mofetil and hydroxychloroquine: an effective treatment for recalcitrant cutaneous lupus erythematosus. J Am Acad Dermatol 2012; 66:160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/48/31498/abstract/35\">",
"      Gammon B, Hansen C, Costner MI. Efficacy of mycophenolate mofetil in antimalarial-resistant cutaneous lupus erythematosus. J Am Acad Dermatol 2011; 65:717.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/48/31498/abstract/36\">",
"      Pisoni CN, Obermoser G, Cuadrado MJ, et al. Skin manifestations of systemic lupus erythematosus refractory to multiple treatment modalities: poor results with mycophenolate mofetil. Clin Exp Rheumatol 2005; 23:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/48/31498/abstract/37\">",
"      Hall RP, Lawley TJ, Smith HR, Katz SI. Bullous eruption of systemic lupus erythematosus. Dramatic response to dapsone therapy. Ann Intern Med 1982; 97:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/48/31498/abstract/38\">",
"      Ludgate MW, Greig DE. Bullous systemic lupus erythematosus responding to dapsone. Australas J Dermatol 2008; 49:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/48/31498/abstract/39\">",
"      Tay YK, Wong SN, Tan T. Bullous systemic lupus erythematosus--a case report and review. Ann Acad Med Singapore 1995; 24:879.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/48/31498/abstract/40\">",
"      McCormack LS, Elgart ML, Turner ML. Annular subacute cutaneous lupus erythematosus responsive to dapsone. J Am Acad Dermatol 1984; 11:397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/48/31498/abstract/41\">",
"      Neri R, Mosca M, Bernacchi E, Bombardieri S. A case of SLE with acute, subacute and chronic cutaneous lesions successfully treated with Dapsone. Lupus 1999; 8:240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/48/31498/abstract/42\">",
"      Tsutsui K, Imai T, Hatta N, et al. Widespread pruritic plaques in a patient with subacute cutaneous lupus erythematosus and hypocomplementemia: response to dapsone therapy. J Am Acad Dermatol 1996; 35:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/48/31498/abstract/43\">",
"      Fenton DA, Black MM. Low-dose dapsone in the treatment of subacute cutaneous lupus erythematosus. Clin Exp Dermatol 1986; 11:102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/48/31498/abstract/44\">",
"      Holtman JH, Neustadt DH, Klein J, Callen JP. Dapsone is an effective therapy for the skin lesions of subacute cutaneous lupus erythematosus and urticarial vasculitis in a patient with C2 deficiency. J Rheumatol 1990; 17:1222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/48/31498/abstract/45\">",
"      Coburn PR, Shuster S. Dapsone and discoid lupus erythematosus. Br J Dermatol 1982; 106:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/48/31498/abstract/46\">",
"      Lindskov R, Reymann F. Dapsone in the treatment of cutaneous lupus erythematosus. Dermatologica 1986; 172:214.",
"     </a>",
"    </li>",
"    <li>",
"     Hall R. Dapsone. In: Comprehensive Dermatologic Therapy, Wolverton S (Ed), WB Saunders Co, Philadelphia 2001. p.230.",
"    </li>",
"    <li>",
"     Hall, RP, Mickle, CP. Dapsone. In: Comprehensive dermatologic drug therapy, 2nd ed, Wolverton, SE (Eds), Elsevier Inc., Philadelphia 2007. p.240.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/48/31498/abstract/49\">",
"      Lu KQ, Brenneman S, Burns R Jr, et al. Thalidomide inhibits UVB-induced mouse keratinocyte apoptosis by both TNF-alpha-dependent and TNF-alpha-independent pathways. Photodermatol Photoimmunol Photomed 2003; 19:272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/48/31498/abstract/50\">",
"      Zampieri S, Alaibac M, Iaccarino L, et al. Tumour necrosis factor alpha is expressed in refractory skin lesions from patients with subacute cutaneous lupus erythematosus. Ann Rheum Dis 2006; 65:545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/48/31498/abstract/51\">",
"      Pelle MT, Werth VP. Thalidomide in cutaneous lupus erythematosus. Am J Clin Dermatol 2003; 4:379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/48/31498/abstract/52\">",
"      Cort&eacute;s-Hern&aacute;ndez J, Torres-Salido M, Castro-Marrero J, et al. Thalidomide in the treatment of refractory cutaneous lupus erythematosus: prognostic factors of clinical outcome. Br J Dermatol 2012; 166:616.",
"     </a>",
"    </li>",
"    <li>",
"     System for thalidomide education and prescribing safety (STEPSTM), Starter Kit and Prescriber Info.  Celegene Corporation, Warren, NJ 2001.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/48/31498/abstract/54\">",
"      Bastuji-Garin S, Ochonisky S, Bouche P, et al. Incidence and risk factors for thalidomide neuropathy: a prospective study of 135 dermatologic patients. J Invest Dermatol 2002; 119:1020.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/48/31498/abstract/55\">",
"      Briani C, Zara G, Rondinone R, et al. Positive and negative effects of thalidomide on refractory cutaneous lupus erythematosus. Autoimmunity 2005; 38:549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/48/31498/abstract/56\">",
"      Ochonisky S, Verroust J, Bastuji-Garin S, et al. Thalidomide neuropathy incidence and clinico-electrophysiologic findings in 42 patients. Arch Dermatol 1994; 130:66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/48/31498/abstract/57\">",
"      Briani C, Zara G, Rondinone R, et al. Thalidomide neurotoxicity: prospective study in patients with lupus erythematosus. Neurology 2004; 62:2288.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/48/31498/abstract/58\">",
"      Clemmensen OJ, Olsen PZ, Andersen KE. Thalidomide neurotoxicity. Arch Dermatol 1984; 120:338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/48/31498/abstract/59\">",
"      Shah A, Albrecht J, Bonilla-Martinez Z, et al. Lenalidomide for the treatment of resistant discoid lupus erythematosus. Arch Dermatol 2009; 145:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/48/31498/abstract/60\">",
"      Braunstein I, Goodman NG, Rosenbach M, et al. Lenalidomide therapy in treatment-refractory cutaneous lupus erythematosus: histologic and circulating leukocyte profile and potential risk of a systemic lupus flare. J Am Acad Dermatol 2012; 66:571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/48/31498/abstract/61\">",
"      Cort&eacute;s-Hern&aacute;ndez J, Avila G, Vilardell-Tarr&eacute;s M, Ordi-Ros J. Efficacy and safety of lenalidomide for refractory cutaneous lupus erythematosus. Arthritis Res Ther 2012; 14:R265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/48/31498/abstract/62\">",
"      Goodfield M, Davison K, Bowden K. Intravenous immunoglobulin (IVIg) for therapy-resistant cutaneous lupus erythematosus (LE). J Dermatolog Treat 2004; 15:46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/48/31498/abstract/63\">",
"      G&eacute;n&eacute;reau T, Chosidow O, Danel C, et al. High-dose intravenous immunoglobulin in cutaneous lupus erythematosus. Arch Dermatol 1999; 135:1124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/48/31498/abstract/64\">",
"      Kreuter A, Hyun J, Altmeyer P, Gambichler T. Intravenous immunoglobulin for recalcitrant subacute cutaneous lupus erythematosus. Acta Derm Venereol 2005; 85:545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/48/31498/abstract/65\">",
"      Lampropoulos CE, Hughes GR, D' Cruz DP. Intravenous immunoglobulin in the treatment of resistant subacute cutaneous lupus erythematosus: a possible alternative. Clin Rheumatol 2007; 26:981.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/48/31498/abstract/66\">",
"      De Pit&agrave; O, Bellucci AM, Ruffelli M, et al. Intravenous immunoglobulin therapy is not able to efficiently control cutaneous manifestations in patients with lupus erythematosus. Lupus 1997; 6:415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/48/31498/abstract/67\">",
"      Arbiser JL, Moschella SL. Clofazimine: a review of its medical uses and mechanisms of action. J Am Acad Dermatol 1995; 32:241.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.hrsa.gov/hansens/clinical/regimens.htm (Accessed on September 23, 2010).",
"    </li>",
"    <li>",
"     file://www.who.int/lep/mdt/clofazimine/en/ (Accessed on September 23, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/48/31498/abstract/70\">",
"      Bezerra EL, Vilar MJ, da Trindade Neto PB, Sato EI. Double-blind, randomized, controlled clinical trial of clofazimine compared with chloroquine in patients with systemic lupus erythematosus. Arthritis Rheum 2005; 52:3073.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/48/31498/abstract/71\">",
"      Mackey JP, Barnes J. Clofazimine in the treatment of discoid lupus erythematosus. Br J Dermatol 1974; 91:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/48/31498/abstract/72\">",
"      Gurfinkel P, Pina JC, Ramos-e-Silva M. Use of clofazimine in dermatology. J Drugs Dermatol 2009; 8:846.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/48/31498/abstract/73\">",
"      Callen JP, Spencer LV, Burruss JB, Holtman J. Azathioprine. An effective, corticosteroid-sparing therapy for patients with recalcitrant cutaneous lupus erythematosus or with recalcitrant cutaneous leukocytoclastic vasculitis. Arch Dermatol 1991; 127:515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/48/31498/abstract/74\">",
"      Tsokos GC, Caughman SW, Klippel JH. Successful treatment of generalized discoid skin lesions with azathioprine. Its use in a patient with systemic lupus erythematosus. Arch Dermatol 1985; 121:1323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/48/31498/abstract/75\">",
"      Shehade S. Successful treatment of generalized discoid skin lesions with azathioprine. Arch Dermatol 1986; 122:376.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/48/31498/abstract/76\">",
"      Ashinoff R, Werth VP, Franks AG Jr. Resistant discoid lupus erythematosus of palms and soles: successful treatment with azathioprine. J Am Acad Dermatol 1988; 19:961.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/48/31498/abstract/77\">",
"      Whisnant JK, Pelkey J. Rheumatoid arthritis: treatment with azathioprine (IMURAN (R)). Clinical side-effects and laboratory abnormalities. Ann Rheum Dis 1982; 41 Suppl 1:44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/48/31498/abstract/78\">",
"      Santiago M. Diarrhoea secondary to azathioprine in two patients with SLE. Lupus 1999; 8:565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/48/31498/abstract/79\">",
"      Assini JF, Hamilton R, Strosberg JM. Adverse reactions to azathioprine mimicking gastroenteritis. J Rheumatol 1986; 13:1117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/48/31498/abstract/80\">",
"      Godeau B, Paul M, Autegarden JE, et al. Hypersensitivity to azathioprine mimicking gastroenteritis. Absence of recurrence with 6-mercaptopurine. Gastroenterol Clin Biol 1995; 19:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/48/31498/abstract/81\">",
"      Eisenbach C, Goeggelmann C, Flechtenmacher C, et al. Severe cholestatic hepatitis caused by azathioprine. Immunopharmacol Immunotoxicol 2005; 27:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/48/31498/abstract/82\">",
"      Snow JL, Gibson LE. The role of genetic variation in thiopurine methyltransferase activity and the efficacy and/or side effects of azathioprine therapy in dermatologic patients. Arch Dermatol 1995; 131:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/48/31498/abstract/83\">",
"      Silman AJ, Petrie J, Hazleman B, Evans SJ. Lymphoproliferative cancer and other malignancy in patients with rheumatoid arthritis treated with azathioprine: a 20 year follow up study. Ann Rheum Dis 1988; 47:988.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/48/31498/abstract/84\">",
"      Sutcliffe N, Smith C, Speight PM, Isenberg DA. Mucosa-associated lymphoid tissue lymphomas in two patients with rheumatoid arthritis on second-line agents, and secondary Sj&ouml;gren's syndrome. Rheumatology (Oxford) 2000; 39:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/48/31498/abstract/85\">",
"      Nero P, Rahman A, Isenberg DA. Does long term treatment with azathioprine predispose to malignancy and death in patients with systemic lupus erythematosus? Ann Rheum Dis 2004; 63:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/48/31498/abstract/86\">",
"      Silverman GJ. Anti-CD20 therapy in systemic lupus erythematosus: a step closer to the clinic. Arthritis Rheum 2005; 52:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/48/31498/abstract/87\">",
"      Kieu V, O'Brien T, Yap LM, et al. Refractory subacute cutaneous lupus erythematosus successfully treated with rituximab. Australas J Dermatol 2009; 50:202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/48/31498/abstract/88\">",
"      Uthman I, Taher A, Abbas O, et al. Successful treatment of refractory skin manifestations of systemic lupus erythematosus with rituximab: report of a case. Dermatology 2008; 216:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/48/31498/abstract/89\">",
"      Hellerstedt B, Ahmed A. Delayed-type hypersensitivity reaction or serum sickness after rituximab treatment. Ann Oncol 2003; 14:1792.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/48/31498/abstract/90\">",
"      Dalziel K, Going G, Cartwright PH, et al. Treatment of chronic discoid lupus erythematosus with an oral gold compound (auranofin). Br J Dermatol 1986; 115:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/48/31498/abstract/91\">",
"      Grabbe S, Kolde G. Coexisting lichen planus and subacute cutaneous lupus erythematosus. Clin Exp Dermatol 1995; 20:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/48/31498/abstract/92\">",
"      Heule F, van Joost T, Beukers R. Cyclosporine in the treatment of lupus erythematosus. Arch Dermatol 1986; 122:973.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/48/31498/abstract/93\">",
"      Yell JA, Burge SM. Cyclosporin and discoid lupus erythematosus. Br J Dermatol 1994; 131:132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/48/31498/abstract/94\">",
"      Obermoser G, Weber F, Sepp N. Discoid lupus erythematosus in a patient receiving cyclosporine for liver transplantation. Acta Derm Venereol 2001; 81:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/48/31498/abstract/95\">",
"      Di Lernia V, Bisighini G. Discoid lupus erythematosus during treatment with cyclosporine. Acta Derm Venereol 1996; 76:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/48/31498/abstract/96\">",
"      Schulz EJ, Menter MA. Treatment of discoid and subacute lupus erythematosus with cyclophosphamide. Br J Dermatol 1971; 85:60.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/48/31498/abstract/97\">",
"      Remer CF, Weisman MH, Wallace DJ. Benefits of leflunomide in systemic lupus erythematosus: a pilot observational study. Lupus 2001; 10:480.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/48/31498/abstract/98\">",
"      Tam LS, Li EK, Wong CK, et al. Double-blind, randomized, placebo-controlled pilot study of leflunomide in systemic lupus erythematosus. Lupus 2004; 13:601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/48/31498/abstract/99\">",
"      Suess A, Sticherling M. Leflunomide in subacute cutaneous lupus erythematosus - two sides of a coin. Int J Dermatol 2008; 47:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/48/31498/abstract/100\">",
"      Chan SK, Hazleman BL, Burrows NP. Subacute cutaneous lupus erythematosus precipitated by leflunomide. Clin Exp Dermatol 2005; 30:724.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/48/31498/abstract/101\">",
"      Elias AR, Tam CC, David-Bajar KM. Subacute cutaneous lupus erythematosus associated with leflunomide. Cutis 2005; 76:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/48/31498/abstract/102\">",
"      Gensburger D, Kawashima M, Marotte H, et al. Lupus erythematosus with leflunomide: induction or reactivation? Ann Rheum Dis 2005; 64:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/48/31498/abstract/103\">",
"      Go&euml;b V, Berthelot JM, Joly P, et al. Leflunomide-induced subacute cutaneous lupus erythematosus. Rheumatology (Oxford) 2005; 44:823.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/48/31498/abstract/104\">",
"      Kerr OA, Murray CS, Tidman MJ. Subacute cutaneous lupus erythematosus associated with leflunomide. Clin Exp Dermatol 2004; 29:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/48/31498/abstract/105\">",
"      Marzano AV, Ramoni S, Del Papa N, et al. Leflunomide-induced subacute cutaneous lupus erythematosus with erythema multiforme-like lesions. Lupus 2008; 17:329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/48/31498/abstract/106\">",
"      De Souza A, Ali-Shaw T, Strober BE, Franks AG Jr. Successful treatment of subacute lupus erythematosus with ustekinumab. Arch Dermatol 2011; 147:896.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/48/31498/abstract/107\">",
"      De Souza A, Strober BE, Merola JF, et al. Apremilast for discoid lupus erythematosus: results of a phase 2, open-label, single-arm, pilot study. J Drugs Dermatol 2012; 11:1224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/48/31498/abstract/108\">",
"      Rodriguez-Castellanos MA, Barba Rubio J, Barba G&oacute;mez JF, Gonz&aacute;lez M&eacute;ndoza A. Phenytoin in the treatment of discoid lupus erythematosus. Arch Dermatol 1995; 131:620.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/48/31498/abstract/109\">",
"      Art&uuml;z F, Lenk N, Deniz N, Alli N. Efficacy of sulfasalazine in discoid lupus erythematosus. Int J Dermatol 1996; 35:746.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/48/31498/abstract/110\">",
"      Carmichael AJ, Paul CJ. Discoid lupus erythematosus responsive to sulphasalazine. Br J Dermatol 1991; 125:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/48/31498/abstract/111\">",
"      Delaporte E, Catteau B, Sabbagh N, et al. [Treatment of discoid lupus erythematosus with sulfasalazine: 11 cases]. Ann Dermatol Venereol 1997; 124:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/48/31498/abstract/112\">",
"      Rudnicka L, Szyma��ska E, Walecka I, S��owi��ska M. Long-term cefuroxime axetil in subacute cutaneous lupus erythematosus. A report of three cases. Dermatology 2000; 200:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/48/31498/abstract/113\">",
"      Torrelo A, Espa&ntilde;a A, Medina S, Ledo A. Danazol and discoid lupus erythematosus. Dermatologica 1990; 181:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/48/31498/abstract/114\">",
"      Englert HJ, Hughes GV. Danazol and discoid lupus. Br J Dermatol 1988; 119:407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/48/31498/abstract/115\">",
"      Richter HI, Krutmann J, Goerz G. [Extracorporeal photopheresis in therapy-refractory disseminated discoid lupus erythematosus]. Hautarzt 1998; 49:487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/48/31498/abstract/116\">",
"      Wollina U, Looks A. Extracorporeal photochemotherapy in cutaneous lupus erythematosus. J Eur Acad Dermatol Venereol 1999; 13:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/48/31498/abstract/117\">",
"      Boeckler P, Liu V, Lipsker D. Extracorporeal photopheresis in recalcitrant lupus erythematosus. Clin Exp Dermatol 2009; 34:e295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/48/31498/abstract/118\">",
"      Fern&aacute;ndez-Guarino M, P&eacute;rez-Garc&iacute;a B, Harto A, Ja&eacute;n P. Discoid lupus erythematosus: good response to treatment with photodynamic therapy. J Eur Acad Dermatol Venereol 2008; 22:1142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/48/31498/abstract/119\">",
"      Romero-Mat&eacute; A, Casta&ntilde;o-Su&aacute;rez E, Garc&iacute;a-Donoso C, et al. Unsuccessful treatment of recalcitrant cutaneous discoid lupus erythematosus with photodynamic therapy. Photodermatol Photoimmunol Photomed 2010; 26:156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/48/31498/abstract/120\">",
"      Wulf HC, Ullman S. Discoid and subacute lupus erythematosus treated with 0.5% R-salbutamol cream. Arch Dermatol 2007; 143:1589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/48/31498/abstract/121\">",
"      Jemec GB, Ullman S, Goodfield M, et al. A randomized controlled trial of R-salbutamol for topical treatment of discoid lupus erythematosus. Br J Dermatol 2009; 161:1365.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13775 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-180.241.123.62-A90D1A112B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_48_31498=[""].join("\n");
var outline_f30_48_31498=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H14890874\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14890783\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1087099\">",
"      APPROACH TO REFRACTORY DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32666738\">",
"      Choice of therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32666745\">",
"      Systemic glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H32666692\">",
"      FIRST-LINE AGENTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1086886\">",
"      Methotrexate",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1087166\">",
"      - Efficacy and administration",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1087357\">",
"      - Adverse effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14890797\">",
"      Systemic retinoids",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1087401\">",
"      - Efficacy and administration",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1087464\">",
"      - Adverse effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10481559\">",
"      Mycophenolate mofetil",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10481566\">",
"      - Efficacy and administration",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10481573\">",
"      - Adverse effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14890811\">",
"      Dapsone",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1087479\">",
"      - Efficacy and administration",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1087486\">",
"      - Adverse effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1088110\">",
"      REMISSION-INDUCING AGENTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1087851\">",
"      Thalidomide",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1088126\">",
"      - Efficacy and administration",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1088133\">",
"      - Adverse effects",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10482425\">",
"      - Lenalidomide",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14890853\">",
"      IVIG",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H32666583\">",
"      - Efficacy and administration",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H32666590\">",
"      - Adverse effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10482853\">",
"      OTHER AGENTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14536481\">",
"      Clofazimine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32666318\">",
"      Azathioprine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14890860\">",
"      Rituximab",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14538552\">",
"      Gold",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10482774\">",
"      Cyclosporine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10482781\">",
"      Cyclophosphamide",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14534301\">",
"      Leflunomide",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16532555\">",
"      Additional therapies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10482982\">",
"      INVESTIGATIONAL THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16532635\">",
"      R-salbutamol",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14890874\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DERM/13775\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/13775|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?15/56/16261\" title=\"picture 1A\">",
"      Discoid lupus - right cheek",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?8/11/8372\" title=\"picture 1B\">",
"      Discoid lupus - left ear",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?6/61/7122\" title=\"picture 2A\">",
"      Subacute cutaneous lupus - papular",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?12/11/12467\" title=\"picture 2B\">",
"      Subacute cutaneous lupus - annular plaques",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?39/1/39958?source=related_link\">",
"      Acitretin: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/17/41241?source=related_link\">",
"      Drug eruptions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/32/28168?source=related_link\">",
"      Drug-induced lupus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/11/28857?source=related_link\">",
"      General principles in the use of immune globulin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/40/16008?source=related_link\">",
"      General principles of the use of cyclophosphamide in rheumatic and renal disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/24/32134?source=related_link\">",
"      Hepatotoxicity associated with chronic oral methotrexate for nonmalignant disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/19/314?source=related_link\">",
"      Initial management of discoid lupus and subacute cutaneous lupus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/32/38409?source=related_link\">",
"      Intravenous immune globulin: Adverse effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?0/62/1000?source=related_link\">",
"      Isotretinoin: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?18/36/19015?source=related_link\">",
"      Leflunomide: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/61/11223?source=related_link\">",
"      Major side effects of low-dose methotrexate",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/33/36378?source=related_link\">",
"      Mucocutaneous manifestations of systemic lupus erythematosus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/50/2855?source=related_link\">",
"      Mycophenolate mofetil: Pharmacology and adverse effects when used in the treatment of rheumatic diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?4/29/4569?source=related_link\">",
"      Mycophenolate: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/42/22184?source=related_link\">",
"      Oral isotretinoin therapy for acne vulgaris",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/32/22026?source=related_link\">",
"      Overview of pharmacogenomics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?16/5/16466?source=related_link\">",
"      Patient information: Discoid lupus (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/27/28090?source=related_link\">",
"      Pharmacology and side effects of cyclosporine and tacrolimus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=related_link\">",
"      Rituximab: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?28/62/29673?source=related_link\">",
"      Thalidomide: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/57/29594?source=related_link\">",
"      Thrombotic complications following treatment of multiple myeloma with thalidomide and its analogues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/6/40042?source=related_link\">",
"      Treatment of psoriasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/4/2120?source=related_link\">",
"      Tumor necrosis factor-alpha inhibitors: Induction of antibodies, autoantibodies, and autoimmune diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/59/38842?source=related_link\">",
"      Use of antiinflammatory and immunosuppressive drugs in rheumatic diseases during pregnancy and lactation",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f30_48_31499="Prevention of infection with arterial catheters";
var content_f30_48_31499=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F65076&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F65076&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Prevention of infection with arterial catheters",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Replacement and relocation of catheter",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Do not routinely replace peripheral arterial catheters.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Perform inspection of site daily&nbsp;for signs of infection, distal ischemia or embolization.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Replace disposable or reusable transducers at 96-hours intervals. Replace other components of the system, including tubing, continuous flush device, and flush solutions at the time the transducer is changed.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Replacement of catheter-site dressing",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Replace dressing when the catheter is removed or replaced, or when the dressing becomes damp, loosened, or soiled. Replace dressings more frequently in diaphoretic patients.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        There is no need to remove a gauze or opaque dressing if the patient has no clinical signs of infection.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Replacement of administration sets",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Replace the intravenous tubing, continuous flush device at the time the transducer is replaced (ie, 96-hour intervals).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Hang time for parenteral fluids",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Replace the flush solution at the time the transducer is replaced (ie, 96-hour intervals).",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_48_31499=[""].join("\n");
var outline_f30_48_31499=null;
var title_f30_48_31500="Reading difficulty tests";
var content_f30_48_31500=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F57171&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F57171&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Selected tests in the evaluation of a child with reading difficulty",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Age groups",
"       </td>",
"       <td class=\"subtitle1\">",
"        Description/comments",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Screening tests",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Parents' Evaluation of Developmental Status: Developmental Milestones (PEDS:DM)",
"       </td>",
"       <td>",
"        0 to 8 years",
"       </td>",
"       <td>",
"        Screens developmental skills including reading and math skills",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Safety Word Inventory and Literacy Screener",
"       </td>",
"       <td>",
"        6 to 14 years",
"       </td>",
"       <td>",
"        Screens overall academic performance with a special focus on reading",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Psychometric tests",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Comprehensive Test of Phonological Processing in Reading",
"       </td>",
"       <td>",
"        5 to 25 years",
"       </td>",
"       <td>",
"        Measures phonologic awareness, phonologic memory, rapid naming, rhyming words, decoding skills",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Woodcock-Johnson III",
"       </td>",
"       <td>",
"        2 to adult",
"       </td>",
"       <td>",
"        Measures general intellectual ability and specific cognitive abilities including decoding, reading fluency, and spelling",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Woodcock-Johnson Reading Mastery",
"       </td>",
"       <td>",
"        &ge;5 years",
"       </td>",
"       <td>",
"        Measures decoding using single words and nonsense words; indicates individual strengths and weaknesses in reading skills; silent reading comprehension",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Gray Oral Reading Test (GORT)",
"       </td>",
"       <td>",
"        6 to 18 years",
"       </td>",
"       <td>",
"        13 increasingly difficult passages, each followed by 5 comprehension questions; provides scores for accuracy, rate, fluency, and comprehension",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Test of Word Reading Efficiency (TOWRE)",
"       </td>",
"       <td>",
"        6 through 24 years",
"       </td>",
"       <td>",
"        Test of speed of oral reading of individual words; measures sight word efficiency and decoding efficiency",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        DIBELS Oral Reading Fluency (DORF)",
"       </td>",
"       <td>",
"        Administered in the middle and end of first grade, beginning, middle, and end of second and third grades",
"       </td>",
"       <td>",
"        Assesses rate and accuracy through standardized passages; identifies children who may need additional instructional support; monitors progress toward instructional goals",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Nelson-Denny Reading Test",
"       </td>",
"       <td>",
"        Grade 9 through college",
"       </td>",
"       <td>",
"        Silent reading test administered under timed and untimed conditions; assesses reading fluency, vocabulary and comprehension",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_48_31500=[""].join("\n");
var outline_f30_48_31500=null;
var title_f30_48_31501="Albumin in nephrosis and CAPD";
var content_f30_48_31501=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F59892&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F59892&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Plasma albumin in nephrotic syndrome and CAPD",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 350px; height: 252px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Relationship between total albumin loss and the plasma albumin concentration in patients undergoing continuous ambulatory peritoneal dialysis (CAPD), in which albumin is primarily lost in the dialysate fluid, and those with the nephrotic syndrome. At any level of albumin loss, the plasma albumin concentration is approximately 1 g/dL (10 g/L) lower in patients with the nephrotic syndrome, suggesting that some factor in addition to urinary albumin excretion must be involved.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Kaysen, GA, Schoenfeld, PY, Kidney Int 1984; 25:107.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_48_31501=[""].join("\n");
var outline_f30_48_31501=null;
var title_f30_48_31502="Gram stain CSF 1 with answer";
var content_f30_48_31502=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F66918&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F66918&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Streptococcus pneumoniae in cerebrospinal fluid",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 369px; height: 240px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Gram stain of cerebrospinal fluid (x1000) shows inflammatory cells and gram-positive diplococci. Streptococcus pneumoniae grew from this specimen.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Harriet Provine.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_48_31502=[""].join("\n");
var outline_f30_48_31502=null;
var title_f30_48_31503="RNS variability due to artifact";
var content_f30_48_31503=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F81617&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F81617&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 608px\">",
"   <div class=\"ttl\">",
"    Repetitive nerve stimulation with variability due to artifact",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 588px; height: 202px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Repetitive nerve stimulation at 2 Hz showing pseudo-decrement of 45 percent, most likely due to stimulator movement and submaximal stimulation.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of&nbsp;David Weinberg, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_48_31503=[""].join("\n");
var outline_f30_48_31503=null;
